

Proteinase-Activated Receptors: Transducers of Proteinase-Mediated Signaling in Inflammation and Immune Response

Martin Steinhoff, Jörg Buddenkotte, Victoria Shpacovitch, Anke Rattenholl, Corinna Moormann, Nathalie Vergnolle, Thomas A. Luger, and Morley D. Hollenberg

Department of Dermatology and Ludwig Boltzmann Institute for Cell and Immunobiology of the Skin (M.S., J.B., V.S., A.R., C.M., T.A.L.), University of Münster, 48149 Münster, Germany; and Department of Pharmacology (N.V., M.D.H.), University of Calgary, Calgary, Canada T2N 4N1

Serine proteinases such as thrombin, mast cell tryptase, trypsin, or cathepsin G, for example, are highly active mediators with diverse biological activities. So far, proteinases have been considered to act primarily as degradative enzymes in the extracellular space. However, their biological actions in tissues and cells suggest important roles as a part of the body's hormonal communication system during inflammation and immune response. These effects can be attributed to the activation of a new subfamily of G protein-coupled receptors, termed proteinase-activated receptors (PARs). Four members of the PAR family have been cloned so far. Thus, certain proteinases act as signaling molecules that specifically regulate cells by activating PARs.

After stimulation, PARs couple to various G proteins and activate signal transduction pathways resulting in the rapid transcription of genes that are involved in inflammation. For example, PARs are widely expressed by cells involved in immune responses and inflammation, regulate endothelial-leukocyte interactions, and modulate the secretion of inflammatory mediators or neuropeptides. Together, the PAR family necessitates a paradigm shift in thinking about hormone action, to include proteinases as key modulators of biological function. Novel compounds that can modulate PAR function may be potent candidates for the treatment of inflammatory or immune diseases. (*Endocrine Reviews* 26: 1–43, 2005)

- I. Introduction
- II. PAR₁ in Inflammation and Immune Response
 - A. Vasculature and heart: PAR₁ antagonists—a novel potential approach for the treatment of cardiovascular diseases
 - B. Platelets

- C. Immune cells
- D. Airways
- E. Gastrointestinal tract
- F. Kidneys and urogenital tract
- G. Brain and peripheral nervous system
- H. Signaling by proteinases via PAR₁
- III. PAR₂ in Inflammation and Immune Response
 - A. Vasculature
 - B. Immune cells
 - C. Arthritis
 - D. Skin
 - E. Airways
 - F. Brain and peripheral nervous system
 - G. Digestive tract and pancreas
 - H. Signaling by proteinases via PAR₂
- IV. PAR₃ and PAR₄
 - A. Biology and distribution of PAR₃ and PAR₄
 - B. Signaling by proteinases via PAR₃ and PAR₄
- V. Conclusions

I. Introduction

First Published Online October 12, 2004

Abbreviations: AP, Activating peptide; AP-1, activator protein-1; [Ca²⁺]_i, intracellular calcium; CGRP, calcitonin-gene related peptide; CNS, central nervous system; COX, cyclooxygenase; cPLA₂, cytosolic phospholipase A₂; DRG, dorsal root ganglion; EGF, epidermal growth factor; EGFR, EGF receptor; EPR-1, effector cell proteinase receptor-1; FAK, focal adhesion kinase; GI, gastrointestinal; GM-CSF, granulocyte-macrophage colony-stimulating factor; GP, glycoprotein; GPCR, G protein-coupled receptor; GRK, G protein-coupled receptor kinase; HMEC, human microvascular endothelial cells; hPAR, human PAR; HUVEC, human umbilical vein endothelial cells; ICAM-1, intercellular adhesion molecule-1; IFN- γ , interferon γ ; IKK, inhibitor of NF κ B kinase; iNOS, inducible NO synthase; JNK, Jun N-terminal kinase; MCP-1, monocyte chemoattractant protein-1; MDCK cells, Madin-Darby canine kidney cells; MMP, matrix metalloproteinase; mPAR, murine PAR; NF κ B, nuclear factor κ B; NK cells, natural killer cells; NK receptor, neurokinin receptor; NO, nitric oxide; PAF, platelet-activating factor; PAR, proteinase-activated receptor; PAR-AP, proteinase-activated receptor activating peptide; PDGF, platelet-derived growth factor; PG, prostaglandin; PI3, phosphoinositide 3; PKA, protein kinase A; PKB, protein kinase B; PKC, protein kinase C; PLC, phospholipase C; PTX, pertussis toxin; Pyk2, proline-rich tyrosine kinase 2; SLP-76, SH2-domain containing leukocyte-specific phosphoprotein of 76 kDa; SMC, smooth muscle cells; SP, substance P; Src, protein tyrosine kinase Src; TK, tyrosine kinase; VCAM-1, vascular cell adhesion molecule-1; VSMC, vascular SMC; ZAP-70, ζ -chain-associated protein kinase of 70 kDa.

Endocrine Reviews is published bimonthly by The Endocrine Society (<http://www.endo-society.org>), the foremost professional society serving the endocrine community.

SERINE PROTEINASES CONSTITUTE a family of proteolytic enzymes characterized by a unique catalytic triad consisting of Ser, His, and Asp. These residues are able to hydrolyze peptide bonds (1). Serine proteinases are produced as inactive precursors or zymogens. Subsequent zymogen conversion into a mature physiologically active enzyme is mediated via a process called “limited proteolysis” or zymogen activation (2–4). In mammals, serine proteases, for example, regulate the hemostatic and fibrinolytic balance, degrade neuropeptides involved in neurogenic inflamma-

tion or serve as modulators of immune response during inflammation (5). Three different types of serine proteinase inhibitors can be distinguished based on their mechanism of action: canonical, noncanonical inhibitors, and serpins (6). An imbalance between these inhibitors and their targeted proteinases can affect immune/inflammatory responses and may result in disease. Moreover, the presence of proteinase inhibitors regulates and limits interactions between proteinases and their receptors (7–11).

Recent studies elucidated the ability of certain serine proteinases to regulate cell function via G protein-coupled receptors (GPCRs). At least two different types of proteinase receptors have been identified involving proteolytic cleavage in their activation mechanism: urokinase receptors and proteinase-activated receptors (PARs) (12–14).

PARs belong to a new subfamily of GPCRs with seven transmembrane domains activated via proteolytic cleavage by serine proteinases (13–16). PAR₁, PAR₃, and PAR₄ are targets for thrombin, trypsin, or cathepsin G (17–20). In contrast, PAR₂ is resistant to thrombin, but can be activated by trypsin, mast cell tryptase, factor Xa, acrosin, gingipain, and neuronal serine proteinases (21–28) (Table 1). Interestingly, PARs are activated by a unique mechanism: proteinases activate PARs by proteolytic cleavage within the extracellular N terminus of their receptors, thereby exposing a novel “cryptic” receptor-activating N-terminal sequence that, remaining tethered, binds to and activates the receptor (Fig. 1) within the same receptor (17, 21, 22). Specific residues (about six amino acids) within this tethered ligand domain are believed to interact with extracellular loop 2 and other domains of the cleaved receptor (29), resulting in activation. This intramolecular activation process is followed by coupling to G proteins and the triggering of a variety of downstream

signal transduction pathways (see Sections II.H, III.H, and IV.B; also see Table 2 and Fig. 2, and Refs. 13, 14, and 16). Thus, PARs are not activated like “classical” receptors because the specific receptor-activating ligand is part of the receptor, whereas the circulating agonist is a relatively non-specific serine proteinase that does not behave like a traditional hormonal regulator akin to insulin.

Several studies during the past few years have also demonstrated that several mechanisms exist to regulate stimulation and termination of PAR-initiated signaling (13–16, 30). Importantly, the availability of PARs at the cell surface is governed by trafficking of the receptor from intracellular stores, and the signaling properties depend on the presence of G proteins and G protein-coupled receptor kinases (GRKs) that modify activity. For PAR₁, PAR₂, and PAR₄, it is well established that short synthetic peptides [PAR-activating peptides (PAR-APs)] designed on their proteolytically revealed tethered ligand sequences can serve as selective receptor agonists (Table 1). Some PAR-APs activate more than one PAR, and they activate receptors at concentrations in the micromolar range as compared with nanomolar potencies of the proteinases themselves (31, 32). Although the PAR₁-AP, SFLLRN-NH₂ also activates PAR₂, PAR₂-APs, like SLIGRL-NH₂ are not capable of activating other PARs. Unfortunately, the relatively low potency (10 to 100 μM EC₅₀) and susceptibility to aminopeptidases (33) limit the utility of the PAR-APs in some bioassay systems. Recently, modified synthetic agonist peptides with higher potency, resistance to aminopeptidases, and greater receptor selectivity have been developed and characterized. These receptor-selective agonists are of use to study the consequences of activating PARs *in vivo* (Table 1) (13, 14, 16, 34). So far, antagonists

TABLE 1. Pharmacology of proteinase-activated receptors and their agonists

| | PAR ₁ | PAR ₂ | PAR ₃ | PAR ₄ |
|---------------------------|---|---|--------------------------|--|
| Amino acid composition | 425 aa (h) | 397 aa (h) | 374 aa (h) | 385 aa (h) |
| Tethered ligand sequence | SFLLR (h) SFFLR (m, r) | SLIGKV (h) SLIGRL (m, r) | TFRGAP (h) SFNGGP (m) | GYPGQV (h) GYPGKV (m) |
| Selective agonist peptide | TFLLR-NH ₂ TFRIFD ^a | SLIGKV-NH ₂ (h) SLIGRL-NH ₂ (m, r) | None known | GYPGKV-NH ₂ GYPGQV-NH ₂ AYPGKF-NH ₂ |
| High-affinity ligands | Thrombin | Trypsin, tryptase, trypsin-2 | Thrombin ^b | Thrombin, trypsin |
| Low-affinity ligands | Trypsin; FVIIa/TF/FXa; granzyme A, plasmin | Matriptase/MT-serine protease 1; Der p3; Der p9; FVIIa/TF/FXa; cockroach proteases | Trypsin > factor Xa | Cathepsin G, factors VIIa/X |
| Inhibitory proteases | Cathepsin G, proteinase-3; elastase; chymase | Elastase, chymase | Cathepsin G | Unknown |
| Selective antagonists | Trans-cinnamoyl-paraffluoro- Phe-Paraguanidino-Phe- Leu-Arg-Arg-NH ₂ Mercaptopropionyl-Phe-Cha- Arg-Lys-Pro-Lys-Pro-Asn- Asp-Lys-NH ₂ Non-peptide antagonists: RWJ56110 and RWJ58259 | None known | None known | Trans-cinnamoyl-YPGKF- NH ₂ |

The letters denote the amino acid sequences of peptides in one letter code: aa, amino acids; h, human; m, mouse; r, rat; NH₂, respective amides.

^a TFRIFD is the *Xenopus* thrombin receptor tethered ligand domain (the human PAR₁ tethered ligand domain sequence, SFLLRN, activates both PAR₁ and PAR₂).

^b Proteinase cleavage but PAR₃ does not generate a calcium signal.




FIG. 1. Classical mechanism of PAR activation and their structural features. The proteinase cleaves the PAR receptor at a particular site (marked by red arrow), unmasking a previously cryptic N-terminal sequence of the receptor (presented in blue), defined as “tethered ligand.” This tethered ligand sequence interacts with the conserved second extracellular loop and activates the same receptor. The human sequences of the tethered ligand, the second extracellular loop, and the intracellular C-terminus are presented in the boxes. Hirudin-like binding domain sequences for PAR₁ and PAR₃ are printed in green.

for PAR₁ (35–37) and PAR₄ (38) have been synthesized, but are not yet available for PAR₂. PAR₃, as will be elaborated upon in Section IV, remains a puzzle, in that studies with the murine receptor indicate that it cannot be activated either by its cognate synthetic tethered ligand peptide or by thrombin (39, 40). Rather than acting as an independent cell regulator, PAR₃ appears to function as a cofactor for the activation of PAR₄ (39). Complementary data documenting PAR-mediated effects in various tissues have been obtained using PAR-deficient (PAR^{-/-}) mice.

Taken together, data obtained using the enzyme activators themselves (trypsin, thrombin), the PAR-APs and using PAR gene-deficient mice provide compelling evidence that PARs play a critical role in the regulation of various physiological and pathophysiological functions in mammals, including humans. This review focuses on the biology and signaling properties of PARs in various mammalian tissues and highlights the current knowledge about the role of PARs during inflammation and immune response. To complement the information summarized in the sections that follow, the reader is encouraged to consult a number of other recent reviews concerning the activation mechanisms and cell biological aspects of PARs (13, 14, 16, 34, 41–45).

II. PAR₁ in Inflammation and Immune Response

Thrombin is an important effector proteinase of the coagulation cascade that leads to formation of a hemostatic plug. Thrombin is thought to act near the site at which it is generated and it is activated when circulating coagulation factors in the blood plasma make contact with tissue factor. Tissue factor is a membrane protein that is usually produced by cells that are separated from blood (*i.e.*, epithelial cells). However, it is also expressed at low levels on circulating monocytes and micro-particles from leukocytes. Tissue factor is associated with the activation of zymogen factor X by factor VIIa. Factor Xa together with its cofactor Va subsequently converts prothrombin to the active enzyme. Thus, plasma coagulation can only take place when the vascular integrity is damaged (15). Thrombin causes shape change of endothelial cells and increased permeability of endothelial cell layers.

However, recent evidence revealed that thrombin is not only a clotting proteinase serving as both a pro- and anticoagulant molecule but also appears to play multifunctional roles related to inflammation, allergy, tumor growth, metastasis, tissue remodeling, thrombosis, and probably wound healing (13, 15, 42, 43). Subsequent to the cloning of PAR₁ (17, 46), it was realized that many of the cellular actions of throm-

TABLE 2. Biology and pathophysiology of PAR activation in different tissues, cells, and species

| Tissue | Cell type | Effect | Refs. |
|---|--|---|--|
| PAR₁-agonist mediated effects | | | |
| Airways (Chinese hamster) | CCL39, PS200 | G _i , PI hydrolysis, pp60 ^{src} , ERK1/2, SHC/Grb-2 kinase, Src/Ras, Fyn, adenylyl cyclase inhibition, growth, mitogenesis | Hung <i>et al.</i> (115) Chen <i>et al.</i> (349, 350) Trejo <i>et al.</i> (351) |
| Airways (PAR ₁ ^{-/-} mouse) | Fibroblasts | [Ca ²⁺] _i ↑, PTX-(in)sensitive and PKC/c-Raf-(in)dependent → MAPK, mitogenesis | Connolly <i>et al.</i> (135) Trejo <i>et al.</i> (351) |
| Airways (guinea pig) | Lung, parenchymal strips | Contraction | Saifeddine <i>et al.</i> (159) |
| Airways (human) | HFL1, adult lung fibroblasts | CTGF ↑ | Chambers <i>et al.</i> (148) |
| Airways (human) | HBEC, A459, BEAS-2B | [Ca ²⁺] _i ↑, IL-6 ↑, IL-8 ↑, PGE ₂ ↑ | Asokanathan <i>et al.</i> (77) |
| Airways (mouse) | Tracheal SMC | PGE ₂ ↑, relaxation/contraction | Lan <i>et al.</i> (152, 153) |
| Airways (rat) | Epithelium, trachea, bronchi | Contraction | Chow <i>et al.</i> (91) |
| Blood (human) | Platelets | AP: integrin-α(IIb)β(3) ↓, Src ↓, FAK ↓, SHP-1 phosphorylation; thrombin: calpain ↑, Src, FAK, and integrin α _{IIb} β ₃ not effected; cytoskeletal reorganization, disaggregation | Ramars <i>et al.</i> (352) |
| Blood (human) | Platelets | [Ca ²⁺] _i ↑, PLC, PI ₃ P, pp72 ^{Syk} , p54/58lynv, p60c-src, annexin V binding, platelet aggregation (ADP and MMP-2 dependent) and activation | Vu <i>et al.</i> (17) Huang <i>et al.</i> (353) Hung <i>et al.</i> (326) Hwa <i>et al.</i> (248) Andersen <i>et al.</i> (122) Kahn <i>et al.</i> (128) Chung <i>et al.</i> (334) |
| Blood (human) | Platelets | Degranulation, TXA ₂ /TXB ₂ ↑ | Henriksen <i>et al.</i> (354) Henriksen and Hanks (117) McRedmond <i>et al.</i> (133) |
| Blood (human) | Platelets | PI3 kinase, PKC, Rhoβγ-subunits, Pyk-2, FAK, Src, adenylyl cyclase inhibition, aggregation | Zhang <i>et al.</i> (204) Ohmori <i>et al.</i> (203, 355) Kim <i>et al.</i> (201) |
| Blood (human) | Platelets | IVSn-14A/T intronic gene-variation associated to PAR ₁ surface density, different agonist response | Dupont <i>et al.</i> (127) |
| Blood (human) | Platelets | p160 ^{ROCK} -mediated shape change; 1) G _{12/13} /Ca ²⁺ -mediated; 2) G _i /PI3 kinase-mediated GPIIb/IIIa activation | Dorsam <i>et al.</i> (356) |
| Blood (human) | Platelets | Induced clearance of cell surface GPIb | Han <i>et al.</i> (357) |
| Blood vessel (human) | HUVEC | G _{βγ} /p85/p110/PI3 kinase and G _{αq} /PKC-δ → Akt → NFκB → ICAM-1 ↑ Rho A, WPB exocytosis, permeability ↑ | Rahman <i>et al.</i> (228, 231, 232) Chi <i>et al.</i> (72) Klarenbach <i>et al.</i> (358) |
| Blood vessel (human) | HUVEC | APC treatment as well as PAR ₁ -AP induces MCP-1 expression | Riewald <i>et al.</i> (359) |
| Blood vessel (human) | HUVEC, HMEC | cPLA ₂ α, PGI ₂ ↑; shear stress → PAR ₁ ↓; TNF-α → PAR ₁ ↓ | Nguyen <i>et al.</i> (101) Shinohara <i>et al.</i> (102) |
| Blood vessel (porcine) | Coronary artery | Endothelium-dependent relaxation | Hwa <i>et al.</i> (248) |
| Bone (human) | Synovial fibroblasts | RANTES mRNA ↑ | Hirano <i>et al.</i> (80) |
| Brain (human) | Brain microvascular endothelial cells, HUVEC | APC → [Ca ²⁺] _i ↑ via EPCR and PAR ₁ ; cyto/neuroprotection | Domotor <i>et al.</i> (360) Cheng <i>et al.</i> (361) |

TABLE 2. *Continued*

| Tissue | Cell type | Effect | Refs. |
|-----------------------------------|----------------------------------|--|--|
| Brain (mouse) | Astrocytes | Hsp90 binds PAR ₁ , affects cytoskeleton, PKC β -1 translocation | Pindon <i>et al.</i> (190) Pai <i>et al.</i> (362) |
| Brain (rat) | Astrocytes | [Ca ²⁺] _i ↑, proliferation, ERK-1/2-activation via 1) PI3-kinase 2) G _o -PLC-Ca ²⁺ -PKC Pyk2/Grb2/Src | Ubl <i>et al.</i> (176, 363) Wang <i>et al.</i> (185) Wang and Reiser (210, 466) |
| Brain (rat) | Astrocytes | Proliferation, reversion of stellation; creatine kinase interacts with PAR ₁ → RhoA → cytoskeletal reorganization | Debeir <i>et al.</i> (191) Mahajan <i>et al.</i> (364) |
| Breast (human) | MDAMB231 | [Ca ²⁺] _i ↑, migration/invasion (G _i /PI3-kinase-mediated) ↓ | Kamath <i>et al.</i> (365) |
| Cardiovascular system (porcine) | Artery | Relaxation | Hwa <i>et al.</i> (248) |
| Cardiovascular system (rat) | Aortic arterial ring | Relaxation | Hollenberg <i>et al.</i> (158) Muramatsu <i>et al.</i> (64) |
| Cardiovascular system (rat) | Fibroblasts, cardiomyocytes | [Ca ²⁺] _i ↑, Src ↑, Fyn ↑, EGFR transactivation, ERK-1/2 and p38 phosphorylation | Sabri <i>et al.</i> (366) |
| Cardiovascular system (rat/mouse) | NRVM, cardiomyocytes | [Ca ²⁺] _i ↑, IP accumulation, EGFR kinase, activation of ERK-1/2 and p38, c-Jun, Akt, ANF, hypertrophy | Steinberg <i>et al.</i> (367) Jiang <i>et al.</i> (368) Sabri <i>et al.</i> (222, 338) |
| Cardiovascular system (rat) | RASMC | [Ca ²⁺] _i ↑ | Takada <i>et al.</i> (76) |
| Endometrium (human) | Endometrial stromal cells | Levonorgestrel → PAR ₁ ↓ | Hague <i>et al.</i> (369) |
| Gallbladder (guinea pig) | SMC | Prostanoid-mediated contraction | Tognetto <i>et al.</i> (370) |
| GI tract (rat) | Esophageal smooth muscle | Contraction, Na ⁺ influx, [Ca ²⁺] _{ex} -influx (PAR ₄ opposed) | Kawabata <i>et al.</i> (371) |
| Immune system (human) | Alveolar macrophages | PAR ₁ ↑ in AMs of smokers | Roche <i>et al.</i> (372) |
| Immune system (rat) | BMCMC | Fibronectin adhesion via (PTX)-sensitive G _i -protein, PI3 kinase, PKC, activation of ERK-1/2 and p38, IL-6 ↑, MMP-9 ↑, β -hexosaminidase ↑ | Vliagoftis <i>et al.</i> (373) |
| Immune system (rat) | Mast cells | Degranulation ↑, degranolysis ↑, heparin release | Umarova <i>et al.</i> (374) |
| Immune system (human) | Monocytes, macrophages | [Ca ²⁺] _i ↑, MCP-1 | Colognato <i>et al.</i> (375) |
| Intestine (guinea pig) | Longitudinal smooth muscle | Contraction, dependent on [Ca ²⁺] _{ex} , TK, COX | Hollenberg <i>et al.</i> (158) Saifeddine <i>et al.</i> (159) |
| Intestine (guinea pig) | Taenia coli | Relaxation | Cocks <i>et al.</i> (376) |
| Intestine (human) | Colonic epithelial cells | Cellular invasion via 1) G α_{12} /G α_{13} -RhoA/RhoD/ROCK 2) G α_q , PLC β , CaMLCK, MLC-phosphorylation | Nguyen <i>et al.</i> (377) |
| Intestine (human) | SCBN cells | [Ca ²⁺] _i ↑, Cl ⁻ secretion via MEK-ERK/MAPK-cPLA ₂ , involves Src, EGFR and COX-1/2 activity | Buresi <i>et al.</i> (156, 378) |
| Intestine (mouse) | Model, smooth muscle | Modulates GI transit, L-type Ca ²⁺ channel, contraction, PI3 kinase, PLC, PKC, TK | Kawabata <i>et al.</i> (161, 379) |
| Intestine (mouse) | Gastric fundus | Relaxation/contraction | Cocks <i>et al.</i> (376) |
| Intestine (rat) | Longitudinal and circular muscle | Biphasic contraction, relaxation | Mule <i>et al.</i> (163) |
| Intestine (rat) | SMC, vascular muscle cells | Irradiation → PAR ₁ ↑ | Wang <i>et al.</i> (164) |

TABLE 2. *Continued*

| Tissue | Cell type | Effect | Refs. |
|--|----------------------------|---|--|
| Kidney (murine) | Model | Renal inflammation | Cunningham <i>et al.</i> (49) |
| Lymph node (human) | LNCaP | RhoA, cytoskeletal reorganization | Greenberg <i>et al.</i> (380) |
| Muscle (mouse) | Neonatal myoblasts | [Ca ²⁺] _i ↑, proliferation | de Niese <i>et al.</i> (381) |
| Nervous system/intestine (guinea pig) | Enteric neurons | Excitatory response, dependent on PLC and [Ca ²⁺] _i | Gao <i>et al.</i> (319) |
| Nervous system (guinea pig) | Myenteric glia | [Ca ²⁺] _i ↑, PLC | Garrido <i>et al.</i> (382) |
| Nervous system (guinea pig) | Myenteric neurons | [Ca ²⁺] _i ↑ | Corvera <i>et al.</i> (196) |
| Nervous system (CNS) (human) | A172 | [Ca ²⁺] _i ↑, PKC-α, PKC-γ, PKC-L | Okamoto <i>et al.</i> (317) |
| Nervous system (human) | Neuronal cells | MMP-1 potentiates PAR ₁ induced ↑ [Ca ²⁺] _i release | Conant <i>et al.</i> (383) |
| Nervous system (PAR ^{-/-} mouse) | Model | Less PAR ₁ → posttraumatic survival of CNS neurons ↑ | Friedmann <i>et al.</i> (186) |
| Nervous system CNS (PAR ^{-/-} mouse) | Primary microglial cells | Activation of p38, p44/42, CD40 ↑, proliferation | Suo <i>et al.</i> (83) |
| Nervous system CNS (human) | Hippocampal neurons | PAR ₁ activation potentiates NMDA receptor activity | Fang <i>et al.</i> (384) |
| Nervous system (rat) | Primary afferent neurons | PAR ₁ -AP: mechanical and thermal analgesia, carrageenan-induced mechanical and thermal hyperalgesia ↓; thrombin: carrageenan-induced mechanical analgesia ↓ | Asfaha <i>et al.</i> (197) Kawabata <i>et al.</i> (198) |
| Nervous system (rat) | Sensory nerves | Plasma extravasation, edema, SP ↑ → NK ₁ receptor activation | de Garavilla <i>et al.</i> (155) |
| Pancreas (human) | MIA PaCa-2 | Adhesion to extracellular matrix-proteins ↑ (laminin, collagen IV, fibronectin); PAR ₁ ↑ in pancreatic cancer | Rudroff <i>et al.</i> (165, 166) |
| Skin (human) | HDMEC, HMEC, HPAEC | G _{αi} -linked Src-Ras-MAPK-pathway activation. PI3 kinase, PAR ₁ expression | Ellis <i>et al.</i> (385) |
| Skin (oral mucosa) (human) | KB cells | [Ca ²⁺] _i ↑, IL-6 ↑, (RgpB)-induced | Lourbakos <i>et al.</i> (28) |
| Skin (human) | Keratinocytes | [Ca ²⁺] _i ↑, proliferation ↑, inhibits differentiation | Derian <i>et al.</i> (275) Algermissen <i>et al.</i> (386) |
| Skin (human) | SIT1 | High TF level and activated PAR ₁ → enhanced metastasis | Bromberg <i>et al.</i> (387) |
| Skin (PAR ₁ ^{-/-} mouse) | Fibroblasts, model | Plasmin activates PAR ₁ → ERK-1/2 → Cyr61 ↑. Sepsis protection, APC activates EPCR/PAR ₁ receptor cascade, MCP-1; 1) G _q → PKC → c-Raf → MAPK 2) G _i → MAPK | Trejo <i>et al.</i> (351) Pendurthi <i>et al.</i> (388) Riewald <i>et al.</i> (81) |
| Vascular system (human) | HASMC | Cyclic strain → PAR ₁ ↑ Low shear stress → PAR ₁ ↑ High shear stress → PAR ₁ ↓ | Papadaki <i>et al.</i> (389) Nguyen <i>et al.</i> (104) |
| Vascular system (human) | HCASMC, HASMC, HAOAF, HAEC | FXa-induced: proliferation, ↑ IL-6, ↑ prothrombotic TF | McLean <i>et al.</i> (86) |
| Vascular system (human) | Pulmonary artery | Endothelium-dependent relaxation | Hamilton <i>et al.</i> (99) |
| Vascular system (PAR ₁ ^{-/-} mice) | Model | Embryonic development; vascular development, endothelium-specific mPAR ₁ expression → reduction of embryonic death | Connolly <i>et al.</i> (135) Griffin <i>et al.</i> (96) |
| Cell line (Chinese hamster) | CHO cells | PAR ₁ third intracellular loop: G _i coupling, MAPK activation, internalization; PAR ₁ C-tail: internalization, PLC coupling | Chen <i>et al.</i> (390, 391) |

TABLE 2. *Continued*

| Tissue | Cell type | Effect | Refs. |
|----------------------------------|---|--|--|
| Cell line (Chinese hamster) | CHO/TF | Ternary complex TF-VII-Xa activates PAR ₁ | Riewald and Ruf (241) |
| Cell line (human) | HeLa | FXa → gene induction, ERK1/2, Cyr61, CTGF | Riewald <i>et al.</i> (239) |
| Cell line (monkey) | COS-7 cells | G ₁₂ , G ₁₃ , G _q , PI hydrolysis, ERK-5 | Shapiro <i>et al.</i> (392) Verrall <i>et al.</i> (29) Fukuhara <i>et al.</i> (393) |
| <i>In vitro</i> assay | <i>In vitro</i> assay | Noncoding RNA (ncR-uPAR) regulates PAR ₁ expression during embryogenesis | Madamanchi <i>et al.</i> (394) |
| HT29 | Human colon cancer cell line | Mitogenic activity up-regulated; p42/p44 activation | Darmoul <i>et al.</i> (395) |
| Model (cynomolgus monkey) | Model, platelets | RWJ-58259 → blood flow ↑; prevents thrombosis and vascular occlusion | Derian <i>et al.</i> (107) |
| Thrombin-mediated effects | | | |
| Airways (bovine) | Tracheal SMC | PI3 kinase, PKB, PI ₃ P | Walker <i>et al.</i> (145) |
| Airways (Chinese hamster) | CCL 39 fibroblasts, PS200, Rat-1) | p21 ^{RAS} /G _i /G _o , p70s6k, p44 | Kahan <i>et al.</i> (396) van Corven <i>et al.</i> (397) |
| Airways (guinea pig) | Trachea, main bronchi | Bronchoconstriction, biphasic change in arterial blood pressure | Cicala <i>et al.</i> (151) Carr <i>et al.</i> (303) |
| Airways (human) | ASM | [Ca ²⁺] _i ↑, PI3 kinase ↑, pp70 ^{s6k} , proliferation; thrombin → GM-CSF ↑ independent of PAR ₁ | Krymskaya <i>et al.</i> (223) Tran and Stewart (398) |
| Airways (human) | ASM, bronchial rings | Contraction | Hauck <i>et al.</i> (150) |
| Airways (human) | Fetal lung fibroblast | α1(D)Procollagen ↑ | Chambers <i>et al.</i> (146) |
| Airways (human) | BEAS-2B, BSMC, NHBE | PDGF-AB ↑ | Shimizu <i>et al.</i> (149) |
| Airways (mouse) | Tracheal SMC | PGE ₂ ↑, relaxation/contraction | Lan <i>et al.</i> (152, 153) |
| Airways (rat) | Epithelium, trachea, bronchi | Contraction | Chow <i>et al.</i> (91) |
| Blood vessel (human) | HUVEC, primary umbilical cords | [Ca ²⁺] _i ↑, IL-6 ↑, PLC, PKC, PGI ₂ , PDGF mRNA ↑, vWf release, P-selectin ↑, neutrophil adhesion, barrier dysfunction, contraction | Sugama <i>et al.</i> (47) Garcia <i>et al.</i> (67) Storck and Zimmermann (399) Chi <i>et al.</i> (72) |
| Blood vessel (bovine) | Pulmonary artery | G _i , [Ca ²⁺] _i ↑, PLC, PKC, PI3 kinase, PGI ₂ ↑, PDGF, p70 ^{s6k} , growth, contraction, permeability | Tiruppathi <i>et al.</i> (400) Garcia <i>et al.</i> (67) Belham <i>et al.</i> (401) |
| Blood vessel (bovine) | VSMC | [Ca ²⁺] _i ↑, IL-6 ↑, MCP-1 ↑ | Kranzhofer <i>et al.</i> (402) Bretschneider <i>et al.</i> (321) |
| Blood vessel (human) | HUVEC, HMEC | [Ca ²⁺] _i -dependent Pyk-2 activation (PKC, Src kinases independent); cPLA ₂ α, COX-2 ↑, PGI ₂ ↑; Shear stress → PAR ₁ ↓; TNF-α → PAR ₁ ↓ | Tiruppathi <i>et al.</i> (400) Nguyen <i>et al.</i> (101) Houliston <i>et al.</i> (78) Keogh <i>et al.</i> (403) Shinohara <i>et al.</i> (102) |
| Blood vessel (porcine) | Pulmonary artery SMC | [Ca ²⁺] _i ↑ | Tiruppathi <i>et al.</i> (400) |
| Bone (rat) | Primary osteoblast-like cells, Saos-2 cells | [Ca ²⁺] _i ↑, alkaline phosphatase activity ↓; TGF-β, thrombin → PAR ₁ ↑; PDGF-BB → PAR ₁ mRNA ↓ | Jenkins <i>et al.</i> (404) Abraham and Mackie (405) |
| Bone (human) | VcaP | PAR ₁ ↑, [Ca ²⁺] _i ↑ | Chay <i>et al.</i> (406) |
| Brain (human) | 1321N1 astrocytoma cells | p21 ^{RAS} , AP-1, mitogenesis; cell rounding, GEF/Rho/G ₁₂ /G ₁₃ | Majumdar <i>et al.</i> (213) LaMorte <i>et al.</i> (214) |
| Brain (human) | Meningioma cells | [Ca ²⁺] _i ↑ | Kaufmann <i>et al.</i> (407) |

TABLE 2. *Continued*

| Tissue | Cell type | Effect | Refs. |
|---------------------------------------|--|---|--|
| Brain (human) | SNB-19 glioblastoma cells | Meizothrombin, thrombin and SFLLRN → $[Ca^{2+}]_i$ ↑, PKA activation, NF κ B-associated translocation of PKA α into nucleus, cAMP independent | Kaufmann <i>et al.</i> (328) Zieger <i>et al.</i> (217) |
| Brain (rat) | C6 glioma cells | $[Ca^{2+}]_i$ ↑, iNOS ↑ | Ubl <i>et al.</i> (176) Meli <i>et al.</i> (85) |
| Brain (rat) | Cholinergic neuron | Modulation of cholin acyltransferase activity | Debeir <i>et al.</i> (408) |
| Brain (rat) | RBCE | $[Ca^{2+}]_i$ ↑ | Domotor <i>et al.</i> (302) |
| Cardiovascular system (rat) | RASMC | $[Ca^{2+}]_i$ ↑ Rho, Rho kinase, migration, proliferation | McNamara <i>et al.</i> (409) Chaikof <i>et al.</i> (410) Seasholtz <i>et al.</i> (219) |
| Circulatory system (rat) | Model | Biphasic change in MABP, hypertension (NO and nerval modulated) | Cicala <i>et al.</i> (411) |
| Connective tissue (human) | Synovial fibroblasts | Proliferation, IL-6 ↑, GM-CSF | Shin <i>et al.</i> (143, 412) |
| Eye (human) | HCEC (human corneal epithelial cells) | $[Ca^{2+}]_i$ ↑, IL-6, IL-8, TNF- α | Lang <i>et al.</i> (339) |
| Immune system (human) | Monocytes (U 937), PBMC (IFN- γ -differentiated) | IL-1 α ↑, IL-1 β ↑, p21 ^{CIP1/WAF1} ↓, cyclin D ₁ ↑ → proliferation; thrombin: IL-6 ↑, TNF- α ↑, PAR ₁ ↑ | Naldini <i>et al.</i> (137, 141, 413) |
| Immune system (human) | Lymphocytes | CD69 ↑, IL-2 ↑ | Mari <i>et al.</i> (235) |
| Immune system (human) | Jurkat T-leukemic cells | $[Ca^{2+}]_i$ ↑, PKC ↑, CD69 ↑, IL-2 ↑, Vav1, ZAP-70, SLP-76 | Mari <i>et al.</i> (235) Bar-Shavit <i>et al.</i> (236) |
| Immune system (rat) | Peritoneal mast cells | NO ↑, PAF ↓ | Strukova <i>et al.</i> (414) |
| Intestine (guinea pig) | Longitudinal smooth muscle | Contraction, dependent on $[Ca^{2+}]_{ex}$, COX | Hollenberg <i>et al.</i> (158) Saifeddine <i>et al.</i> (159) |
| Intestine (guinea pig) | Taenia coli | Relaxation | Cocks <i>et al.</i> (376) |
| Intestine (mouse) | Gastric fundus | Relaxation/contraction | Cocks <i>et al.</i> (376) |
| Kidney (canine) and intestine (human) | MDCK, MDCKts.src, colonic PCmsrc epithelial cells, HCT-8/S11 | PAR ₁ /G α_i inhibit TFFs-induced invasion; PAR ₁ /G α_{oif} inhibit invasion | Faivre <i>et al.</i> (168) Regnauld <i>et al.</i> (169) |
| Kidney (human) | Glomerular mesangial cells | pp125 ^{FAK} | Choudhury <i>et al.</i> (415) |
| Kidney (rat) | GEC, GMC | Clusterin mRNA ↑, TGF- β ↑ | Laping <i>et al.</i> (416) |
| Liver (human) | HepG2 | PKC, JNK/p38 MAPK | Mitsui <i>et al.</i> (417) |
| Monocytes (human) | Mononuclear cells | IL-1 ↑, IL-6 ↑ | Naldini <i>et al.</i> (82) |
| Nervous system (chicken) | Motoneurons | Neuronal apoptosis, caspases-1 and -3 | Turgeon <i>et al.</i> (418) |
| Nervous system/intestine (guinea pig) | Enteric neurons | Excitatory response, dependent on PLC and $[Ca^{2+}]_i$ | Gao <i>et al.</i> (319) |
| Nervous system (mouse) | NB2a | Morphological changes | Pai and Cunningham (419) |
| Skeletal muscle (human) | Myocytes | $[Ca^{2+}]_i$ ↑ | Mbebi <i>et al.</i> (420) |
| Skin (human) | HMEC | GRK5 → PAR ₁ phosphorylation, PAR ₁ -mediated $[Ca^{2+}]_i$ increase ↓ | Tiruppathi <i>et al.</i> (105) |
| Skin (human) | Keratinocytes | $[Ca^{2+}]_i$ ↑, proliferation, inhibits differentiation | Derian <i>et al.</i> (275) Algermissen <i>et al.</i> (386) |
| Skin (human) | Primary FS4 fibroblasts, prostate DU145, CHRF | CVEGF, PI3 kinase, serine/threonine kinase | Huang <i>et al.</i> (421) |

TABLE 2. *Continued*

| Tissue | Cell type | Effect | Refs. |
|---|---|---|---|
| Skin (mouse) | Fibroblasts | Fibroblast/macrophage ratio ↑, fibroblast proliferation, epithelial and endothelial cells ↑, neovascularization → wound healing ↑ | Strukova <i>et al.</i> (414) |
| Skin (mouse) | NIH-3T3 fibroblasts | Gα ₁₂ /Gα ₁₃ , RAF-1, TK, ERK1/2, RhoA-mediated transformation | Apostolidis and Weiss (422) Martin <i>et al.</i> (90) |
| Urogenital tract (human) | RT4, HUR | AA ↑, PGE ₂ release, iPLA ₂ , PAF, phospholipid hydrolysis | McHowat <i>et al.</i> (170) Rickard and McHowat (423) |
| Vascular system (guinea pig) | Carotid artery | Biphasic change in arterial blood pressure (hypertension/hypotension) | Cicala <i>et al.</i> (151) |
| Vascular system (human) | VSMC | [Ca ²⁺] _i ↑, ERK-1/2 activation, mitogenesis | Bretschneider <i>et al.</i> (220) |
| Vascular system (rat) | VSMC | p38 MAPK, cAMP-response element promotor dependent transcription, growth | Ghosh <i>et al.</i> (221) |
| Vascular system (rat) | VSMC | Progesteron, gestodene → PAR ₁ ↑ → TF-expression ↑, procoagulant activity ↑ | Herkert <i>et al.</i> (68) |
| Vascular system (rat) | VSMC | α1(I)procollagen (mRNA) ↑ | Dabbagh <i>et al.</i> (100) |
| Cell line (human) | CHRF-288 | Blebbing, PI3 kinase | Vemuri <i>et al.</i> (424) |
| PAR₂-agonist mediated effects | | | |
| Airways (guinea pig) | Epithelial cells, SMC | Bronchoconstriction/bronchorelaxation; trypsin but not AP caused | Ricciardolo <i>et al.</i> (290) |
| Airways (guinea pig) | Tracheal epithelial cells | [Ca ²⁺] _i ↑ | Oshiro <i>et al.</i> (425) |
| Airways (guinea pig) | Trachea, upper bronchi | Bronchoprotection to histamine | Cicala <i>et al.</i> (293) |
| Airways (guinea pig) | Tracheal rings | Trypsin: contraction, NK-receptor involved; AP has no effect | Carr <i>et al.</i> (303) |
| Airways (human) | A549 | [Ca ²⁺] _i ↑, proliferation, GM-CSF ↑, eotaxin ↑, PI hydrolysis, Der p3 and Der p9 → PLC activation; MMP-9 release, MEK-1, MAPK, NFκB | Böhm <i>et al.</i> (154) Vliagoftis <i>et al.</i> (297) Sun <i>et al.</i> (343) |
| Airways (human) | A549, HBE | Thermolysin → [Ca ²⁺] _i ↑ | Ubl <i>et al.</i> (296) |
| Airways (human) | Bronchial epithelial cells | Inhibits ion transport (basolateral K ⁺ -permeability ↓) | Danahay <i>et al.</i> (426) |
| Airways (human) | Bronchial SMC | [Ca ²⁺] _i ↑, contraction, contributes to allergic inflammation and immunity | Schmidlin <i>et al.</i> (291) |
| Airways (human) | Epithelial cells | PAR ₂ in asthmatic tissue ↑ | Knight <i>et al.</i> (427) |
| Airways (human) | Fibroblasts | Proliferation | Akers <i>et al.</i> (428) |
| Airways (human) | HASMC | [Ca ²⁺] _i ↑, histamine-mediated contraction ↑ | Chambers <i>et al.</i> (294) |
| Airways (human) | HBEC, A459, BEAS-2B | [Ca ²⁺] _i ↑, IL-6 ↑, IL-8 ↑, PGE ₂ ↑ | Asokanathan <i>et al.</i> (77) |
| Airways (human) | SAECs, A549 | GM-CSF ↑, eotaxin ↑ | Vliagoftis <i>et al.</i> (272) |
| Airways (human) | SMC | Proliferation, via a PTX-sensitive G protein, [Ca ²⁺] _i ↑, PKC, PLC, IP ₃ | Berger <i>et al.</i> (318, 320) |
| Airways (human, guinea pig, rat, mouse) | Bronchial, epithelial (isolated airway) | COX-dependent bronchorelaxation, bronchoconstriction inhibited | Cocks <i>et al.</i> (292) |
| Airways (mouse) | Model | Inhibits neutrophil recruitment; eosinophil recruitment, hyperreactivity, allergic inflammation | Moffatt <i>et al.</i> (270) Schmidlin <i>et al.</i> (271) |

TABLE 2. *Continued*

| Tissue | Cell type | Effect | Refs. |
|---------------------------------|---|--|---|
| Airways (mouse) | Tracheal SMC | Relaxation, PGE ₂ ↑, COX-2, E-type prostanoid-2 receptor activation | Lan <i>et al.</i> (152, 153) |
| Airways (rat) | Epithelium, trachea, bronchi | Contraction, epithelium-dependent relaxation | Chow <i>et al.</i> (91) |
| Airways (guinea pig) | Epithelium trachea | Reduction of response to LPS, potentially mediated via PKC-ε and PKC-α | Oshiro <i>et al.</i> (429) |
| Blood (human) | Platelets | [Ca ²⁺] _i ↑, platelet aggregation, (RgpB)-induced | Lourbakos <i>et al.</i> (329) |
| Blood vessels (human) | HUVEC | [Ca ²⁺] _i ↑, IL-6 ↑, COX-2 ↑, PGI ₂ ↑; Rho A, WPD exocytosis | Chi <i>et al.</i> (72) Houliston <i>et al.</i> (78) Klarenbach <i>et al.</i> (358) |
| Blood vessels (human) | HUVEC | FXa → [Ca ²⁺] _i ↑, EPR-1 dependent | Bono <i>et al.</i> (322) |
| Blood vessels (human) | Model | Vasodilatation | Robin <i>et al.</i> (430) |
| Blood vessels (human) | Vascular wall cells (HAoAF, HCSCM, HASMC) | FXa: proliferation, [Ca ²⁺] _i ↑, IL-6 ↑, prothrombotic TF ↑; TF/FVIIa-induced cell migration | McLean <i>et al.</i> (86) Marutsuka <i>et al.</i> (431) |
| Blood vessel (mouse) | Isolated mesenteric arteriole | Relaxation (NO-cGMP-dependent and independent) | McGuire <i>et al.</i> (432) |
| Blood vessels (mouse) | Mouse model of hindlimb ischemia | Angiogenesis, hemodynamic recovery | Milia <i>et al.</i> (433) |
| Blood vessels (rat) | Aorta and jugular veins | LPS → PAR ₂ ↑, regulation of blood pressure, relaxation via endothelium and NO-dependent mechanism | Hwa <i>et al.</i> (248) Cicala <i>et al.</i> (434) Compton <i>et al.</i> (259) |
| Bone (rat) | Osteoblasts | [Ca ²⁺] _i ↑ | Abraham <i>et al.</i> (254) |
| Brain (human) | Meningioma cells | [Ca ²⁺] _i ↑ | Kaufmann <i>et al.</i> (301) |
| Brain (human) | CCF-STTG1 | TNF-α secretion; trypsin: ERK, p38 | Kim <i>et al.</i> (435) |
| Brain (rat) | Astrocytes | [Ca ²⁺] _i , proliferation | Wang <i>et al.</i> (185) |
| Brain (rat) | RBCE | [Ca ²⁺] _i ↑ | Domotor <i>et al.</i> (302) |
| Cardiovascular system (bovine) | VSMC | [Ca ²⁺] _i ↑, NFκB ↑ | Bretschneider <i>et al.</i> (321) |
| Cardiovascular system (human) | CASM | FXa → ERK-1/2 phosphorylation, mitogenesis | Koo <i>et al.</i> (323) |
| Cardiovascular system (human) | HUVEC, endothelial cultures | [Ca ²⁺] _i ↑, vWf release, mitogenesis | Mirza <i>et al.</i> (97) Storck <i>et al.</i> (266) |
| Cardiovascular system (human) | SMC | Mitogenesis, PDGF release | Bono <i>et al.</i> (436) |
| Cardiovascular system (rat) | Endothelium (aortic rings) | Relaxation, NO ↑ | Kawabata <i>et al.</i> (437) |
| Cardiovascular system (rat) | Neonatal ventricular cardiomyocytes | [Ca ²⁺] _i ↑, IP ₃ , ERK-1/2, p38, hypertrophy | Sabri <i>et al.</i> (222) |
| Cardiovascular system (rat) | SMC | Relaxation/contraction | Al Ani <i>et al.</i> (246) Saifeddine <i>et al.</i> (250) Emilsson <i>et al.</i> (438) Roy <i>et al.</i> (439) |
| Circulatory system (rat) | Model | Biphasic change in MABP, NO and nerval-modulated hypertension, NO-modulated hypotension | Cicala <i>et al.</i> (411) |
| Exocrine glands (mouse and rat) | Salivary, parotid, sublingual | Glandular exocrine secretion, saliva production, amylase secretion, mucin secretion (via TK activation, partially NO involved) | Kawabata <i>et al.</i> (310, 311, 440) |

TABLE 2. *Continued*

| Tissue | Cell type | Effect | Refs. |
|--------------------------|--|--|--|
| Gallbladder (guinea pig) | SMC | Prostanoid-mediated contraction | Tognetto <i>et al.</i> (370) |
| GI tract (human) | MKN-1 | Integrin $\alpha_5\beta_1$ -dependent adhesion to fibronectin (high) and vitronectin (low), G _i -protein, Src kinase, proliferation | Miyata <i>et al.</i> (441) |
| GI (guinea pig) | Pepsinogen-secreting (chief) cells | Stimulation of pepsinogen secretion | Fiorucci <i>et al.</i> (442) |
| GI tract (rat) | Gastric SMC | Contraction | Al Ani <i>et al.</i> (246) Saifeddine <i>et al.</i> (250) |
| GI tract (rat) | Intestinal-neurogenic mechanism | Mucus secretion ↑, cytoprotection (via CGRP1 and NK ₂ stimulation, triggered by CGRP tachykinin release from sensory neurons) | Kawabata <i>et al.</i> (312) |
| GI (human) | Colon mast cells | Up-regulation of tryptase and histamine release | He <i>et al.</i> (443) |
| GI tract (rat) | Model approach | Acid secretion suppressed (independently of prostanoid production and sensory neurons) | Nishikawa <i>et al.</i> (444) |
| Heart (rat) | Isolated | Inflammation ↓, neutrophil recruitment ↓, endothelium-dependent coronary vasodilation, EDHF ↑, vanilloid receptor-1 activation, c-fibers involved | Napoli <i>et al.</i> (345) McLean <i>et al.</i> (445) |
| Immune system (human) | Eosinophils | Superoxide production, degranulation | Miike <i>et al.</i> (267) |
| Immune system (human) | Jurkat T-leukemic cell line | Vav1, ZAP-70, SLP-76 | Bar-Shavit <i>et al.</i> (236) |
| Immune system (human) | Mononuclear cells | Cathepsin G → [Ca ²⁺] _i ↑ | Roche <i>et al.</i> (372) |
| Immune system (human) | Monocytes, macrophages | [Ca ²⁺] _i ↑ | Colognato <i>et al.</i> (375) |
| Immune system (human) | Neutrophils | Gingipain-R → [Ca ²⁺] _i ↑ | Lourbakos <i>et al.</i> (27) |
| Immune system (human) | Neutrophils | [Ca ²⁺] _i ↑, CD11b ↑ | Howells <i>et al.</i> (252) |
| Immune system (rat) | Leukocytes, mast cells | [Ca ²⁺] _i ↑, rolling ↑, adhesion ↑, migration ↑ | Vergnolle (262) D'Andrea <i>et al.</i> (147) |
| Intestine (guinea pig) | Taenia coli | Relaxation (only AP) | Cocks <i>et al.</i> (376) |
| Intestine (guinea pig) | Submucosal neurons | Mast cell degranulation (tryptase) → hyperexcitability | Reed <i>et al.</i> (256) |
| Intestine (human) | Colon cancer cell lines (T84, Caco-2, HT-29, C1.19A) | Autocrine-secreted trypsinogen activates PAR ₂ | Ducroc <i>et al.</i> (446) |
| Intestine (human) | HT-29 | [Ca ²⁺] _i ↑, proliferation, TGF- α ↑, ERK-1/2 phosphorylation, EGFR transactivation | Darmoul <i>et al.</i> (447, 467) |
| Intestine (human) | Rectal mucosa biopsies | Cl ⁻ secretion ↑, [Ca ²⁺] _i ↑ required | Mall <i>et al.</i> (448) |
| Intestine (mouse) | Distal colon | Cl ⁻ and K ⁺ secretion | Cuffe <i>et al.</i> (449) |
| Intestine (mouse) | Gastric fundus | Relaxation/contraction | Cocks <i>et al.</i> (376) |
| Intestine (mouse) | Model | Luminal proteinases → inflammation, PAR ₂ ↑, granulocyte infiltration, wall thickness ↑, tissue damage ↑, T-helper cell type 1 cytokine | Cenac <i>et al.</i> (340) |
| Intestine (mouse) | Model | Modulate GI transit, L-type Ca ²⁺ channel | Kawabata <i>et al.</i> (161) |
| Intestine (mouse) | Small intestine | Induce contraction through NK receptors (NK ₁ and NK ₂) | Zhao and Shea-Donohue (450) |

TABLE 2. *Continued*

| Tissue | Cell type | Effect | Refs. |
|---|---|--|--|
| Intestine (mouse) | Model (epithelial, neuronal) | TNBS-induced colitis ↓ (antiinflammatory), myeloperoxidase activity ↓, CD44 expression on lamina propria T lymphocytes ↓, IFN-γ ↓, IL-2 and IL-12 ↓, COX-2 ↓, iNOS ↓, TNF-α ↑ | Fiorucci <i>et al.</i> (298) |
| Intestine (mouse) | Model | NO and capsaicin-sensitive afferent neurons involved in colonic inflammation and paracellular permeability | Cenac <i>et al.</i> (451) |
| Intestine (porcine) | Model | Opioid- and prostanoid-modulated anion secretion, neurogenic mechanism | Green <i>et al.</i> (313) |
| Intestine (rat) | Chief cells of gastric mucosa | Pepsin secretion ↑ | Kawao <i>et al.</i> (452) |
| Intestine (rat) | Colon | Spinal Fos ↑, permeability ↑, (pot. visceral hyperalgesia) | Coelho <i>et al.</i> (308) |
| Intestine (rat) | hBRIE 380 (epithelial cell line) | [Ca ²⁺] _i ↑, IP ₃ , AA, PGE ₂ , PGF _{1α} | Böhm <i>et al.</i> (154) Kong <i>et al.</i> (253) |
| Intestine (rat) | Longitudinal (lm) and circular muscle (cim) | Biphasic contraction, relaxation; lm, contraction: L-type Ca ²⁺ channel, sr-derived Ca ²⁺ , PKC, PLC, TK; relaxation: L-type Ca ²⁺ channel, TK, apamin-sensitive K ⁺ channels; cim: sr-derived Ca ²⁺ , apamin-sensitive K ⁺ channels | Mule <i>et al.</i> (162, 163) |
| Kidney (mouse) | Cortical duct cells | Cl ⁻ secretion | Bertog <i>et al.</i> (453) |
| Kidney (rat) | Afferent arteriole | NO dependent and independent vasodilation | Trottier <i>et al.</i> (347) |
| Nervous system (guinea pig) | Enteric neurons (intestinal) | Excitatory response PLC and [Ca ²⁺] _i dependent | Gao <i>et al.</i> (319) |
| Nervous system (guinea pig) | Myenteric neurons | [Ca ²⁺] _i ↑, PLC, sphingosine kinase | Corvera <i>et al.</i> (196) Garrido <i>et al.</i> (382) |
| Nervous system (CNS) (human) | A172 (glioblastoma cell line) | [Ca ²⁺] _i ↑, PKC-α, PKC-γ, PKC-λ, proliferation ↓ | Okamoto <i>et al.</i> (317) |
| Nervous system (wobbler mutant mouse) | Motor neuron | PAR ₁ ↑ → motoneuron degeneration and neuronal cell death | Festoff <i>et al.</i> (193) |
| Nervous system (PNS) (rat and mouse) | Nociceptive primary afferent neurons | Fos ↑, SP ↑, NK ₁ receptor activation, mechanical hyperalgesia, thermal hyperalgesia (via transactivation of capsaicin receptor) | Kawabata <i>et al.</i> (304) Vergnolle <i>et al.</i> (305) Kawao <i>et al.</i> (454) |
| Nervous system (PNS, sensory) (rat) | C-fibers | [Ca ²⁺] _i ↑, SP ↑, CGRP ↑, edema ↑, plasma extravasation, leukocyte recruitment | Steinhoff <i>et al.</i> (243) |
| Nervous system (mast cell depleted rat) | Sensory neurons | Spinal Fos ↑ | Kawabata <i>et al.</i> (307) |
| Nervous system (CNS) (rat) | Thoracic DRG | Enhances capsaicin- and KCl-evoked CGRP release, Fos ↑ | Hoogerwerf <i>et al.</i> (314) |
| Pancreas (dog) | PDEC | [Ca ²⁺] _i ↑, Cl ⁻ and K ⁺ conductance ↑ | Nguyen <i>et al.</i> (315) |
| Pancreas (human) | MIA PaCa-2 | [Ca ²⁺] _i ↑, PKC activation, inositol 1,4,5-triphosphate, proliferation | Kaufmann <i>et al.</i> (455) |
| Pancreas (mouse) | Pancreatic acini | Amylase secretion ↑, NO involved | Kawabata <i>et al.</i> (440) |
| Pancreas (mouse, rat) | Pancreatic duct cells | Pancreatic juice secretion | Kawabata <i>et al.</i> (311) |
| Pancreas (rat) | Pancreatic acini | Amylase secretion | Böhm <i>et al.</i> (154) |
| Skeletal muscle (rat) | Myoblasts | [Ca ²⁺] _i ↑, proliferation | Chinni <i>et al.</i> (456) |

TABLE 2. *Continued*

| Tissue | Cell type | Effect | Refs. |
|---|--|--|--|
| Skin (human) | HDMEC | IL-6 ↑, IL-8 ↑, IL1β ↑, NFκB ↑, eNOS ↑ | Shpacovitch <i>et al.</i> (263, 284) |
| Skin (oral mucosa) (human) | HSC-2, KB cells (oral epithelial cell line) | (RgpB)-induced: [Ca ²⁺] _i ↑, IL-6 ↑; proteinase-3 activates PAR ₂ | Lourbakos <i>et al.</i> (28) Uehara <i>et al.</i> (341) |
| Skin (human) | Keratinocytes | [Ca ²⁺] _i ↑, inhibits proliferation and differentiation, phagocytosis ↑, pigmentation, melanin ingestion ↑, IL-6 ↑, GM-CSF expression ↑, NFκB activation → ICAM-1 ↑, Rho-dependent phagocytosis | Santulli <i>et al.</i> (247) Derian <i>et al.</i> (275) Wakita <i>et al.</i> (283) Hou <i>et al.</i> (282) Schechter <i>et al.</i> (289) Steinhoff <i>et al.</i> (24) Seiberg <i>et al.</i> (457) Sharlow <i>et al.</i> (458) Buddenkotte <i>et al.</i> (287) Scott <i>et al.</i> (468) |
| Skin (human) | Mast cells | [Ca ²⁺] _i ↑, degranulation; PAR ₂ induces pruritus | D'Andrea <i>et al.</i> (147) Steinhoff <i>et al.</i> (24) |
| Skin (human) | NCTC2544 (keratinocyte cell line) | c-Jun activation, p38 phosphorylation, IKKα, IKKβ, NFκB activation (partially via PKC) | Kanke <i>et al.</i> (286) |
| Skin (mouse PAR ₂ ^{-/-}) | Model | Type IV allergic dermatitis | Kawagoe <i>et al.</i> (288) Seeliger <i>et al.</i> (285) |
| Testes (human) | Fibroblasts, HEFF2, HMC-1 | Tryptase and SLIGKV-induced proliferation via COX-2 → PGJ ₂ → PPAR-γ | Frungieri <i>et al.</i> (245) |
| Testes (human) | Vascular cremaster muscle (perivenula injections) | Leukocyte rolling ↑, rolling velocity ↓, P-selectin ↑, inflammation | Lindner <i>et al.</i> (268) |
| Testes (rat) | Peritubular cells | [Ca ²⁺] _i ↑, PKC activation | Meinhardt <i>et al.</i> (459) |
| Ureter (mouse) | Circular muscle | Beating ↑ | Moffatt and Cocks (460) |
| Urogenital tract (human) | RT4 | AA ↑, PGE ₂ release, iPLA2 activation | McHowat <i>et al.</i> (170) |
| Cell line (Chinese hamster) | CHO | Ternary complex FVIIa/TF/FXa activates PAR ₂ | Riewald and Ruf (241) |
| Cell line (Chinese hamster) | CHO | Acrosin → [Ca ²⁺] _i ↑ | Smith <i>et al.</i> (26) |
| Cell line (Chinese hamster) | CHO | PAR ₂ N-linked glycosylation regulates receptor expression and agonist sensitivity | Compton <i>et al.</i> (461) |
| Cell line (rat) | KNRK | [Ca ²⁺] _i ↑, PKC mediates termination of signaling | Böhm <i>et al.</i> (154) |
| Cell line (human) | PC-3 | Genistein → PAR ₂ mRNA ↓ | Li and Sarkar (462) |
| Cell line (human) | HMC-1 | Induction of TNF-α secretion | Kim <i>et al.</i> (463) |
| Eye (human) | Corneal epithelial cells (HCECs) | [Ca ²⁺] _i ↑, IL-6 ↑, IL-8 ↑, TNF-α ↑ | Lang <i>et al.</i> (339) |
| Cell line (human) | LNCaP (left supraclavicular lymph node metastasis) | RhoA, cytoskeletal reorganization | Greenberg <i>et al.</i> (380) |
| PAR₃-agonist mediated effects | | | |
| Blood (mouse) | Platelets | Platelet activation, PI hydrolysis, ATP secretion | Ishihara <i>et al.</i> (18, 324) Kahn <i>et al.</i> (19) |
| Blood (PAR ₃ ^{-/-} , PAR ₄ ^{-/-} mouse) | Platelets | Protection against thrombosis, cofactor for thrombin cleavage | Nakanishi-Matsui <i>et al.</i> (39) Sambrano <i>et al.</i> (40) Weiss <i>et al.</i> (325) |
| Immune system (human) | Jurkat T-leukemic cells | Vav1, ZAP-70, SLP-76 phosphorylation | Bar-Shavit <i>et al.</i> (236) |

TABLE 2. *Continued*

| Tissue | Cell type | Effect | Refs. |
|---|--|---|--|
| PAR₄-agonist mediated effects | | | |
| Airway (human) | HBEC (primary bronchial epithelial cells, A459, BEAS-2B) | IL-6 ↑, IL-8 ↑, PGE ₂ ↑, [Ca ²⁺] _i ↑ | Asokanathan <i>et al.</i> (77) |
| Airway (mouse) | Tracheal SMC | Contraction/relaxation, PGE ₂ ↑ | Lan <i>et al.</i> (152, 153) |
| Airway (rat) | Epithelium, trachea, bronchi | Relaxation (epithelium-dependent) | Chow <i>et al.</i> (91) |
| Blood (human) | Platelets | Gingipain → [Ca ²⁺] _i ↑, platelet aggregation; cathepsin G activates PAR ₄ | Sambrano <i>et al.</i> (330) Lourbakos <i>et al.</i> (329) |
| Blood (human) | Platelets | [Ca ²⁺] _i ↑, ADP-dependent platelet aggregation, TXB ₂ ↑ | Andersen <i>et al.</i> (122) Chung <i>et al.</i> (334) Covic <i>et al.</i> (333) Kahn <i>et al.</i> (19) Henriksen and Hanks (117) |
| Blood (human, mouse) | Platelets | Activation, thrombosis protection | Sambrano <i>et al.</i> (40) Kahn <i>et al.</i> (19, 128) |
| Blood (human, mouse) | Platelets | Adenylyl cyclase inhibition via ADP release, P2Y ₁₂ -receptor activation, G _i -dependent and -independent | Kim <i>et al.</i> (201) |
| Blood (rat) | Platelets | Endostatin release | Ma <i>et al.</i> (118) |
| Brain (rat) | Astrocytes | [Ca ²⁺] _i ↑, toxic effect | Wang <i>et al.</i> (185) |
| Cardiovascular system (human) | Endothelium | IL-1 α and TNF- α treatment → PAR ₄ ↑ relaxation | Hamilton <i>et al.</i> (464) |
| GI tract (rat) | Esophageal smooth muscle | Relaxation | Kawabata <i>et al.</i> (371) |
| Immune system (rat) | Leukocytes | Rolling ↑, adhesion ↑, migration ↑ | Vergnolle <i>et al.</i> (74) |
| Nervous system/intestine (guinea pig) | Enteric neurons | Excitatory response, dependent on PLC and [Ca ²⁺] _i ↑ | Gao <i>et al.</i> (319) |
| Vascular system (human) | VSMC | [Ca ²⁺] _i ↑, ERK-1/2 activation, mitogenesis | Bretschneider <i>et al.</i> (220) |
| Transfected (<i>Xenopus</i>) | Oocyte | [Ca ²⁺] _i ↑ | Kahn <i>et al.</i> (19) |
| Cardiovascular system (PAR ₁ ^{-/-} mouse) | Cardiomyocytes, fibroblasts | Early ERK-1/2 activation involves G _q /PLC/PKC and Src; late ERK-1/2 activation involves Src, EGFR, and/or ErbB2; IP accumulation, hypertrophy | Sabri <i>et al.</i> (338) |

↑, Up-regulated/activated; ↓, down-regulated; →, resulting in; AA, arachidonic acid; AMs, alveolar macrophages; ANF, atrial natriuretic factor; ASM, airway SMCs; BMCMC, bone marrow-derived cultured mast cells; BSMC, bronchial SMCs; CaMLCK, calmodulin myosin light-chain kinase; CASM, coronary artery SMCs; CHO, Chinese hamster ovary; CTGF, connective tissue growth factor; CVEGF, vascular endothelial growth factor C; Cyr61, cysteine rich protein 61; EDHF, endothelium-derived hyperpolarizing factor; eNOS, endothelial NO synthase; EPCR, endothelial protein C receptor; ErbB2, receptor protein-tyrosine kinase ErbB2 (erythroblastosis); FXa, factor Xa; Fyn, Src-family tyrosin kinase; GEC, glomerular epithelial cells; GEF, guanine nucleotide exchange factor; GMC, glomerular mesangial cells; Grb-2, growth factor binding protein-2; HAEC, human aortic endothelial cells; HAOAF, human adventitial fibroblasts; HASMC, human airway smooth muscle cells; HBE(C), human bronchial epithelial (cells); HCASMC, human coronary artery smooth muscle cells; HCEC, human corneal epithelial cells; HDMEC, human dermal microvascular endothelial cells; HFL, human fetal lung; HMC, human mast cells; HPAEC, human pulmonary artery endothelial cells; Hsp, heat-shock protein; HUR, human urothelial cells; LPS; lipopolysaccharide; MABP, mean arterial blood pressure; MEK-1, MAPK kinase-1; ncR-uPAR, noncoding RNA upstream of the *PAR1* gene; NHBE, normal human bronchial epithelial cells; NMDA, N-methyl-D-aspartate; NRVM, neonatal rat ventricular myocytes; P2Y₁₂-receptor, platelet ADP receptor subtype; PBMC, peripheral blood mononuclear cells; PC, prostate cancer; PDEC, pancreatic duct epithelial cells; PI, phosphatidylinositol; PI₃P, PI-trisphosphate; PNS, peripheral nervous system; PPAR γ , peroxisome proliferator-activated receptor γ ; RANTES, regulated upon activation, normal T cells expressed and secreted; RASMC, rat aortic smooth muscle cells; RBCE, rat brain capillary endothelial cells; RgpB, arginine-specific gingipain B; ROCK, Rho-associated coiled-coil forming protein kinase; SAEC, small airway epithelial cells; SHP-1, SH2 domain containing nontransmembrane protein tyrosin phosphatase-1; TF, tissue factor; TFFs, trefoil factors; TK, tyrosine kinase; TNBS, trinitrobenzene sulfonic acid; TX, thromboxane; vWf, von Willebrand factor; WAF, wild-type p53 associated factor; WPB, Weibel-Palade body.

bin (*e.g.*, platelet aggregation, angiogenesis, endothelial cell permeability, vasoregulation, gene regulation, leukocyte trafficking, immunomodulation) could be attributed to the activation of its GPCR (40, 47–53).

PAR₁ has been detected in a variety of tissues, including platelets; endothelial cells; fibroblasts; monocytes; T cells

positive for CD 8, CD 16, and either CD 56 or CD 57 (54, 55); natural killer (NK) cells (48); CD 34⁺ hematopoietic progenitor cells (56); dental pulp cells (57); smooth muscle cells (SMC); epithelial cells; neurons; glial cells; mast cells; and certain tumor cell lines (17, 54, 58–61). A receptor with high affinity for thrombin has also been detected in rat peritoneal




FIG. 2. Diagram showing the major G protein-mediated signaling pathways coupled to PAR₁. Dashed lines or circles represent signaling pathways or intermediates that are not fully revealed to be activated by PAR₁, but are in favor of other G protein-coupled receptors or are typical intermediate-accompanying molecules. Drawing represents a composition of signaling events of different tissues, cell types, and species (also see Table 2).

macrophages (62). It should be pointed out, however, that PAR₁ very likely does not represent the only target for thrombin, in that other (non-PAR) high-affinity binding sites for thrombin [*e.g.*, on platelets or macrophages (62)] and other conserved thrombin sequences apart from the catalytic domain (63) may also play a role in the cellular actions of thrombin in a variety of target tissues.

A. Vasculature and heart: PAR₁ antagonists—a novel potential approach for the treatment of cardiovascular diseases

PAR₁ can potentially regulate vascular function under both physiological as well as pathophysiological conditions (15, 42). A number of studies have revealed that thrombin and other agonists of PAR₁ can affect the vascular tone. For example, before the discovery of PAR₁, it was observed that thrombin can regulate vascular tone by an endothelial-dependent mechanism involving the release of nitric oxide (NO) (64). It is now recognized that this effect of thrombin is due to the activation of PAR₁. Moreover, thrombin and PAR₁ agonists can contract vascular SMC (VSMC) by a direct effect that requires extracellular Ca²⁺ (64). Thus, in isolated

coronary artery and aorta preparations, PAR₁ mediates relaxation (64, 65). In contrast, PAR₁ agonists contract human placental and umbilical arteries (66). Furthermore, PAR₁ mediates prostanoid generation and secretion, cellular contraction and barrier dysfunction, and enhanced expression of platelet-derived growth factor (PDGF) in human and bovine endothelial cells (67). Interestingly, progestins such as progesterone or gestodene up-regulate PAR₁ expression and thereby stimulate thrombin-induced tissue factor-dependent surface procoagulant activity in the rat vascular system, suggesting a role of thrombin in hormone-induced thrombosis via PAR₁ activation (68).

Recent observations support a role of thrombin and PAR₁ in regulation of functions normal (69–71, 73) and atherosclerotic (75) endothelium. In normal human arteries, PAR₁ is mostly confined to the endothelium, whereas during atherogenesis, its expression is enhanced in regions of inflammation associated with macrophage influx, smooth muscle cell proliferation, and an increase in mesenchymal-like intimal cells (75). *In vivo*, a neutralizing antibody to PAR₁ has been observed to reduce expression of mRNA for the proliferating cell nuclear antigen, an index of intimal and

neointimal smooth muscle cell accumulation in rat arteries during balloon angioplasty. These data suggest that PAR₁ regulates proliferation and accumulation of neointimal SMC during tissue repair (76).

Thrombin and PAR₁ agonists cause a rapid but transient contraction of endothelial cells in various tissues resulting in gap formation and increased permeability of plasma proteins and inflammatory cells. Several mediators are involved in this PAR₁ modulated process such as cytokines, kinins, and biogenic amines (67, 72, 77-95).

It was also revealed that PAR₁ plays a crucial role during vascular ontogenesis. Interestingly, about 50% of the PAR₁-deficient mouse embryos die at midgestation with bleeding from multiple sites. However, a PAR₁ transgene driven by an endothelial-specific promoter prevented death of PAR₁-deficient embryos (96), indicating that PAR₁ modulates endothelial cell function in developing blood vessels, thereby contributing to vascular development and homeostasis in mice (88, 96).

Vascular wall cells respond to the procoagulant factor Xa by an increase in intracellular Ca²⁺ ([Ca²⁺]_i) and by assembly of this factor into prothrombinase complexes that even enhance this effect. Additionally, factor Xa stimulation of PAR₁ leads to an increased production of tissue factor, a prothrombotic agent, underlining the important role of PAR₁ for thrombosis (86). Together, these results point to a pivotal role of PAR₁ in vascular homeostasis and thrombosis.

PAR₁ agonists are also mitogenic, stimulating proliferation of endothelial cells (97, 98), mediating endothelium-dependent relaxation to thrombin and trypsin in human pulmonary arteries (99), and causing the release of IL-6 from human microvascular endothelial cells (HMEC) (72). Because PAR₁ up-regulates α 1(I)-procollagen synthesis in VSMC, one may speculate that PAR₁ plays a role in vascular wound healing (100).

Finally, factors that regulate PAR₁ function on endothelial cells have also been studied. For example, PAR₁ is down-regulated by shear stress (101) and inflammatory mediators such as TNF- α (102), and is directly modulated by thrombomodulin (103) in human endothelial cells. On the other hand, cyclic mechanical stress leads to an up-regulation of PAR₁ in VSMC (104). In contrast to PAR₂, little is known about the inflammatory mediators that regulate PAR₁ expression in unstimulated or stimulated endothelial cells.

As of yet, only a few studies exist about the role of GRKs in regulating PAR₁ in endothelial cells. Only recently, Tirupathi *et al.* (105) found a crucial role of the isoform GRK-5 on thrombin-induced desensitization of PAR₁.

It is also necessary to mention the recently demonstrated role of PAR₁ in vascular associated pathological processes in which thrombin is involved. The role of PAR₁ in thrombus formation was recently investigated in an animal model. Cook *et al.* (106) examined the role of PAR₁ in intravascular thrombus formation in an experimental model of arterial thrombosis in the African green monkey. Using a blocking antibody to PAR₁, this group demonstrated a dramatically diminished thrombin-stimulated aggregation and secretion of human platelets, whereas platelet activation induced by the PAR₁ agonist SFLLR-NH₂ was not affected. These results demonstrated that a specific blockade of PAR₁ activation by

thrombin can prevent arterial thrombosis in this animal model without significantly altering hemostatic parameters. The data suggest that PAR₁ is crucially involved in this disease and is an attractive antithrombotic therapeutic target, although it probably has to be inhibited in concert with the low-affinity thrombin receptor PAR₄ to fully prevent platelet activation (see Section II.A).

A demonstrated role of PAR₁ in intravascular thrombus formation and knowledge about side effects of thrombin inhibitors made appealing an idea to investigate the potency of PAR₁ antagonists as antithrombotic therapeutic drugs. Indirect thrombin inhibitors like heparin and warfarin, which prevent the circulation of thrombin, or the newly developed direct thrombin inhibitor ximelagatran (465) are currently used for the treatment of cardiovascular diseases, *e.g.*, myocardial infarction, atherosclerosis, and thrombosis. However, they carry potential bleeding liabilities as an undesirable side effect when administered in chronic patients. Because it is now well known that human platelet responses to thrombin are mainly mediated via PAR₁ (19), direct inhibition of this receptor instead of the proteinase represents an attractive way to circumvent possible side effects by thrombin inhibitors.

PAR₁ possesses several extra- and intracellular sites that are crucial for its function and that might represent possible targets for antagonists (107). On the extracellular side, blocking of the cleavage site or the hirudin-like domain could inhibit N-terminal cleavage. Bradykinin or peptides derived thereof, also known as thrombostatins, have been shown to prevent thrombin-induced platelet aggregation (108). In addition, antibodies directed against both the cleavage site and the hirudin-binding site have been generated (106, 109). Binding of the antagonist to either the tethered ligand or extracellular loop 2 prevents interaction of the novel N terminus with the extracellular loop. Several small synthetic antagonists have been developed that block the binding site of the tethered ligand. However, peptide antagonists based on modifications of the tethered ligand were relatively unstable or showed only limited inhibitory activity (35). Thus, a second generation of indole or indazole-based peptide-mimetic antagonists was created that block binding of both the tethered ligand and the proteinase (110). One of these was recently shown to prevent thrombus formation in nonhuman primates (107). In addition, several nonpeptide inhibitors were developed. However, it was not reported whether these compounds were PAR₁-specific (111). On the intracellular side, the G protein binding sites are possible targets for pharmacological intervention. One approach used the transfection of endothelial cells with a G α minigene (112). However, this might suppress all signaling pathways that involve G α . Another more specific approach used so-called "pepducins," peptides that were derived from the third intracellular loop of PAR₁. These peptides were able to permeate the cells and also carried a membrane anchor (113, 114).

In summary, two preclinical studies with primates demonstrated that PAR₁ antagonists have indeed a therapeutic potential for the treatment of cardiovascular diseases (106, 107). However, extensive research needs to be done for the development of orally administered PAR₁ antagonists be-

cause only those drugs are thought to be suitable for chronic patients (111).

B. Platelets

Activation of platelets by thrombin or APs specific for PAR₁ is characterized by calcium influx; cytoskeletal reorganization; platelet aggregation; degranulation (17, 115, 116); thromboxane production (117); mobilization of the adhesion molecule P-selectin and the CD40 ligand to the platelet surface (119); stimulation of serotonin and epinephrine release (120); enhanced expression of CD62, PDGF (AB) and PDGF(BB) (121); and exposure of anionic phospholipids (phosphatidylserine, phosphatidylethanolamine) that support blood clotting (122). Thrombin has also been demonstrated to stimulate vascular endothelial growth factor release in megakaryocytes and platelets (123). The growth factor in turn is able to induce proliferation of endothelial cells. In addition, tissue inhibitor of matrix metalloproteinase (MMP)-4 that colocalized with MMP-2 in resting platelets was released upon platelet aggregation induced by collagen and thrombin. However, a direct effect using specific PAR₁ agonists has not been shown yet (124). The density of human PAR₁ on the platelet cell surface was estimated to be about 1500 molecules per resting platelet (125). A recently reported intronic polymorphism in the PAR₁ gene leads to decreased expression on the platelet surface and thus to a lower response to the AP (126, 127). PAR₁ is a high-affinity thrombin receptor in humans: receptor blocking using an antagonist, domain specific antibodies, or simply by desensitization led to inhibition of responses at 1 nM thrombin but only to attenuated responses at 30 nM (128).

High-affinity thrombin binding of platelets is possibly associated via the membrane glycoprotein (GP)Ib-IX-V complex. This interaction is lost in patients suffering from the Bernard-Soulier syndrome, a disease where GPIb-IX-V is not expressed (129). The same condition can be mimicked using either monoclonal antibodies directed against GPIb or proteolytic removal of this protein from the platelet surface (130). Under these conditions, platelet aggregation is either delayed or requires higher thrombin concentrations.

Recently, Schmidt *et al.* (131) reported that the gene encoding IQ motif containing GTPase activating protein-2, a scaffolding protein for filopodial extension during platelet activation, was identified within the human PAR gene cluster at 5q13, flanked by the PAR1 gene and encompassing the PAR3 gene. Only thrombin- or PAR₁-AP-activated platelets showed a rapid translocation of IQ motif containing GTPase activating protein-2 to the platelet cytoskeleton. This suggests that a functional genomic unit evolved to mediate thrombin signaling events in humans (132).

PAR₁ on platelets also seems to play an important role during bacterial invasion: the cysteine proteinase gingipain from *Porphyromonas gingivalis* was reported to activate the receptor leading to uncontrolled activation of the host cells (28). The enzyme streptokinase derived from *Streptococcus sp.* is widely used in the treatment of coronary thrombosis. It functions as a plasminogen activator that forms an active complex with plasminogen of the host that is able to cleave PAR₁ (133). In mouse platelets, PAR₁ does not seem to play

a role: PAR₁ expression was hardly detectable, and a specific AP did not activate rodent platelets (23, 134, 135). Moreover, platelets derived from PAR₁-deficient mice responded to thrombin-like wild-type platelets (135).

C. Immune cells

For some time, an important role for serine proteinases and PARs for the modulation of leukocyte effector functions has been proposed (136). As of yet, only limited data about the regulation of immune and inflammatory responses by PARs are available. It is well documented that PARs influence monocyte motility and chemotaxis, modulate pleiotropic cytokine responses, contribute to mononuclear cell proliferation, and induce apoptosis in various immune cells (84, 137). Recently, it was shown that PAR₁ is capable of stimulating elastase secretion from macrophages (138). Moreover, functional thrombin receptors are expressed on human T lymphoblastoid cells (139). However, the receptor subtype(s) (PAR₁, PAR₃, and PAR₄) have not been characterized as of yet. Human α -thrombin stimulated five different T lymphoblastoid cell lines to increase intracellular free Ca²⁺ concentrations and to activate protein kinase C (PKC), whereas thrombin receptors were absent in B cell lines. Thus, PARs may regulate T cell function during inflammation and immune responses, but the precise mechanism is still unknown. Granzyme A from cytotoxic and helper T lymphocytes appears to interact with PAR₁ in astrocytes to regulate thrombin function (140). Interestingly, granzyme A blocked the thrombin-induced platelet aggregation in a dose-dependent manner by cleaving PAR₁, presumably downstream from its thrombin targeted activation site, thereby reducing the response to subsequent challenge with thrombin; but granzyme A itself did not induce a signal in thrombin-stimulated platelets. Thus, granzyme A may interact with PAR₁ in a manner that is insufficient to cause aggregation, but sufficient to disarm the ability of the receptor to respond to thrombin. Finally, these observations demonstrate that granzyme A release occurring during immune responses within blood vessels would not directly cause platelet aggregation. Thus, the T cell-derived proteinase granzyme A seems to inhibit responses triggered by thrombin during inflammation or tissue injury.

PAR₁ modulates chemotaxis in inflammatory cells. Besides IL-8 secretion (71), thrombin induces production of monocyte chemoattractant protein-1 (MCP-1) in monocytes, probably via PAR₁ (58). However, other PAR₁-specific agonists were not used in this study. Therefore, it cannot be excluded that other thrombin receptors are involved. IL-8 secretion is up-regulated by interferon- γ (IFN- γ) and diminished by prostaglandin (PG)E₂ (51), suggesting a role in cytokine modulation. Furthermore, PAR₁ is capable of inducing IL-1 as well as IL-6 production in monocytes (82). These cytokines are known to be proangiogenic, implicating PAR₁ in angiogenesis and tissue repair. However, IFN- γ -differentiated growth-arrested U937 cells also respond to PAR₁ agonist administration by overcoming cell arrest and revert to a high proliferation rate via regulation of p21^{CIP1/WAF1} and cyclin D₁. Together, these results may help to explain how

thrombin promotes tissue repair and unrestricted proliferation in malignant tissues (137, 141).

Because thrombin, via PAR₁, is chemotactic for large granular lymphocytes in humans (55), large granular lymphocytes can enhance the effects of PAR₁ in patients with inflammatory disorders (142–144). Moreover, thrombin modulates activity of NK cells (48). For example, thrombin can enhance NK cell-mediated cytotoxicity and IL-2 production in rheumatoid arthritis, and PAR₁ may therefore play an important role in this inflammatory process, as well as in NK cell responsiveness to IL-2.

D. Airways

Various cells in mammalian airways such as epithelial cells, SMC, and fibroblasts abundantly express PAR₁ on the cell surface. Several recent studies also suggest that PAR₁ may play an important role in inflammatory lung diseases such as neutrophilic alveolitis, pulmonary fibrosis, and asthma (50, 77, 91, 145–149).

In the airways of different species, PAR₁ exerts a dual role leading to stimulation of contraction on the one hand and relaxation on the other hand. For example, thrombin stimulates contraction of human bronchial rings (150) and constriction in guinea pig bronchi (as does AP) (151), but activates constriction as well as relaxation in mouse tracheal SMC (152, 153). In these mouse studies, trypsin, thrombin, and peptide agonists of PAR₁, PAR₂, and PAR₄ induced relaxant responses of isolated tracheal smooth muscle preparations, which were mediated by a prostanoid, probably PGE₂. This effect was abolished by indomethacin, the cyclooxygenase (COX)-2 inhibitor, nimesulide, and a prostanoid receptor antagonist (AH6809). PAR₁ and PAR₄ synthetic peptides induced a rapid, transient, contractile response that preceded the relaxant response. Interestingly, the relaxations but not the contractions were inhibited by indomethacin, indicating that this response is mediated by cyclooxygenase products.

E. Gastrointestinal tract

PAR₁ was detected in the lamina propria, the submucosa, endothelial cells, and nerves of the gastrointestinal (GI) tract (154–157). The GI tract expresses relatively high levels of PAR₁ mRNA compared with other tissues, both in mice and humans. The functional role of PAR₁ as a receptor mediating thrombin-induced effects in the GI tract is far from being resolved because thrombin can also interact with PAR₃ and PAR₄ (18, 20, 74). Several studies suggest a role for PAR₁ in regulating GI motility. In guinea pigs, PAR₁ mediates contraction of longitudinal smooth muscle tissue, dependent on extracellular Ca²⁺ (158, 159). In mouse intestine, PAR₁ agonists modulate the function of L-type Ca-channels and also cause contraction (161). Similar results have been observed in rats (162, 163). Irradiation by fractionated X-radiation leads to up-regulation of PAR₁ at the protein level, indicating a regulatory role of external trigger factors such as irradiation on PAR₁ expression (164). Stimulation of PAR₁ upon adhesion of pancreatic carcinoma cells to extracellular matrix proteins such as laminin, collagen IV, and fibronectin has

been observed in a pancreatic carcinoma cell line (MIA PaCa-2) (165, 166). Other studies have pointed out a role for PAR₁ in intestinal secretory pathways. Buresi *et al.* (156) have shown that selective PAR₁ agonists stimulated Ca²⁺-dependent chloride secretion in intestinal epithelial cells. This PAR₁-induced intestinal chloride secretion involves protein tyrosin kinase Src (Src), epidermal growth factor (EGF) receptor (EGFR) transactivation, activation of a MAPK pathway, phosphorylation of cytosolic phospholipase A₂ (cPLA₂), and cyclooxygenase activity. The presence of functional PAR₁ on intestinal epithelium and the fact that PAR₁ activation leads to ion secretion suggest that PAR₁ might have important implications for intestinal barrier functions. PAR₁ activation on intestinal surfaces could lead to a secretory response, thus contributing to diarrhea, a symptom of intestinal inflammation. More recent observations further suggest a role of PAR₁ in intestinal inflammation. We have shown that intracolonic administration of PAR₁ agonists caused inflammation and disruption of intestinal barrier integrity (53). Taken together, these results suggest a proinflammatory role of PAR₁ in the gut (reviewed in Ref. 167). However, additional studies using PAR₁ antagonists and/or PAR₁-deficient mice will have to verify the role of PAR₁ in the pathogenesis of inflammatory bowel diseases.

F. Kidneys and urogenital tract

Recently, a crucial role of PAR₁ in the cell-mediated renal inflammation of crescentic glomerulonephritis has been demonstrated *in vivo* (49). In wild-type mice treated with hirudin (a direct thrombin inhibitor, characterized by a bifunctional mechanism of inhibition, exclusive specificity and strong ability to bind the enzyme) and in PAR₁-deficient animals, the proinflammatory effect of thrombin was significantly reduced. Moreover, treatment of wild-type mice with the PAR₁ peptide agonist (SFLLRN-NH₂) augmented the inflammatory response, suggesting that PAR₁ plays an important role in renal inflammation *in vivo*. Unfortunately, as mentioned above, the peptide SFLLRN-NH₂ can also activate PAR₂ with a comparable potency, and therefore a role of PAR₂ in renal inflammation cannot be ruled out by this study. Surprisingly, although highly expressed in human kidneys, data clarifying a role for PAR₁ in inflammation of human kidneys are still lacking.

Recent data revealed that PAR₁ is involved in cellular invasion of a transfected canine kidney cell line. PAR₁ agonists abrogated G_{α_(olf)}-mediated invasion of MDCKts.src cells in collagen gels, indicating an important role for PAR₁ in tumor metastasis (168, 169). Using the human urogenital cell line RT4, studies done *in vitro* have revealed that PAR₁ and PAR₂ agonists are capable of activating iPLA₂ accompanied by release of PGE₂, which may provide cytoprotection during an acute inflammatory reaction (170).

G. Brain and peripheral nervous system

Recent studies are in favor of an important role of thrombin and PARs in the brain under normal and pathophysiological conditions such as trauma, inflammation, or tumorigenesis (171, 172). Under pathophysiological conditions, *i.e.*,

during breakdown of the blood-brain barrier, circulating thrombin in the bloodstream may enter the central nervous system (CNS), leading to activation of PAR₁ or PAR₄. Additionally, neurons and glia cells are capable of generating prothrombin (173). Most data so far have been achieved by investigating PAR₁ (13, 14, 174). In rat brain, PAR₁ is expressed by neurons of the neocortex, cingulate cortex, subsets of thalamic and hypothalamic nuclei, discrete layers of the hippocampus, cerebellum, and olfactory bulb, as well as by astroglia (60). Striggow *et al.* (175) showed that all four PAR subtypes are expressed in rat brain. PAR₁ expression was most abundant in the hippocampus, amygdala, and cortex. Interestingly, the expression of PAR₁, PAR₂, and PAR₃ was up-regulated during experimentally induced ischemia.

In human brain, PAR₁ is expressed in neurons and astrocytes (175). Cultured rat glia cells (C6) express both functional PAR₁ and PAR₂ (176, 177). Moreover, PAR₁ agonists induce up-regulation of inducible NO synthase (iNOS) in these cells (85) and promote neuronal survival after ischemia (178) or brain trauma (179). PAR₁ also protects astrocytes and neurons from apoptosis induced by hypoglycemia and oxidative stress during inflammation (180). In contrast, thrombin may also exert cytotoxic effects on neurons and induce neurite retraction (181, 182), which may be at least in part due to PAR₁. Functional studies further revealed that PAR₁ agonists cause retraction of neurites by neuroblastoma cells (181) and induce Ca²⁺ mobilization by hippocampal neurons (178).

In astrocytes, thrombin stimulates aggregation, morphological changes, and proliferation via PAR₁ and induces intracellular caspase pathways leading to apoptosis in a cultured motor neuron cell line (NSC19) (183, 184). Both PAR₁ and PAR₂ stimulate enhanced proliferation of astrocytes (185). Friedmann *et al.* (186) reported a key role of thrombin in PAR₁-mediated postinjury neuron survival. They demonstrated that the toxicity of thrombin on neurons can be controlled by down-regulation of PAR₁ and/or release of antithrombin III by T cells. Interestingly, prothrombin expression was enhanced 24 h after injury, whereas PAR₁, PAR₃, and nexin-1 mRNA expression was unchanged (187). Nexin-1 is a thrombin inhibitor that also appears to control thrombin-PAR₁ interactions in a rat trauma model (171, 187, 188). Thus, the whole factory needed to regulate and modulate thrombin function, including receptor as well as activating and inhibiting proteinases, can be generated in the brain. However, PAR₁ also induces the reversal of astrocyte stellation in mice and rat (189–191). A comparable process is caused by exogenous or endogenous injuries of the CNS, triggering astrogliosis.

Taken together, these data clearly indicate a functional role of PAR₁ during inflammation and injury in the CNS. However, in some studies using thrombin as an agonist, activation of other PARs and a role of other molecules like thrombomodulin cannot be excluded. For example, thrombin itself up-regulates thrombomodulin in astrocytes in a dose-dependent manner (192). Thus, future studies taking into account all CNS-derived PARs, their proteinases, and proteinase inhibitors are necessary to fully explore the role of PARs in the brain. Finally, some authors suggest a role of thrombin in Alzheimer's disease, amyotrophic lateral scler-

osis, or HIV encephalitis, probably via activation of PARs (182, 193, 194).

Accumulating data also indicate the role of PAR₁ in the peripheral nervous system. In rat peripheral nerves, PAR₁ is expressed by primary afferent neurons (195). From these observations, one may speculate that thrombin may also regulate inflammatory responses in the peripheral nervous system via PAR₁. Indeed, very recently it has been demonstrated that PAR₁ is expressed by a large proportion of primary spinal afferent neurons (155). Thus, thrombin directly signals to sensory neurons by cleaving PAR₁. Moreover, administration of PAR₁ agonists can induce plasma extravasation and edema, which were blocked by ablation of sensory nerves and administration of antagonists to the neurokinin-1 receptor, supporting the idea that thrombin cleaves PAR₁ on sensory nerves to stimulate release of SP, which in turn interacts with the NK₁ receptor to induce neurogenic inflammation. Thus, thrombin triggers neurogenic inflammation via PAR₁ (155). However, because PAR₂ and PAR₄ mRNA are also expressed in the CNS, it cannot be excluded that proinflammatory effects of thrombin in the nervous system may, in addition, be mediated by other PARs. Functional studies further revealed that PAR₁ agonists induce Ca²⁺ mobilization in enteric neurons, and regulate both excitatory and inhibitory neurons of the myenteric plexus in guinea pig small intestine, *e.g.*, by releasing neuropeptides (196).

Recently, Vergnolle and co-workers (197) as well as other groups (198) examined the effects of PAR₁ agonists on nociceptive responses to mechanical and thermal noxious stimuli. Interestingly, intraplantar injection of selective PAR₁ agonists induced an enhanced nociceptive threshold and withdrawal latency resulting in mechanical and thermal analgesia. However, thrombin was analgesic in response to mechanical, but not to thermal, stimuli. Moreover, application of PAR₁-AP with carrageenan significantly reduced the hyperalgesia. Thus, thrombin may play a dual nociceptive-analgesic role, and future studies will be required to determine whether PAR₁ agonists might be of therapeutic use for the treatment of pain.

H. Signaling by proteinases via PAR₁

Investigations during the last few years revealed that the above-mentioned PAR₁-mediated effects are transduced by various signaling pathways leading to diverse functions of PAR₁ under physiological and pathophysiological conditions. These findings were recently reviewed (13). However, in the current work we focus on the signaling events mediated via PAR₁ in different tissues and cell types (Table 2).

1. *Platelets.* After its generation from prothrombin, thrombin plays multiple roles in the blood coagulation cascade that are mediated by interaction with a number of physiological substrates, effectors, and inhibitors. The accumulation of thrombin at sites of vascular injury provides the recruitment of platelets into a growing hemostatic plug. When added to human platelets *in vitro*, thrombin causes platelets to change shape, stick to each other, and secrete the contents of their storage granules. How this is accomplished is still not fully

understood, but a major step forward occurred since the identification of PAR₁ in the 1990s. This finding shed light on the way by which an extracellular protease may initiate intracellular events.

Mammalian GTP-binding proteins (G proteins) fall into four families that are typically referred to by the designation of the α -subunit: G_s, G_i, G_{q/11}, and G_{12/13}. Human platelets express at least one member of the G_s family and four members of the G_i family (G_{i1}, G_{i2}, G_{i3}, and G_z), which, among other functions, stimulate or inhibit cAMP formation by adenylyl cyclase (199). In addition, platelets express one or more members of the G_{q/11} family and members of the G_{12/13} family (G₁₂ and G₁₃) (199).

A number of different G protein α -subunits have been shown to bind to PAR₁, including members of the G_i, G_{q/11} and G_{12/13} families (200). However, the knowledge of these interactions in humans under physiological and pathophysiological conditions is still far from completion.

Kim *et al.* (201) have demonstrated that thrombin and PAR₁-AP, as well as PAR₄-AP, induce G_i pathway stimulation in human platelets. Additionally, the authors demonstrated that thrombin, PAR₁-AP, and PAR₄-AP cause platelet aggregation independently of G_i stimulation (201). Offermanns *et al.* (202) also demonstrated a direct interaction between G₁₂, G₁₃, and PAR₁. Additionally, it was reported that thrombin-mediated cleavage of the PAR₁ (and PAR₄; see Section IV.B) receptor leads to calcium-dependent and calcium-independent shape changes of human platelets in consequence of direct activation of both G_q and G_{12/13} pathways, respectively (115, 202). Therefore, current evidence suggests that PAR₁ interacts with G_q, G_{12/13}, and possibly G_i protein family members in human platelets. In turn, these data suggest an activation of downstream signaling cascade members after PAR₁ stimulation on human platelets. Among such members are phospholipase C (PLC)- β , phosphoinositide 3 (PI3)-kinase, and monomeric G proteins.

Indeed, PI3 kinase was demonstrated to play an important role in some PAR₁ or thrombin-mediated cellular effects such as cytoskeletal reorganization, alterations in cell motility, cell survival, and mitogenesis. For example, thrombin is able to activate multiple PI3-kinase isoforms, including the recently discovered 110-kDa isoforms that can be directly activated by G protein $\beta\gamma$ -subunits (145, 150, 203). Stimulation of platelets by PAR₁ leads to the activation of PI3 kinase, which is dependent on the small G protein Rho (204). Recently, Trumel *et al.* (205) have demonstrated that PI3 kinase plays an important role in the PAR₁-dependent reorganization of the platelet cytoskeleton via myosin heavy chain translocation and stable association of signaling complexes with the actin cytoskeleton. Interestingly, the activity of small G proteins such as Rac and cdc42 in platelets may be regulated through PAR₁ stimulation, but the role of PI3 kinase in these events remains to be determined (206). In their recent study, Vaidyula and Rao (207) provided evidence that in human platelets PLC- β 2 plays a major role in responses to PAR₁ and PAR₄ activation, and that PLC- β 2 is required for the sustained rise in [Ca²⁺]_i concentration upon thrombin activation.

Putting all of this together, current data suggest that

thrombin activates human platelets by cleaving and activating PAR₁ and PAR₄. In turn, PAR₁ activates the members of G_{q/11}, G_{12/13}, and perhaps G_i families, leading to the activation of PI3 kinase, PLC- β , and monomeric G proteins (Rho, Rac, and possibly Rap1), and also causes an increase of cytosolic Ca²⁺ concentration and inhibition of cAMP formation.

Additionally, it is important to note that despite the fact that human platelets express both PAR₁ and PAR₄, these receptors appear to be activated by different thrombin concentrations. Cleavage of human PAR₄ requires a higher concentration of thrombin than does cleavage of PAR₁, and it is likely that PAR₁ is the predominant signaling receptor at low thrombin concentrations (208, 209).

Mouse platelets provide an interesting contrast to human platelets: whereas human platelets express functional PAR₁ and PAR₄, mouse platelets express PAR₃ and PAR₄, although in the latter case signaling appears to be mediated entirely by PAR₄, with PAR₃ serving to facilitate PAR₄ cleavage at low thrombin concentrations (for details, see Section IV.A) (39, 40).

2. Cells in the nervous system. PAR₁, as mentioned above, appears to affect various processes in both the central and peripheral nervous systems (45, 210). Among such processes are: neuroinflammation and neurodegeneration, neuritogenesis, astrocyte proliferation, and synaptic plasticity. However, here we would like to focus on data concerning the involvement of PAR₁ in intracellular signaling cascades in neuronal cells.

PAR₁ may have an effect on various intracellular signaling cascades within neuronal cells (171, 181, 189). By coupling to different G proteins, PAR₁ affects a wide range of neuronal cell functions. For example, the necessity of PAR₁ coupling to G₁₂ was demonstrated for thrombin-stimulated DNA synthesis in 1321N1 astrocytoma cells (211). Interestingly, injection of antibodies directed against G₁₂ abolished the thrombin-stimulated DNA synthesis (212). Additional studies performed on 1321N1 astrocytoma cells revealed that thrombin treatment causes a concentration-dependent rounding. One may speculate that such an effect of thrombin could be Rho-dependent. The Rho family of small GTPases is known to be involved in the control of cytoskeletal changes via modulation of actin polymerization. Indeed, this thrombin-induced rounding of 1321N1 astrocytoma cells was Rho-dependent and mediated via G₁₂ (213).

Moreover, LaMorte *et al.* (214) demonstrated binding of PAR₁ to G_q by using the same cell line. The authors also showed that thrombin stimulation induces Ras-GTP complex formation and that Ras is required for PAR₁-mediated activation of PLC in 1321N1 astrocytoma cells (214). This is especially interesting because thrombin is known to be a factor regulating the proliferation of astrocytes. This effect of thrombin appears to be associated with G_{o/i}- and G_q-mediated pathways. Wang and coworkers recently shed some light on the downstream cascade events of PAR₁ signaling (174, 210). G_q-Mediated PLC activity results in Ca²⁺ mobilization and activation of PKC, which phosphorylates a non-receptor tyrosine kinase, proline-rich tyrosine kinase (Pyk2). Interestingly, the activation of other nonreceptor tyrosine

kinases like Src and focal adhesion kinase (FAK) was also demonstrated after thrombin stimulation. Pyk2 is a factor that is able to connect GPCRs to ERK1/2 activation. Therefore, Pyk2, acting together with Src-tyrosine kinase, causes the activation of the ERK/MAPK pathway, which mediates the proliferative effect of thrombin. Additionally, the same group of authors demonstrated that the G_{α_i} -mediated PI3 kinase pathway is also involved in thrombin-induced astrocyte proliferation (174).

Thrombin is also known to exhibit both beneficial and unfavorable effects in hippocampal neurons and astrocytes (178, 180, 215). Donovan and colleagues (184, 216) found that tyrosine kinases, serine/threonine kinases, and the actin cytoskeleton are involved in both pro- and antiapoptotic effects of thrombin in neuronal cells. However, there was no involvement of G_{α_i} and the PI3 kinase pathway observed in these thrombin effects.

Additionally, Zieger *et al.* (217) demonstrated the existence of a novel PAR_1 -associated signaling pathway in the nervous system. According to these data, PAR_1 participates in cAMP-independent PKA activation in SNB-19 glioblastoma cells. Moreover, PAR_1 stimulation causes the activation of transcriptional factor nuclear factor κB (NF κB) in this cell type (217).

In summary, besides morphological and proliferative effects described above that are mediated via $G_{12/13}$, G_q , and $G_{\alpha_{iv}}$ respectively, thrombin also affects activation of transcriptional factors such as activator protein-1 (AP-1) in neuronal cells (214).

3. *SMC*. Thrombin exerts direct effects on vascular cells such as SMC and endothelial cells via interactions with PARs (218). As mentioned in *Sections II.H.1* and *II.H.2*, PAR_1 interacts with $G_{12/13}$, G_q , and G_i to elicit diverse downstream signaling events. For example, thrombin-stimulated DNA synthesis and cell migration are associated with activation of the G_{13} signaling pathway in SMC. The G_{13} signaling cascade includes the activation of Rho and thus induction of cytoskeletal changes affecting cell migration (219). The G_q -dependent signaling pathway includes the activation of PLC, which in turn leads to MAPK phosphorylation and receptor tyrosine kinase transactivation, both necessary events in thrombin-mediated proliferation. It is interesting that the thrombin-mediated activation of MAPKs such as ERK1/2 was recently demonstrated in SMC. As noticed, PAR_1 caused rapid phosphorylation, whereas PAR_4 induced prolonged phosphorylation of these kinases in SMC (220). Additionally, Ghosh *et al.* (221) have shown that thrombin activates p38 MAPK in a time-dependent manner in VSMC. Furthermore, Sabri *et al.* (222) demonstrated that PAR_1 agonists induce activation of Jun N-terminal kinase (JNK) and Akt/PKB in rat ventricular cardiomyocytes.

After dissociation of the G protein heterodimer, $G_{\beta\gamma}$ interactions activate phosphoinositide 3-kinase, which promotes $[Ca^{2+}]_i$ release that is required for SMC growth in response to thrombin stimulation (223).

It is also interesting that PAR_1 signaling can modulate gene transcription induced by cytokines in SMC. Thrombin, acting via PAR_1 , can block IL-6-induced signal transducer and ac-

tivator of transcription 3/Sis-inducible factor-A (Stat3/SIF-A) activation (224).

In summary, since the discovery of PARs, considerable progress in our understanding of thrombin signaling in SMC was achieved. This allowed some light to be shed on signaling events associated with SMC proliferation, migration, and synthesis of extracellular matrix proteins (*e.g.*, collagen) after thrombin stimulation. However, additional studies are necessary to reveal the role of thrombin in SMC apoptosis, vascular lesion formation, and wound-healing associated pathways.

4. *Endothelial cells*. Thrombin is known to affect various functions of endothelial cells. Among these are cell rounding, changes of cell-cell junctions, proliferation, barrier function, and permeability. These thrombin-induced effects appear to be mediated via PARs, particularly PAR_1 (225, 226). A major step forward was reached in recent studies, which revealed important intracellular signaling events underlying PAR_1 -mediated effects in endothelial cells (227).

PAR_1 was demonstrated to interact with $G_{\alpha_{iv}}$, G_q , and probably $G_{12/13}$ in endothelial cells (228, 229). As well as it was demonstrated for neuronal cells, PAR_1 -mediated cytoskeletal changes in endothelial cells (cell rounding) are associated with the activation of RhoA (225). Additionally, in the same work it was demonstrated that PAR_1 -AP stimulation rapidly enhanced vascular permeability in a mouse skin assay (225). Moreover, it was found that binding of PAR_1 to pertussis toxin (PTX)-sensitive G proteins (however only to G_{α_o} but not to G_i) is also necessary for thrombin-induced changes of endothelial barrier permeability (229). The activation of the MAPK signaling pathway by thrombin in endothelial cells was also demonstrated. This activation plays a crucial role in thrombin-induced effects of endothelial cell functions such as chemokine and cytokine production as well as the expression of cell adhesion molecules (89, 230, 231).

The role of thrombin and PAR_1 in the activation of transcriptional factor networks was intensively investigated in recent publications. Malik and coauthors (228, 231, 232) studied the involvement of PAR_1 in the activation of NF κB in endothelial cells. Their studies showed that $G_{\alpha_{iq}}$ and the $G_{\beta\gamma}$ dimer are responsible for NF κB activation and intercellular adhesion molecule-1 (ICAM-1) transcription in endothelial cells induced by the PAR_1 agonist thrombin and the PAR_1 -specific AP TFLLRNPNDK. Furthermore, transfection experiments strongly supported simultaneous activation of $G_{\beta\gamma}$ /PKC- δ /p38 and $G_{\beta\gamma}$ /PI3-kinase pathways that converge into the Akt pathway, leading to subsequent NF κB activation and ICAM-1 expression (228, 231, 232). Moreover, thrombin-induced stimulation of vascular cell adhesion molecule-1 (VCAM-1) production involves the inducible binding of p65 NF κB to a tandem NF κB motif in the 5' flanking region (233). Taken together, these findings suggest that in the case of ICAM-1 and VCAM-1, p65 NF κB is necessary for transducing the thrombin response in endothelial cells.

Additionally, thrombin-mediated induction of VCAM-1 was shown to involve the inducible binding of GATA-2 to a tandem GATA motif in the upstream promoter region (234). Interestingly, the effect of thrombin on GATA-2 DNA bind-

ing and transcriptional activity was found to be mediated by a PI3K, PKC- δ -dependent signaling pathway (233).

It is important to note that thrombin effects on transcriptional factor networks have been more deeply investigated in endothelial cells than in other cell types. These data explain, at least in part, thrombin-mediated effects on the production of cell adhesion molecules and some chemokines in endothelial cells. Subsequently, this accounts for thrombin effects at leukocyte migration via endothelial barrier (ICAM-1 serves as a ligand for leukocyte β_2 integrins and promotes leukocyte adhesion) and leukocyte recruitment.

5. Immune cells. The participation of PARs in T cell signaling pathways has also been demonstrated (235). Recently, Bar-Shavit *et al.* (236) have examined a possible involvement of Vav 1 in PAR-mediated signaling in human Jurkat T cells. The Vav family has three known members in mammalian cells (Vav, Vav2, and Vav3) and one in nematodes (CelVav) (237). Tyrosine phosphorylation of Vav1 regulates its activity as a guanine-nucleotide exchange factor for the Rho-like small GTPases RhoA, Rac1, and cdc 42, which affect cytoskeletal reorganization and activation of stress-activated protein kinases/JNKs. Bar-Shavit *et al.* (236) clearly showed that activation of PARs induces tyrosine phosphorylation of Vav1 in Jurkat T-leukemic cells. Because ζ -chain-associated protein kinase of 70 kDa (ZAP-70) and SH2-domain containing leukocyte-specific phosphoprotein of 76 kDa (SLP-76) have been shown to associate physically with Vav1 and because this association is critical for normal functioning of T cells, it was tempting to investigate whether ZAP-70 and SLP-76 are involved in PAR-induced signaling cascades. Indeed, an increase of tyrosine phosphorylation of ZAP-70 and SLP-76 was observed after activation of Jurkat cells with PAR-APs. Moreover, phosphorylation of Vav1 in response to PAR stimulation was dependent on p56^{lck} (236). Unfortunately, because nonselective PAR-APs were used in the studies done with the Jurkat cells (236), it is difficult to distinguish between the effects of PAR₁ and PAR₂ in this T cell model system. Furthermore, because of the lack of the ability of PAR₃-derived peptides to activate PAR₃ (39), the role of PAR₃ in T cell signaling remains unknown.

6. Factor Xa signaling mediated via PAR₁. Most of the PAR₁-associated signaling events have been observed subsequent to cell stimulation by thrombin. However, recently a possible role of PAR₁ in coagulation factor Xa-mediated signaling has been demonstrated (238–240). The coagulation proteinase factor Xa is generated at sites of vascular injury and inflammation after formation of the tissue factor/VIIa (TF/VIIa) complex. Coagulation factor Xa has been shown to be mitogenic for SMC (238) and elicits inflammatory responses in endothelial cells. Riewald and Ruf (241) have presented new data indicating the involvement of PAR₁ in Xa-mediated signaling. They used HeLa cells expressing only PAR₁ and demonstrated that factor Xa induces NF κ B activation and MAPK phosphorylation in these cells. Inhibition studies with specific antibodies revealed that factor Xa responses were mediated via PAR₁ (241). Thus, factor Xa (or potentially other serine proteinases) may substitute for thrombin in proteolytic signaling via PAR activation. In endothelial cells, which

also express PAR₂, Camerer *et al.* (240) have shown that factor Xa signaling was mediated not only by PAR₁, but also to a large extent via PAR₂. Together, PAR-1 and PAR-2 appear to account for more than 90% of factor Xa signaling in endothelial cells (240).

In summary, the multiple biological as well as inflammatory and immune responses of thrombin that are mediated by PAR₁ [including 1) vasoregulation; 2) increased vascular permeability; 3) cellular adhesion and infiltration of leukocytes; 4) angiogenesis; 5) stimulation of the production of inflammatory mediators such as cytokines, neuropeptides, NO and prostanoids, for example; 6) regulation of extracellular matrix proteins; and 7) induction of signal transduction pathways which are involved in immunomodulation] suggest an important role of PAR₁ during inflammation and immune response.

III. PAR₂ in Inflammation and Immune Response

PAR₂ is expressed in brain, lia (DRG), eye, airway, heart, GI tract, pancreas, kidney, liver, prostate, ovary, testes, and skin (21–22, 24, 154, 242–245) and is found in various cell types such as epithelial cells, endothelial cells, SMC, osteoblasts, as well as immune cells such as T cells, neutrophils, mast cells, or eosinophils (97, 154, 246–254). On the other hand, platelets do not express PAR₂ (248). Recent findings point to an important role for PAR₂ under physiological and pathophysiological conditions in many tissues (Table 2). However, the endogenous enzymes responsible for activating PAR₂ in many tissues remain to be determined. Many endogenous or exogenous trypsin-like enzymes may cleave and activate PAR₂. Expression of trypsinogen-2 mRNA and its translation product has been demonstrated in endothelial cells (255). Interestingly, various types of human cancer cells secrete enzymes with trypsin-like specificity (255) that may activate PAR₂. In human skin, trypsinogen-4 generated by keratinocytes and trypsinogen-2 from human dermal microvascular endothelial cells can activate PAR₂ *in vitro* (M. Steinhoff, unpublished observation). Another candidate is mast cell tryptase, a major secretory protein of human mast cells. Mast cells from mice and rats are more heterogeneous regarding their protease content, although they also produce proteases with tryptic specificity. Tryptase has been shown to activate PAR₂ on epithelial as well as endothelial cells and neurons (23, 196, 243, 251, 256). The observation that tryptase can activate PAR₂ suggests a role of this receptor in humans under circumstances when mast cells are involved, *e.g.*, during inflammation, hypersensitivity reactions, and wound repair (24, 257). However, the ability of human tryptase to activate PAR₂ appears to be restricted by receptor glycosylation at an N-terminal residue just proximal to the receptor's cleavage activation site (258, 259). Notwithstanding, the effects of tryptase on cells *in vitro* often mimic those of PAR₂ activation: tryptase up-regulates IL-1 β and IL-8 secretion, enhances the presence of intracellular adhesion molecules/selectins on endothelial cells, mediates accumulation of neutrophils and eosinophils, produces vascular leakage, and is mitogenic for epithelial cells, fibroblasts, and SMC (260–263). That said, direct proof that PAR₂ mediates the effects of tryptase during inflammation *in vivo* is still lacking.

A. Vasculature

In the vasculature, PAR₂ has many effects that are proinflammatory. Agonists of PAR₂ induce relaxation in the rings of rat aorta or porcine coronary artery dependent on endothelial NO synthase activity (246, 248, 250). This effect is abolished in the absence of endothelium (246, 250). In contrast, trypsin stimulates contraction of the rabbit aorta in the absence of endothelium (264). In the intact rat, iv injection of SLIGRL-NH₂ produces a marked fall in blood pressure, consistent with release of NO from endothelial cells (248). Furthermore, PAR₂ agonists increase IL-6 production (72), induce von Willebrand factor release, and serve as a mitogen for human umbilical vein endothelial cells (HUVEC) (97, 265, 266).

Moreover, it was demonstrated that some inflammatory mediators are able to affect the expression of PAR₂ in endothelial cells. In HUVEC, PAR₂ mRNA is up-regulated by TNF- α and IL-1 α , cytokines that act together to orchestrate the acute inflammatory response (25, 265).

In summary, PAR₂ mediates vasodilation, plasma protein extravasation, as well as endothelial cell proliferation in the cardiovascular system. Thus, this receptor can be regarded as an important factor in neovascularization. Moreover, PAR₂ can be considered as a vascular sensor for trypsin-like proteinases of the coagulation cascade, which play an important role in cardiovascular medicine.

B. Immune cells

Although information has been acquired about the role of PAR₂ in epithelial and endothelial function, relatively little is known so far about the role of this receptor in the immune system. As was recently demonstrated, PAR₂ is expressed by various cells involved in immune response, such as T cell lines, eosinophils, neutrophils, and mast cells (147, 160, 249, 252, 267). Accumulating evidence points to a role of PAR₂ in the regulation of leukocyte function. Some of the PAR₂-mediated effects on leukocyte behavior have been observed *in vivo* in rodents (262). In this model, it has been reported that the PAR₂-AP (SLIGRL-NH₂) caused a significant increase in leukocyte migration into the peritoneal cavity after ip injection. Furthermore, PAR₂-APs induced a significant increase in leukocyte rolling and adherence by a mechanism depending on the release of platelet-activating factor (262). Lindner *et al.* (268) have also demonstrated the importance of PAR₂ for leukocyte adhesion and rolling. In a model of acute inflammation induced by tissue trauma, they showed that PAR₂-deficient mice have a decreased leukocyte rolling capacity compared with wild-type mice. Conversely, activation of PAR₂ by a specific PAR₂-AP in wild-type mice induced a significant reduction of leukocyte rolling velocity, an increased leukocyte rolling flux as well as increased leukocyte adhesion (268).

Howells *et al.* (252) reported that a specific PAR₂-AP as well as trypsin are able to activate PAR₂ on human neutrophils. PAR₂ activation caused shape changes and up-regulation of CD11b/CD18 in these cells. In a coculture of human neutrophils with endothelial cells, PAR₂ agonists induced L-selectin shedding and CD11b/CD18 up-regulation in neu-

trophils (268). We demonstrated that PAR₂ agonists induce [Ca²⁺]_i release in human neutrophils and enhance neutrophil motility in 3-D collagen gel lattices (269). Moreover, Loubakos *et al.* (27) demonstrated that a bacterial proteinase, gingipain-R from *P. gingivalis*, activates PAR₂ on human neutrophils. Because many bacteria with pathogenicity in humans produce serine proteinases with trypsin-like activity, it can be assumed that certain pathogenic effects of bacteria in many tissues can be mediated through PAR₂. For example, Loubakos *et al.* (28) reported that activation of PAR₂ by bacterial gingipain R leads to IL-6 secretion in human oral epithelial cells. In mouse airways, PAR₂ agonists were capable of inhibiting the recruitment of neutrophils induced by bacterial proteinase (270), suggesting a direct role of PAR₂ on neutrophil function *in vivo*. From these data, one may speculate that PAR₂ may serve as a receptor for serine proteinases derived from bacteria, viruses, or even fungi and may thus directly trigger inflammatory or immune responses *in vivo* induced by microorganisms. However, this intriguing hypothesis remains to be verified.

Recent work has shed some light on the role of PAR₂ on eosinophil function. Miike *et al.* (267) clearly demonstrated that human eosinophils express functional PAR₂. Furthermore, trypsin as well as a specific PAR₂-AP was able to induce degranulation and superoxide production in human eosinophils. More recently, Temkin *et al.* (79) reported that human mast cell tryptase induced up-regulation of IL-8 mRNA and caused IL-8 release from human eosinophils. A comparable effect of tryptase on eosinophil IL-6 expression and release was also observed. This effect of tryptase appears to be activated via the protein kinase/AP-1 signaling pathway (79). Schmidlin *et al.* (271) have also demonstrated that PAR₂ mediates infiltration of eosinophils and hyperreactivity in allergic inflammation of the airway. Furthermore, PAR₂ activation releases survival factors such as granulocyte-macrophage colony-stimulating factor (GM-CSF) from eosinophils (272). Together, these results are clearly in favor of an important role of PAR₂ in eosinophil regulation and in inflammatory/allergic diseases in which eosinophils are involved.

Several T cell lines also express PAR₂ (244). Trypsin as well as a synthetic PAR₂-AP induce [Ca²⁺]_i mobilization in the Jurkat and HPB.ALL T cell lines (249). In Jurkat cells, the involvement of PARs, possibly PAR₂, in Vav1-mediated signaling was clearly demonstrated (236).

The localization of PAR₁ and PAR₂ on human mast cells was first reported by D'Andrea *et al.* (147). As shown by immunohistochemistry, PAR₂ was localized not only on the cell membrane of mast cells, but also on the membrane of the intracellular tryptase-positive granules (147). Moreover, rat peritoneal mast cells also express PAR₂ mRNA (273). However, the precise role of PAR₂ in mast cells especially with regard to a potential autocrine regulatory mechanism via tryptase activation requires additional investigation. In summary, these results provide evidence for a role of serine proteinases in directly regulating immune cells and immune responses via PARs. An understanding of the molecular mechanisms by which PAR₂ is involved in immune regulation will aid the design of new antiinflammatory drugs that can target proteinase-activated receptors.

C. Arthritis

Arthritis is a chronic inflammatory disease that is characterized by joint swelling, vasodilatation, edema, hyperemia, pain, and recruitment of inflammatory cells, especially neutrophils and macrophages, but also lymphocytes. Very recently, it was demonstrated that PAR₂ participates in the pathophysiology of arthritis (274). Using PAR₂-deficient mice, the authors showed that PAR₂ deficiency results in a marked reduction of swelling responses of experimentally induced monoarthritis. However, no differences were observed concerning joint damage when compared with wild-type mice. Using an enzymatic approach (β -galactosidase), they also showed positive β -gal staining in endothelial cells of blood vessels. Two weeks after induction of monoarthritis, however, a significant increase of β -gal staining of extravascular inflammatory cells was observed in PAR₂^{+/+} mice compared with PAR₂^{-/-} mice. Examination of the knee joint showed dramatic arthritic changes in PAR₂^{+/+} mice characterized by synovial hyperplasia, an enhanced inflammatory infiltrate, and cartilage damage. Thirty days after the induction of monoarthritis, the cartilage was completely replaced by pannus in PAR₂^{+/+} mice. In contrast, PAR₂^{-/-} mice showed an intact appearance of the cartilage similar to normal and control joints. This is in favor of an important role of PAR₂ as a mediator of proinflammatory responses in the joints. Moreover, a novel synthetic PAR₂ peptide agonist (ASKH95, phenylacetyl-LIGKV-OH) revealed proinflammatory effects after intraarticular injection like synovial hyperemia and joint swelling. These results clearly demonstrate that ASKH95 induces signs of chronic inflammation such as long-lasting swelling responses, vasodilatation, and tissue destruction. Interestingly, ASKH95 showed a longer-lasting proinflammatory effect in the tissue compared with the classical SLIGRL PAR₂ agonist peptide. This may be due to different rates of degradation, longer receptor activation by ASKH95, or most likely different lipophilicity. The underlying mechanisms of the PAR₂-mediated inflammatory effect in this chronic disease, however, are not fully explored yet. Potential mediators may be cytokines or prostanoids, for example. Thus, PAR₂ may play an essential role in the pathophysiology of arthritis, and PAR₂ antagonists may be beneficial for the treatment of this chronic inflammatory disease.

D. Skin

PAR₂ may play an important role in cutaneous inflammation. Keratinocytes and dermal endothelial cells express functional PAR₂ and are important targets of inflammatory mediators (247, 275, 276). In humans, PAR₂ is also expressed by dermal immunocompetent cells, which so far have not been characterized (24), and by dermal sensory nerves (277). Potential endogenous activators of PAR₂ in human skin are mast cell tryptase, proteinases of the trypsin-family produced by keratinocytes (trypsinogen-4), and proteinases of the fibrinolysis cascade, such as factor VII/Xa, which could be released during inflammation and wound healing. Exogenous activators of PAR₂ may be serine proteinases generated by bacteria, fungi, and house dust mites, although direct evidence on keratinocytes is still lacking. Indirect evidence

for bacterial-induced activation of PAR₂ is coming from the observation that bacterial gingipain activates the receptor on buccal keratinocytes (28). At certain stages of atopic dermatitis or psoriasis, mast cells are in close contact to basal keratinocytes or are recruited into the epidermal layer (278). Numerous mast cells are found in the dermis in close proximity to blood vessels and at the dermal-epidermal border in atopic dermatitis and psoriasis. Thus, tryptase or other skin-derived proteinases may activate PAR₂ to induce inflammatory changes and thereby contribute to the pathophysiology of atopic dermatitis and psoriasis. It is well known that intradermal injection of tryptase into the skin results in vasodilatation and erythema, followed by leukocyte infiltration and local induration (279), indicating a role of tryptase in cutaneous inflammation. Moreover, tryptase is an important long-term marker in body fluids for systemic anaphylaxis and other immediate hypersensitivity allergic reactions (280). Thus, it is possible that PAR₂ mediates the systemic effects of tryptase in certain skin diseases.

Serine proteinases other than tryptase may also activate PAR₂. Cytotoxic T cells, which express PAR₂ (249), also produce the trypsin-like enzyme granzyme A (281), suggesting a potential role for PAR₂ in regulating T cells in inflammatory dermatoses. In summary, proteinases in the skin are signaling molecules that may directly regulate the function of target cells by activating PAR₂. PAR₂ as well as PAR₁ agonists regulate cytokine production such as IL-8 (282), IL-6, and GM-CSF (283) in cultured human keratinocytes. Furthermore, PAR₂ may also regulate proliferation and differentiation in the skin. Similar to TGF- β , PAR₂ agonists inhibit proliferation or differentiation of human neonatal keratinocytes, whereas PAR₁ agonists stimulate proliferation (275). In contrast, agonists of both PAR₂ and PAR₁ are mitogenic for endothelial cells (248). Thus, our observations in normal and inflamed human skin suggest a functional role of PAR₂ in different cell types of human skin during inflammation.

In human skin, PAR₂ is only weakly expressed by microvascular endothelial cells. Studies done *in vitro* revealed that PAR₂ is functionally expressed by human dermal microvascular endothelial cells and that PAR₂ agonists induce up-regulation and release of IL-6 and IL-8 in a concentration-dependent fashion (263). Moreover, PAR₂ regulates expression of cell adhesion molecules in primary cultures of human endothelial cells (284) and cell lines (268). These findings are supported by *in vivo* findings demonstrating a role of PAR₂ in the adhesion, rolling, and extravasation of leukocytes in rat venules. Finally, PAR₂ appears to play a role in the regulation of leukocyte/endothelial interactions in humans and mice *in vivo*, as shown for atopic dermatitis or experimentally induced contact dermatitis (285). Together, these results strongly support the idea that PAR₂ plays an important role in leukocyte/endothelial interactions during inflammation and immune response.

The knowledge about the signaling cascades involved in PAR₂-induced inflammatory and immune responses by keratinocytes is still incomplete. Recently, Kanke *et al.* (286) have shown that PAR₂ agonists stimulate activation of inhibitory κ B kinases (IKK α and IKK β), and also stimulate NF κ B-DNA binding. Our own data using primary human keratinocytes also clearly demonstrate that PAR₂ activates NF κ B (287).

Moreover, PAR₂ is directly involved in the NFκB-mediated regulation of keratinocyte ICAM-1, which is an important molecule for the regulation of keratinocyte immune responses such as host defense, allergy, and recruitment of inflammatory cells into the epidermis (287).

Finally, recent data suggest a role of PAR₂ during cutaneous inflammation *in vivo*. In a murine model of experimentally induced allergic contact dermatitis, a proinflammatory role of PAR₂ agonists was demonstrated (285, 288). Stimulation of PAR₂ resulted in increased ear swelling responses with a maximum after 48 h. Independently, our group confirmed the proinflammatory effects of PAR₂ agonists in a model of experimentally induced allergic and irritant contact dermatitis using PAR₂-deficient mice. Moreover, we examined the underlying mechanisms responsible for PAR₂-induced effects during contact dermatitis (285). These results clearly indicate that PAR₂ is involved in edema formation, plasma extravasation, up-regulation of cytokines (IL-6), cell adhesion molecules (ICAM-1), and selectins (E-selectin) in mice. Intravital microscopy studies further showed that velocity and adhesion of leukocytes is impaired in PAR₂-deficient mice compared with controls. Moreover, *in vivo* studies by microdialysis confirmed a role of PAR₂ in mediating vascular responses such as edema formation and plasma extravasation also in human skin. Finally, *ex vivo* studies in skin biopsies of human volunteers are in favor of a role for PAR₂ in selectin regulation of dermal blood vessels because PAR₂ agonists induced a marked increase of E-selectin immunoreactivity in dermal endothelial cells in comparison to control tissues. Together, these results support a regulatory role of PAR₂ during cutaneous inflammation and immune response.

E. Airways

Several observations are in favor of an important role of PAR₂ in airway inflammation. Firstly, tryptase (251, 289) seems to play an important role in airway inflammation and hyperresponsiveness (253). Secondly, PAR₂ is markedly up-regulated after exposure to proinflammatory stimuli or cytokines (265) that have been shown to play a role in chronic airway diseases. Morphological studies have demonstrated PAR₂ immunoreactivity in endothelium and smooth muscle of bronchial vessels. These observations are consistent with a similar distribution in other tissues and with the known ability of PAR₂ agonists to cause arterial relaxation as well as contraction in certain arteries (290). Moreover, PAR₂ is expressed by bronchial, tracheal, epithelial and SMC which may result in direct or indirect bronchomotor effects leading to pathophysiological conditions in the airways such as asthma or chronic obstructive pulmonary disease. Interestingly, PAR₂ agonists are capable of causing bronchoconstriction (291). Whether this response is dependent on secondary effects such as the generation of bronchoactive peptides or other mediators remains to be determined. However, studies done *in vitro* suggest further that PAR₂ agonists also produce a relaxant effect in isolated main bronchi (292). Thus, PAR₂ agonists may cause dose-dependent bronchoconstrictor or bronchodilator effects in the airways, with high agonist concentrations favoring bronchoconstriction. NO and pro-

stanoids like PGE₂ may be involved in this process, because potentiation of PAR₂-induced bronchoconstriction has been observed upon inhibiting NO synthase or after prostanoid generation and COX-2 activation (153). In conclusion, there is strong evidence that PAR₂ stimulation activates contractile and dilator mechanisms in the airways. The reason why the predominant effect in guinea pig airways *in vivo* is bronchoconstriction, however, is not known at present. In addition to the potentially bronchoprotective effects observed by Cocks *et al.* (292) in rat bronchial preparations, others have shown that PAR₂ may also mediate bronchoprotection in guinea pig airways (293). However, other observations show that PAR₂ can act as an enhancer of histamine-mediated contraction (294). The study of Cocks *et al.* (292) showed that trypsin colocalized with PAR₂ in airway epithelial cells, where PAR₂ activation resulted in relaxation of airway preparations by the release of cytoprotective PGE₂. Prostanoids may be important mediators of PAR₂ activity in the airways not only in the lung, but also in the GI tract (152, 153, 253, 295). It is tempting to speculate that tryptase and/or other proteinases with trypsin-like activity, released in close proximity to the cells expressing PAR₂, may stimulate this receptor during airway inflammation. Finally, intensive staining of PAR₂ in the apical region of the airway epithelium might suggest an activating role of proteinases, for instance bacterial proteinases, present in the airway lumen (296). Very recently, PAR₂ was shown to stimulate the release of MMP-9 in a human epithelial cell line (297), providing a strong hint that PAR₂ is involved in the orchestration and reorganization of lung extracellular matrix proteins.

It was also revealed that PAR₂ stimulation of airway epithelial cells leads to the release of eosinophil survival-promoting factors such as GM-CSF (272). Moreover, in human respiratory epithelial cells, PAR₂, like PAR₁, stimulates IL-6, IL-8, and PGE₂ release (77).

Profound evidence for an involvement of PAR₂ in allergic inflammation of the airways is provided by the recent work of Schmidlin *et al.* (271). To study the involvement of PAR₂ in airway inflammation, they used PAR₂-deficient mice and mice overexpressing human PAR₂ (PAR₂tg). PAR₂ is known to be up-regulated by inflammatory agents. Sensitization of wild-type mice by injection of ovalbumin led to infiltration of immune cells into the lumen of the airways and induced hyperreactivity, whereas both infiltration of eosinophils into the lumen and airway hyperreactivity was exacerbated in PAR₂tg mice. In contrast, infiltration of immune cells and airway hyperreactivity was markedly diminished in PAR₂-deficient mice. Additionally, in PAR₂^{-/-} mice the IgE response was strongly reduced, implicating a role of PAR₂ in immune response. Remarkably, intranasal administration of PAR₂-AP in wild-type mice stimulated increased recruitment of macrophages, confirming the proinflammatory role of PAR₂ in the airways, whereas altered PAR₂ expression mainly influenced eosinophil infiltration.

In summary, evidence exists for a proinflammatory as well as antiinflammatory role of PAR₂ in airway inflammation. This dual role may be explained by the various tissues, cells, methodological approaches, and inflammatory model systems (acute *vs.* chronic, mouse strains) that have been used to evaluate this role of PAR₂ in the airways. So far, it appears

that PAR₂ is a sensor receptor that releases proinflammatory mediators in the early phase and antiinflammatory molecules in the late phase of “regulated inflammation.” Under “dysregulated” inflammatory situations such as chronic disease states, PAR₂ may exert antiinflammatory effects, as shown in a colitis model (298), or proinflammatory effects, as demonstrated in an asthma model (271). Thus, additional studies using human and mouse (knock-out) models of pulmonary dysfunction are necessary to fully explain the role of PAR₂ during inflammation and immune response.

F. Brain and peripheral nervous system

By immunohistochemistry, PAR₂ has been localized in various compartments of the nervous system such as brain, spinal cord, DRG, and peripheral nerves, with different receptor densities found during various stages of mouse development (299). At d 14, PAR₂-staining was observed throughout the mouse brain. Among the hippocampal formation, PAR₂ was localized in the subiculum, in pyramidal cells throughout the CA1, CA2, CA3, and hilus region, and in granular cells of the dentate area. Additionally, staining for PAR₂ was observed in all cortical layers, amygdaloid nuclei, striatum, thalamus, and hypothalamus (175). Peripheral nerves were intensively stained after d 14. Similarly, PAR₂ has also been detected in human brain (276). In rat brain, PAR₂ is also expressed by neurons of the hippocampus (175, 300), meningeal cells (301), as well as astrocytes (176, 185). PAR₂ is abundantly expressed in various subareas and is transiently up-regulated during oxygen and glucose deprivation (175). Moreover, PAR₂ activation is cytotoxic for isolated rat hippocampal neurons in a concentration-dependent manner (300).

Domotor *et al.* (302) recently reported that agonists of PAR₂ induce Ca²⁺ responses in brain microvascular endothelial cells. This effect may be modulated by elastase and plasmin, which regulate PAR₂ signaling. Studies of the actions of PAR₂ agonists on CNS targets suggest an important role of PAR₂ during injury, growth, apoptosis, and probably memory.

Very recently, PAR₂ has been localized on rat sensory neurons (243). Moreover, functional data strongly support the idea that the peripheral nervous system is directly regulated by PAR₂ during neurogenic inflammation. Neuropeptides such as calcitonin gene-related peptide and substance P (SP) from primary spinal afferent neurons are known as important mediators of neurogenic inflammation in many organs. Because of the close proximity of tryptase-containing mast cells to spinal afferent fibers, and because agonists of PAR₂ cause effects similar to those of tryptase in many tissues, comprising many of the characteristics of neurogenic inflammation, it was speculated that serine proteinases or other PAR₂ agonists may activate PAR₂ on sensory neurons to stimulate neuropeptide release and may thus regulate inflammation. Indeed, it was shown that agonists of PAR₂ can induce inflammation by a neurogenic mechanism that depends on the release of calcitonin-gene related peptide (CGRP) and SP from primary spinal afferent neurons. However, there also appears to be a nonneurogenic component of PAR₂-induced inflammation because granulocyte infiltra-

tion triggered by PAR₂ in a paw edema inflammation model was unaffected by sensory denervation or by neuropeptide receptor antagonists. Thus, PAR₂ agonists may also act directly on endothelial cells or on neutrophils themselves to stimulate inflammation-related granulocyte adhesion and infiltration (14, 250). It is possible that serine proteinases may activate PAR₂ on spinal afferent neurons under pathophysiological inflammatory circumstances. In a similar manner, serine proteinases may regulate enteric neuronal function by cleaving PAR₂ in a Ca²⁺-dependent manner (196). Trypsin, which is released by airway epithelial cells, but not the PAR₂ agonist peptide sequence SLIGRL, induced a marked contraction in guinea pig bronchi via SP release. Thus, non-PAR mediated effects of trypsin may also regulate neuropeptide function in the lung (303).

Several reports strongly suggest a role of PAR₂ in the central transmission of pain and nociception in rats and mice (304–306). Intraplantar administration of low doses of PAR₂ agonists, which do not induce inflammation, resulted in a long-lasting hyperalgesia. Interestingly, these effects of PAR₁ agonists were more efficacious in comparison with other inducers of hyperalgesia such as PGE₂ (0.3 μg). In the spinal cord, PAR₂ agonists induced an up-regulation of c-fos, a marker of activated nociceptive neurons (305, 307, 308). Another study also reported a role of PAR₂ in a rat visceral pain model (308). PAR₂ agonists administered *in vivo* clearly increased abdominal colonic contractions. This effect was inhibited by an NK₁ receptor antagonist, but not by the PG inhibitor indomethacin (308). However, additional studies are necessary to fully explain the underlying direct or indirect effects of PAR₂-induced nociception. For example, neuropeptides released from neurons upon PAR₂ stimulation may activate the release of nociceptive mast cell mediators such as kinins or prostanoids (309).

The observation that PAR₂ agonists are involved in the transmission of neurogenic inflammation and pain subsequently draws the question whether PAR₂ may be involved in the central transmission of pruritus. Itching is one of the most frequent symptoms in dermatological diseases and accompanies inflammatory and immune responses of many diseases such as hypersensitivity reactions or urticaria, for example. Indeed, neuronal PAR₂ appears to be involved in the induction of pruritus in human skin (277). Moreover, the endogenous PAR₂ agonist tryptase was increased up to 4-fold in atopic dermatitis patients, and PAR₂ expression was markedly enhanced on primary afferent nerve fibers in skin biopsies of atopic dermatitis patients. Intracutaneous injection of specific PAR₂ agonists provoked enhanced and prolonged itch when applied intralesionally. Thus, PAR₂ activation on cutaneous sensory nerves may be a novel pathway for the transmission of itch and inflammatory responses during atopic dermatitis and probably other skin diseases. PAR₂ antagonists may be promising therapeutic targets for the treatment of cutaneous neurogenic inflammation and pruritus (277).

In summary, PAR₂ may play an important regulatory role in the central and peripheral nervous system in normal and disease states, including neurogenic inflammation.

G. Digestive tract and pancreas

In rats, Kawabata *et al.* (167, 310, 311) detected PAR₂ mRNA in the sublingual, submaxillary, and parotid salivary glands. Of these three distinct salivary glands, the sublingual exhibited the strongest responses to PAR₂ activation resulting in the secretion of mucin. This response appeared to be mediated in part via a tyrosine kinase signal pathway, because genistein, an inhibitor of several tyrosine and other protein kinases, attenuated the effect. Pretreatment with the alkaloid capsaicin, which activates the transient receptor potential of vanilloid type 1 and which, in turn, is known to play a major role in inflammatory thermal nociception, failed to abrogate the secretion of mucin from salivary glands but abolished the PAR₂-triggered cytoprotective secretion of mucus in the stomach. These results provide both a sensory neuron-independent and -dependent mechanism for PAR₂-regulated exocrine secretion (312). Additional support for a role of PAR₂ in salivary gland secretion was provided by data showing that a PAR₂ agonist can stimulate amylase secretion from rat parotid gland slices *in vitro* (311).

In the GI tract, PAR₂ is highly expressed by enterocytes, where it is localized on the apical and basolateral membranes (253, 313). Moreover, myocytes of the muscularis mucosae and muscularis externa as well as neuronal elements are immunoreactive for PAR₂. Recent observations indicate that trypsin may regulate enterocytes by cleaving and triggering PAR₂ at the apical membrane (253) to induce the generation of PGE₂ and PGF_{1 α} , suggesting that PAR₂ may have a cytoprotective as well as an inflammatory effect on the GI tract. Moreover, mucosal mast cell proteinases may possibly activate PAR₂ on enterocytes and colonic myocytes. PAR₂-mediated inhibition of intestinal motility may contribute to inflammatory conditions in which mast cells are involved.

Trypsin may activate PAR₂ in the pancreas itself under physiological and pathophysiological conditions because trypsin can be prematurely activated in the inflamed pancreas (314). PAR₂ seems to play an important role also in pancreatic nociception because injection of an AP specific for PAR₂ can activate and sensitize pancreas-specific afferent neurons *in vivo* (314). Moreover, Hoogerwerf *et al.* (314) found that stimulating DRG with a PAR₂-AP resulted in enhanced capsaicin- and KCl-stimulated release of calcitonin gene-related peptide, which is a marker for nociceptive signaling.

PAR₂ is expressed by both acinar cells, which release digestive enzymes, and duct cells, which produce fluid and bicarbonate. In isolated pancreatic acini, trypsin and PAR₂ agonists stimulate amylase release (154) (N. W. Bunnett, personal communication). *In vivo* studies revealed the secretion of pancreatic juice after PAR₂ activation (167). Interestingly, PAR₂ agonists applied to the basolateral but not apical membrane of monolayers of pancreatic duct cells increase short circuit currents due to activation of Ca²⁺-sensitive Cl⁻ and K⁺ channels (315). These effects may be of relevance in pancreatitis when trypsin is released across the basolateral membrane.

H. Signaling by proteinases via PAR₂

There are relatively few studies examining the involvement of PAR₂ in signaling cascades compared with the rel-

atively large number of studies concerning PAR₁-mediated intracellular signaling (13, 14). So far, there are only indirect data indicating that PAR₂ interacts with G_q/G₁₁ (activation of calcium signaling) and possibly with G₀/G_i (316). Whether or not PAR₂ binds to other G proteins, such as G₁₂ or G₁₃, remains unclear.

Interaction of PAR₂ with G_i and G_q suggests a subsequent activation of PLC, PKC, and MAPK pathways. These signaling pathways can affect various cell activities including cell proliferation, morphological changes, motility and survival, and gene transcription regulation (Table 2 and Fig. 3). Indeed, as demonstrated for neuronal cells and SMC, stimulation by trypsin as well as PAR₂-AP leads to subsequent activation of PLC and PKC (317, 318). Kanke *et al.* (286) demonstrated that PAR₂ agonists (trypsin as well as the AP SLIGKV-NH₂) stimulate JNK and p38 MAPK activation in a human keratinocyte cell line (NCTC2544). Moreover, Vouret-Craviari *et al.* (225) described PAR₂-induced activation of RhoA in HUVEC revealing a possible mechanism underlying PAR₂-mediated effects at cytoskeleton in macrovascular endothelial cells. Together, these data shed some light on the potential signaling mechanisms underlying PAR₂-associated cellular effects such as depolarization response in neuronal cells, proliferation and mitogenic response in SMC, proliferation and differentiation of keratinocytes, and cytoskeletal changes in endothelial cells (225, 275, 319, 320).

Additionally, the effects of trypsin as well as PAR₂-AP on the activation of nuclear transcriptional factors have recently been demonstrated. It was shown that PAR₂ agonists stimulate NF κ B-DNA binding activity and activation of upstream kinases IKK α and IKK β (286). The effects of PAR₂ stimulation on NF κ B or IKK also have been described in other studies performed on different cell types (13, 263, 287, 297, 321).

It is also important to pay attention to factor Xa signaling mediated via PAR₂. It was mentioned in Section II.H.6 that this factor induces signaling events via PAR₁; the potential role of PAR₂ in such signaling remained unclear for a long time. Recently, however, the involvement of PAR₂ activation in coagulation factor Xa signaling has been reported. In HUVEC, factor Xa interacts with a protein called effector cell proteinase receptor-1 (EPR-1). This interaction is associated with signal transduction, generation of intracellular second messengers, and modulation of cytokine gene expression. Inhibitors of factor Xa blocked these responses (322). Additionally, direct cleavage of PAR₂ by factor Xa has been demonstrated, reflecting the complexity of PAR₂-induced signaling. These data allowed the authors to suggest that factor Xa induces endothelial cell activation via a novel cascade of receptor activation involving docking to EPR-1 and proteolytic cleavage of PAR₂ (322).

As already mentioned extensively in Section II.H, PAR₁ and PAR₂ both account for around 90% of endothelial factor Xa-mediated signaling in mice. In contrast, PAR₁ virtually accounts for all factor Xa-induced activation in fibroblasts, indicating potential cell-specific synergistic effects of PAR receptors on target cells (25).

Moreover, Koo *et al.* (323) demonstrated an involvement of PAR₂ in factor Xa signaling by analyzing factor Xa-induced




FIG. 3. Diagram showing the major G protein-mediated signaling pathways coupled to PAR₂. Dashed lines or circles represent signaling pathways or intermediates that are not fully revealed to be activated by PAR₂, but are in favor of other G protein-coupled receptors or are typical intermediate-accompanying molecules. Drawing represents a composition of signaling events of different tissues, cell types, and species (also see Table 2).

stimulation of coronary artery SMC using cell proliferation and ERK1/2 activation as indices of response. Furthermore, factor Xa-induced ERK1/2 activation was not desensitized by preincubation of the cells with thrombin. However, ERK1/2 activation was markedly attenuated by prior exposure of the cells to PAR₂-AP (SLIGKV-NH₂). The mitogenic effect of factor Xa was significantly reduced in the presence of an anti-PAR₂ monoclonal antibody that attenuates receptor activation, demonstrating the specificity of these effects (323). Together, these observations suggest that various signaling cascades are involved in PAR₂-mediated signaling. Clearly, we are just beginning to understand the variety of PAR₂-induced cell signaling pathways regulated under physiological conditions and during disease.

IV. PAR₃ and PAR₄

A. Biology and distribution of PAR₃ and PAR₄

As already mentioned, murine platelets do not express PAR₁. The observation that thrombin was still capable of

inducing Ca responses in these cells led to the identification of PAR₃ (18). In humans, PAR₃ is expressed in bone marrow, heart, brain, placenta, liver, pancreas, thymus, small intestine, stomach, lymph nodes, and trachea, although the cell types remain to be identified. In mouse, PAR₃ is expressed by megakaryocytes and platelets, among other cell types. The receptor is necessary for normal thrombin signaling in mouse platelets because blocking of the hirudin-like domain of PAR₃ using a specific antibody prevented mouse platelet activation by low but not by high concentrations of thrombin. The same result was observed with PAR₃-deficient platelets (19, 324). This also shows that PAR₃ is a high-affinity thrombin receptor in mouse that is activated by proteolytic cleavage. Interestingly, murine PAR₃ (mPAR₃) itself does not lead to thrombin signaling even when overexpressed, indicating that the receptor has lost its ability to function autonomously during evolution (39, 40). Knocking out the *PAR3* gene in mice leads to protection of the animals against thrombosis but has a relatively mild effect on hemostasis (325) (Table 2). However, analysis of PAR₃ expression in human platelets

showed that the receptor is not produced or is hardly produced by these cells (128). This suggests that in humans PAR₃ does not play a major role for platelet activation in contrast to the mouse system.

Antibodies specific for PAR₁ inhibited human platelet activation by low but not by high concentrations of thrombin (125, 326). In mice, PAR₃ is necessary for normal thrombin signaling in platelets. This indicates the presence of more than one thrombin receptor on the surface of these cells. Indeed, a fourth receptor was cloned, named PAR₄ (19, 20, 128). So far, PAR₄ has been cloned from human, mouse, and rat tissues (19, 20, 327). In humans, PAR₄ is widely expressed in brain (175), testes, placenta, lung, liver, pancreas, thyroid, skeletal muscle, and small intestine (20). In rats, PAR₄ is expressed in esophagus, stomach, duodenum, jejunum, distal colon, spleen, and brain (327, 328).

Both in mice and humans, platelets utilize two thrombin receptors. PAR₄ is a low-affinity receptor in platelets both in humans and mice. However, mouse platelets use PAR₃ and PAR₄ instead of PAR₁ and PAR₄ to respond to thrombin (19). In humans, platelet effects of thrombin appear to be mediated predominantly by PAR₁. Only at high concentrations and when PAR₁ activation has been inhibited is platelet activation by thrombin dependent on PAR₄. Signals mediated by PAR₄ result in calcium influx (19, 122, 329), thromboxane production (117), endostatin secretion in rat platelets (118), and platelet aggregation (122) (Table 2). However, selective activation of human PAR₄ (hPAR₄) resulted in a weaker response compared with hPAR₁-mediated signaling because anionic phospholipids were not exposed on the surface of hPAR₄-activated platelets. Interestingly, hPAR₄ can also be activated by cathepsin G, a neutrophil granule proteinase (330). Cathepsin G mediates neutrophil-platelet interactions at sites of vascular injury or inflammation. Inhibition of hPAR₁ had no effect on platelet responses to cathepsin G, indicating a specific activation of PAR₄.

Patients with Hermansky-Pudlak syndrome, an autosomal recessive disorder, lack platelet dense granules and have no ADP autocrine response. However, these patients show only a mild bleeding phenotype (331, 332). It was hypothesized that the defect of ADP autocrine response was compensated by signaling through PAR₄ because the activation of this receptor occurs well after ADP release in normal individuals (333). Therefore, the ADP-autocrine response does not seem to be necessary for platelet aggregation as long as PAR₄ is strongly activated. However, it was observed by another laboratory that PAR₄-induced, but not PAR₁-induced, aggregation was entirely ADP-dependent using a specific AP for PAR₄ (334). Moreover, the authors found that subthreshold concentrations of an AP-activating PAR₁ potentiated the effects of a PAR₄-AP to stimulate maximal aggregation. In addition, both prostacyclin (PGI₂) and S-nitroso-glutathione, an NO-releasing agent, reduced AP-stimulated aggregation and fibrinogen-receptor up-regulation.

PAR₄^{-/-} mice had markedly increased bleeding times (40). In addition, the platelets of these mice failed to change shape, mobilize calcium, or aggregate in response to thrombin. Ma *et al.* (118) observed that a specific AP for PAR₄ could induce endostatin release in rat platelets. A selective PAR₄ antagonist prevented endostatin release. In human platelets,

specific agonists for PAR₁ or PAR₄ stimulated thromboxane production (117). Thromboxane produced by the combined stimulation of PAR₁ and PAR₄ was additive, suggesting the presence of two pathways for thrombin-induced thromboxane production in platelets. Blocking PAR₁ function with a domain-specific antibody resulted in substantial inhibition of thrombin signaling. However, PAR₄ can mediate platelet activation in response to high concentrations of thrombin (128). hPAR₄ itself showed no pharmacological effect at either 1 nM or 30 nM thrombin. However, blocking of both hPAR₁ and hPAR₄ resulted in a profound inhibitory response even at high concentrations of the proteinase (128). This shows that hPAR₄ activation is not necessary for robust responses in platelets when hPAR₁ function is intact. Thus, inhibition of hPAR₁ alone is probably not sufficient when seeking new antithrombotic therapies; it might be necessary to block both receptors simultaneously (106, 128). hPAR₄ seems to play a role as a backup signaling device that might mediate thrombin signaling to distinct effectors or with different kinetics compared with PAR₁. It might also allow platelets to respond to proteinases other than thrombin. Moreover, both receptors might be able to directly interact with each other.

The fact that mPAR₃ alone does not result in thrombin signaling on mouse platelets showed that mPAR₃ functions as a cofactor that promotes cleavage and activation of PAR₄ at low concentrations of thrombin (39, 40). Interestingly, knocking out the *PAR3* or the *PAR4* gene leads to a similar degree of protection against thrombosis in mice (40, 325). In humans, both hPAR₁ and hPAR₄ may independently mediate thrombin signaling (20, 128, 177). Thus, the mouse system does not have a direct analog in the human platelet. However, mPAR₃ promoted cleavage and activation of hPAR₄ as effectively as mPAR₄. Thus, hPAR₄ can be "cofactored" by PAR₃ *in vitro*, but it remains unclear whether or not cofactors such as PAR₁ play a direct role in hPAR₄ activation *in vivo* (39).

This reservoir of multiple thrombin receptors including PAR₁, PAR₃, and PAR₄ may allow for a precise regulation of thrombin-induced inflammatory stimuli under different pathophysiological conditions and the fine-tuned induction of different signal transduction pathways.

In endothelial cells, thrombin induces a rapid but transient activation of endothelial cells by stimulating the secretion of PGI₂ or platelet-activating factor (PAF) and by inducing the production of cell adhesion molecules (P-selectin, E-selectin) (47, 69, 70). Thrombin and a nonselective AP also induce synthesis and release of cytokines from endothelial cells such as IL-1, IL-6, and IL-8 (71, 72). Moreover, they regulate the cytokine-independent expression of ICAM-1 and VCAM-1 on human endothelial cells and cause an increased adhesion of monocytes to endothelial cells. This effect can be diminished by blocking antibodies (anti-CD 18, anti-CD 49d) (73). In the past, the effects observed above had been attributed to the activation of PAR₁. However, a recent *in vivo* study has shown that thrombin-induced leukocyte rolling and adhesion to vascular walls is mediated via PAR₄ (74). Although thrombin can trigger the recruitment of leukocytes to sites of inflammation, the PAR₁ antagonist RWJ-56110 does not block this effect. In contrast, a PAR₄-AP is able to reproduce

the effects of thrombin on leukocyte rolling and adherence, indicating that this proinflammatory effect of thrombin is due to the activation of PAR₄ and not PAR₁ (74). Thus, PAR₄ appears to function in early events of inflammatory reaction, in terms of recruiting leukocytes to the site of injury.

In contrast to a potential participation of PAR₁ in stimulating the angiogenic process (335), PAR₄ may play an opposing role. Apart from its antiangiogenic role via the activation of platelets, PAR₄ can also affect the arterial system by stimulating vascular smooth muscle mitogenesis (220).

PAR₄, like PAR₁ and PAR₂, also appears to be linked to signal transduction processes that modulate airway smooth muscle tone, because a PAR₄-AP caused a rapid transient contractile response in a murine tracheal preparation. This contraction was followed by a transient relaxant phase. The underlying molecular mechanism is still unclear, but the relaxation appears to be dependent on PAR₄-stimulated and COX-2-generated PGE₂ production, which activates the E-type prostanoid 2 receptor (152, 153).

In conclusion, preliminary data strongly suggest an important pathophysiological role of PAR₄ in vascular homeostasis and platelet function. However, the role of PAR₃ as a signaling molecule and the precise function of PAR₄ during inflammation and immune response remain to be clarified.

B. Signaling by proteinases via PAR₃ and PAR₄

PAR₃ and PAR₄ are the most recent members of the proteinase-activated receptor family. They are activated by thrombin. Subsequent to the cloning of PAR₃ (18) and PAR₄ (19, 20), relatively few publications have appeared examining the involvement of these receptors in signaling cascades. One puzzle that is yet to be resolved, as already mentioned, is the inability of PAR₃ to signal in response to its tethered ligand-derived peptide or to thrombin (39, 40). Until this issue is resolved unequivocally, a meaningful discussion about PAR₃ signaling is not possible. In contrast, PAR₄ appears to be capable of activating both G₁₂/G₁₃ and G_q pathways (201, 336, 337).

As mentioned above, PAR₄ appears to be involved in the same signaling cascades as PAR₁ in human platelets. In contrast, mouse platelets express PAR₃ and PAR₄, but only PAR₄ appears to serve as a real signaling receptor, and PAR₃ serves solely to facilitate cleavage of PAR₄ by thrombin (39).

Studying downstream signaling events in which PAR₁ and PAR₄ could be involved in VSMC, Bretschneider *et al.* (220) revealed that these receptors have distinct downstream signaling kinetics. Later, activation of MAPKs after stimulation of PAR₄ was demonstrated. In their recent work, Sabri *et al.* (338) investigated PAR₄-mediated signaling in cardiomyocytes derived from PAR₁^{-/-} mice. Using AYPGKF-NH₂, a modified PAR₄ agonist with an increased binding potency to PAR₄, they were able to demonstrate p38 phosphorylation as well as slight activation of PLC and ERK1/2. Additionally, thrombin and PAR₄-AP, but not PAR₁-AP, were able to activate Src in these cells, clearly indicating that the action of thrombin on Src activation is mediated by PAR₄, and not by PAR₁ in these cells. Further studies implicated the involve-

ment of Src and EGFR kinase activity in the PAR₄-dependent p38 signaling pathway (338).

Recently, the involvement of PAR₄ in factor Xa-mediated signaling has been demonstrated. Camerer *et al.* (25) revealed that expression of PAR₁, PAR₂, and PAR₄ in *Xenopus* oocytes confers calcium signaling in response to factor Xa. They further showed that PAR₄-AP (AYPGKF-NH₂) stimulated increased phosphoinositide hydrolysis in endothelial cells and that responses to AYPGKF-NH₂ are absent in PAR₄^{-/-} endothelial cells (240). Accordingly, PAR₄-mediated phosphoinositide hydrolysis in response to factor Xa has been clearly demonstrated (25).

V. Conclusions

There is no doubt that PARs play an important regulatory role during inflammation and immune response. Recent findings consolidate the concept that serine proteinases act as autocrine, paracrine, or endocrine mediators that talk directly to cells (13–15, 30). Some of these proteinase-stimulated effects are mediated through activation of proteinase-activated receptors, resulting in signal transduction pathways that are involved in inflammation and immune response. In many cases, PARs appear to play a proinflammatory role due to activation of proinflammatory mediators and cytokines (28, 59, 67, 72, 77–90, 94, 99, 263, 272, 274, 282, 283, 295, 339–345). In other instances, a protective and antiinflammatory role of PARs has been observed (52, 292, 298, 312, 346–348). Various serine proteinases, which serve as PAR activators, are relevant mediators during inflammation (Table 2). However, the precise role of PARs and serine proteinases in different tissues, cell types, and states of inflammation remains to be determined.

Open questions include: 1) For the several proteinases that are released in various tissues from different cell types during inflammation, what is their mechanism of regulation and what is their functional relevance? 2) What is the significance of the existence of multiple receptor subtypes for one proteinase, and how might these common proteinase targets be differentially regulated? 3) Which immune cells express functional PARs in humans *in vivo*, and what is their biological relevance? 4) Which are the endogenous proteinases that activate PAR₂ in human inflammation *in vivo*? 5) Which factors influence the regulation of PARs during inflammation or host defense? 6) Which effects of PAR-activating proteinases are non-PAR-mediated effects? 7) Which are the cell-specific signaling pathways and molecular mechanisms (transcription factors) after selective PAR activation in different inflammatory states and tissues? 8) What role do PARs play in neuronal transmission in humans? 9) Can PAR agonists or antagonists be used as therapeutic agents during inflammation or immune response in human diseases?

Thus, an integrative understanding of a regulatory role of serine proteinases as extracellular degradative enzymes as well as hormone-like signaling messengers in part via PARs and their counterregulation by extracellular proteinase inhibitors and intracellular molecules should lead to effective therapeutic approaches for various inflammatory/immune diseases such as thrombosis, sepsis, bacterial infections, gin-

ginitis, asthma, hyperreactivity reaction, lung fibrosis, renal inflammation, rheumatoid arthritis, colitis ulcerosa, Crohn's disease, pancreatitis, Alzheimer's disease, amyotrophic lateral sclerosis, HIV encephalitis, atopic dermatitis, contact dermatitis, rosacea, wound repair, and infertility, for example, as well as pathophysiological symptoms such as pain and pruritus, in the future.

Acknowledgments

Address all correspondence and requests for reprints to: Martin Steinhoff, M.D., Ph.D., Department of Dermatology and Boltzmann Institute for Immunobiology of the Skin, University of Münster, von-Esmarch-Strasse 58, 48149 Münster, Germany. E-mail: msteinho@uni-muenster.de.

This work was supported by grants from the Federal Ministry of Education and Research (Interdisciplinary Center for Clinical Research, Münster Fö. II-703-04; German Research Association, STE 1014; Collaborative Research Center (SFB) 293; SFB 492 to M.S.), Schering Foundation (to M.S., V.S.), C.E.R.I.E.S., Paris, France, and Boltzmann-Institute, Münster, Germany (to T.A.L., M.S.); Novartis Research Foundation (Vienna, Austria); Rosacea Foundation (to M.S.), and Boehringer-Ingelheim Fonds (to J.B.). The work of M.D.H. and N.V. is supported by funds from the Canadian Institutes for Health Research, the Kidney Foundation of Canada (to M.D.H.), the Heart and Stroke Foundation of Canada (to M.D.H.), by a Johnson & Johnson Focused Giving Grant, and by the Ileitis Colitis Foundation (to N.V.).

References

- Barrett AJ, Rawlings ND, Woessner JF 1998 Proteolytic enzymes: nomenclature and classification. Handbook of proteolytic enzymes. New York: Academic Press; 13–29
- Rinderknecht H 1986 Activation of pancreatic zymogens: normal activation, premature intrapancreatic activation, protective mechanism against inappropriate activation. Dig Dis Sci 31:314–321
- Neurath H, Walsh K 1976 Role of proteolytic enzymes in biological regulation (a review). Proc Natl Acad Sci USA 73:3825–3832
- Walsh PN, Ahmad S 2002 Proteases in blood clotting. Essays Biochem 38:95–111
- Thomas CA, Yost Jr FJ, Snyderman R, Hatcher VB, Lazarus GS 1977 Cellular serine proteinase induces chemotaxis by complement activation: proteinases of human epidermis; a possible mechanism for polymorphonuclear leukocyte chemotaxis. Nature 269:521–522
- Krowarsch D, Cierpicki T, Jelen F, Otlewski J 2003 Canonical protein inhibitors of serine proteases. Cell Mol Life Sci 60:2427–2444
- Cumashi A, Ansuini H, Celli N, De Blasi A, O'Brien PJ, Brass LF, Molino M 2001 Neutrophil proteases can inactivate human PAR3 and abolish the co-receptor function of PAR3 on murine platelets. Thromb Haemost 85:533–538
- Muehlenweg B, Assfalg-Machleidt I, Parrado SG, Burgle M, Creutzburg S, Schmitt M, Auerswald EA, Machleidt W, Magdolen V 2000 A novel type of bifunctional inhibitor directed against proteolytic activity and receptor/ligand interaction. Cystatin with a urokinase receptor binding site. J Biol Chem 275:33562–33566
- Kinlough-Rathbone RL, Perry DW, Rand ML, Packham MA 1999 Effects of cathepsin G pretreatment of platelets on their subsequent responses to aggregating agents. Thromb Res 95:315–323
- Hayes KL, Tracy PB 1999 The platelet high affinity binding site for thrombin mimics hirudin, modulates thrombin-induced platelet activation, and is distinct from the glycoprotein Ib-IX-V complex. J Biol Chem 274:972–980
- Lu B, Figini M, Emanuelli C, Geppetti P, Grady EF, Gerard NP, Ansell J, Payan DG, Gerard C, Bunnett N 1997 The control of microvascular permeability and blood pressure by neutral endopeptidase. Nat Med 3:904–907
- Blasi FCP 2002 uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 3:932–943
- Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R 2001 Proteinase-activated receptors. Pharmacol Rev 53:245–282
- Déry O, Corvera CU, Steinhoff M, Bunnett NW 1998 Proteinase-activated receptors: novel mechanisms of signaling by serine proteases. Am J Physiol 274:C1429–C1452
- Coughlin SR 2000 Thrombin signalling and protease-activated receptors. Nature 407:258–264
- Hollenberg MD, Compton SJ 2002 International union of pharmacology. XXVIII. Proteinase-activated receptors. Pharmacol Rev 54:203–217
- Vu TK, Hung DT, Wheaton VI, Coughlin SR 1991 Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64:1057–1068
- Ishihara H, Connolly AJ, Zeng D, Kahn ML, Zheng YW, Timmons C, Tram T, Coughlin SR 1997 Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 386:502–506
- Kahn ML, Zheng YW, Huang W, Bigornia V, Zeng D, Moff S, Farese Jr RV, Tam C, Coughlin SR 1998 A dual thrombin receptor system for platelet activation. Nature 394:690–694
- Xu WF, Andersen H, Whitmore TE, Presnell SR, Yee DP, Ching A, Gilbert T, Davie EW, Foster DC 1998 Cloning and characterization of human protease-activated receptor 4. Proc Natl Acad Sci USA 95:6642–6646
- Nystedt S, Larsson AK, Aberg H, Sundelin J 1995 The mouse proteinase-activated receptor-2 cDNA and gene. Molecular cloning and functional expression. J Biol Chem 270:5950–5955
- Nystedt S, Emilsson K, Larsson AK, Strombeck B, Sundelin J 1995 Molecular cloning and functional expression of the gene encoding the human proteinase-activated receptor 2. Eur J Biochem 232:84–89
- Molino M, Barnathan ES, Numerof R, Clark J, Dreyer M, Cumashi A, Hoxie JA, Schechter N, Woolkalis M, Brass LF 1997 Interactions of mast cell tryptase with thrombin receptors and PAR-2. J Biol Chem 272:4043–4049
- Steinhoff M, Corvera CU, Thoma MS, Kong W, McAlpine BE, Caughey GH, Ansel JC, Bunnett NW 1999 Proteinase-activated receptor-2 in human skin: tissue distribution and activation of keratinocytes by mast cell tryptase. Exp Dermatol 8:282–294
- Camerer E, Huang W, Coughlin SR 2000 Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci USA 97:5255–5260
- Smith R, Jenkins A, Loubakos A, Thompson P, Ramakrishnan V, Tomlinson J, Deshpande U, Johnson DA, Jones R, Mackie EJ, Pike RN 2000 Evidence for the activation of PAR-2 by the sperm protease, acrosin: expression of the receptor on oocytes. FEBS Lett 484:285–290
- Loubakos A, Chinni C, Thompson P, Potempa J, Travis J, Mackie EJ, Pike RN 1998 Cleavage and activation of proteinase-activated receptor-2 on human neutrophils by gingipain-R from *Porphyromonas gingivalis*. FEBS Lett 435:45–48
- Loubakos A, Potempa J, Travis J, D'Andrea MR, Andrade-Gordon P, Santulli R, Mackie EJ, Pike RN 2001 Arginine-specific protease from *Porphyromonas gingivalis* activates protease-activated receptors on human oral epithelial cells and induces interleukin-6 secretion. Infect Immun 69:5121–5130
- Verrall S, Ishii M, Chen M, Wang L, Tram T, Coughlin SR 1997 The thrombin receptor second cytoplasmic loop confers coupling to Gq-like G proteins in chimeric receptors. Additional evidence for a common transmembrane signaling and G protein coupling mechanism in G protein-coupled receptors. J Biol Chem 272:6898–6902
- Coughlin SR 1999 How the protease thrombin talks to cells. Proc Natl Acad Sci USA 96:11023–11027
- Scarborough RM, Naughton MA, Teng W, Hung DT, Rose J, Vu TK, Wheaton VI, Turck CW, Coughlin SR 1992 Tethered ligand agonist peptides. Structural requirements for thrombin receptor activation reveal mechanism of proteolytic unmasking of agonist function. J Biol Chem 267:13146–13149
- Blackhart BD, Emilsson K, Nguyen D, Teng W, Martelli AJ, Nystedt S, Sundelin J, Scarborough RM 1996 Ligand cross-reactivity within the protease-activated receptor family. J Biol Chem 271:16466–16471
- Coller BS, Springer KT, Scudder LE, Kutok JL, Ceruso M, Prestwich GD 1993 Substituting isoserine for serine in the throm-

- bin receptor activation peptide SFLLRN confers resistance to aminopeptidase M-induced cleavage and inactivation. *J Biol Chem* 268:20741–20743
34. **Hollenberg MD** 2002 PARs in the stars: proteinase-activated receptors and astrocyte function. Focus on "Thrombin (PAR-1)-induced proliferation in astrocytes via MAPK involves multiple signaling pathways." *Am J Physiol Cell Physiol* 283:C1347–C1350
 35. **Bernatowicz MS, Klimas CE, Hartl KS, Peluso M, Allegretto NJ, Seiler SM** 1996 Development of potent thrombin receptor antagonist peptides. *J Med Chem* 39:4879–4887
 36. **Andrade-Gordon P, Maryanoff BE, Derian CK, Zhang HC, Addo MF, Darrow AL, Eckardt AJ, Hoekstra WJ, McComsey DF, Oksenberg D, Reynolds EE, Santulli RJ, Scarborough RM, Smith CE, White KB** 1999 Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor. *Proc Natl Acad Sci USA* 96:12257–12262
 37. **Ahn HS, Foster C, Boykow G, Stamford A, Manna M, Graziano M** 2000 Inhibition of cellular action of thrombin by N3-cyclopropyl-7-[[4-(1-methylethyl)phenyl]methyl]-7H-pyrrolo[3,2-]quinazoline-1,3-diamine (SCH 79797), a nonpeptide thrombin receptor antagonist. *Biochem Pharmacol* 60:1425–1434
 38. **Wu CC, Hwang TL, Liao CH, Kuo SC, Lee FY, Lee CY, Teng CM** 2002 Selective inhibition of protease-activated receptor 4-dependent platelet activation by YD-3. *Thromb Haemost* 87:1026–1033
 39. **Nakanishi-Matsui M, Zheng YW, Sulciner DJ, Weiss EJ, Lude-man MJ, Coughlin SR** 2000 PAR3 is a cofactor for PAR4 activation by thrombin. *Nature* 404:609–613
 40. **Sambrano GR, Weiss EJ, Zheng YW, Huang W, Coughlin SR** 2001 Role of thrombin signalling in platelets in haemostasis and thrombosis. *Nature* 413:74–78
 41. **Schmidlin F, Bunnett NW** 2001 Protease-activated receptors: how protease signal to cells. *Curr Opin Pharmacol* 1:575–582
 42. **Coughlin SR** 2001 Protease-activated receptors in vascular biology. *Thromb Haemost* 86:298–307
 43. **Cirino G, Napoli C, Bucci M, Cicala C** 2000 Inflammation-coagulation network: are serine protease receptors the knot? *Trends Pharmacol Sci* 21:170–172
 44. **Vergnolle N, Ferazzini M, D'Andrea MR, Buddenkotte J, Steinhoff M** 2003 Proteinase-activated receptors: novel signals for peripheral nerves. *Trends Neurosci* 26:496–500
 45. **Noorbakhsh F, Vergnolle N, Hollenberg MD, Power C** 2003 Proteinase-activated receptors in the nervous system. *Nat Rev Neurosci* 4:981–990
 46. **Rasmussen UB, Vouret-Craviari V, Jallat S, Schlesinger Y, Pages G, Pavirani A, Lecocq JP, Pouyssegur J, Obberghen-Schilling E** 1991 cDNA cloning and expression of a hamster α -thrombin receptor coupled to Ca^{2+} mobilization. *FEBS Lett* 288:123–128
 47. **Sugama Y, Tirupathi C, Offakidevi K, Andersen TT, Fenton JW, Malik AB** 1992 Thrombin-induced expression of endothelial P-selectin and intercellular adhesion molecule-1: a mechanism for stabilizing neutrophil adhesion. *J Cell Biol* 119:935–944
 48. **Naldini A, Carney DH** 1996 Thrombin modulation of natural killer activity in human peripheral lymphocytes. *Cell Immunol* 172:35–42
 49. **Cunningham MA, Rondeau E, Chen X, Coughlin SR, Holdsworth SR, Tipping PG** 2000 Protease-activated receptor 1 mediates thrombin-dependent, cell-mediated renal inflammation in crescentic glomerulonephritis. *J Exp Med* 191:455–462
 50. **Ludwicka-Bradley A, Tourkina E, Suzuki S, Tyson E, Bonner M, Fenton JW, Hoffman S, Silver RM** 2000 Thrombin upregulates interleukin-8 in lung fibroblasts via cleavage of proteolytically activated receptor-I and protein kinase C- γ activation. *Am J Respir Cell Mol Biol* 22:235–243
 51. **Suk K, Cha S** 1999 Thrombin-induced interleukin-8 production and its regulation by interferon- γ and prostaglandin E2 in human monocytic U937 cells. *Immunol Lett* 67:223–227
 52. **Vergnolle N, Hollenberg MD, Wallace JL** 1999 Pro- and anti-inflammatory actions of thrombin: a distinct role for proteinase-activated receptor-1 (PAR1). *Br J Pharmacol* 126:1262–1268
 53. **Chin AC, Vergnolle N, MacNaughton WK, Wallace JL, Hollenberg MD, Buret AG** 2003 Proteinase-activated receptor 1 activation induces epithelial apoptosis and increases intestinal permeability. *Proc Natl Acad Sci USA* 100:11104–11109
 54. **Howells GL, Macey M, Curtis MA, Stone SR** 1993 Peripheral blood lymphocytes express the platelet-type thrombin receptor. *Br J Haematol* 84:156–160
 55. **Howells GL, Macey M, Murrell AM, Green AR, Curtis MA, Stone SR** 1994 Thrombin receptor expression and function in large granular lymphocyte proliferative disorders. *Br J Haematol* 88:383–388
 56. **DiCuccio MN, Shami P, Hoffman M** 1996 A functional tethered ligand thrombin receptor is present on human hematopoietic progenitor cells. *Exp Hematol* 24:914–918
 57. **Chang MC, Lin CP, Huang TF, Lan WH, Lin YL, Hsieh CC, Jeng JH** 1998 Thrombin-induced DNA synthesis of cultured human dental pulp cells is dependent on its proteolytic activity and modulated by prostaglandin E2. *J Endod* 24:709–713
 58. **Colotta F, Sciacca FL, Sironi M, Luini W, Rabiet MJ, Mantovani A** 1994 Expression of monocyte chemotactic protein-1 by monocytes and endothelial cells exposed to thrombin. *Am J Pathol* 144:975–985
 59. **Grandaliano G, Valente AJ, Abboud HE** 1994 A novel biologic activity of thrombin: stimulation of monocyte chemotactic protein production. *J Exp Med* 179:1737–1741
 60. **Weinstein JR, Gold SJ, Cunningham DD, Gall CM** 1995 Cellular localization of thrombin receptor mRNA in rat brain: expression by mesencephalic dopaminergic neurons and codistribution with prothrombin mRNA. *J Neurosci* 15:2906–2919
 61. **Arena CS, Quirk SM, Zhang YQ, Henrikson KP** 1996 Rat uterine stromal cells: thrombin receptor and growth stimulation by thrombin. *Endocrinology* 137:3744–3749
 62. **Kudahl K, Fisker S, Sonne O** 1991 A thrombin receptor in resident rat peritoneal macrophages. *Exp Cell Res* 193:45–53
 63. **Bar-Shavit R, Wilner GD** 1986 Biologic activities of nonenzymatic thrombin: elucidation of a macrophage interactive domain. *Semin Thromb Hemost* 12:244–249
 64. **Muramatsu I, Lanionu A, Moore GJ, Hollenberg MD** 1992 Vascular actions of thrombin receptor peptide. *Can J Physiol Pharmacol* 70:996–1003
 65. **Ku DD** 1986 Mechanism of thrombin-induced endothelium-dependent coronary vasodilation in dogs: role of its proteolytic enzymatic activity. *J Cardiovasc Pharmacol* 8:29–36
 66. **Tay-Uyboco J, Poon MC, Ahmad S, Hollenberg MD** 1995 Contractile actions of thrombin receptor-derived polypeptides in human umbilical and placental vasculature: evidence for distinct receptor systems. *Br J Pharmacol* 115:569–578
 67. **Garcia JG, Patterson C, Bahler C, Aschner J, Hart CM, English D** 1993 Thrombin receptor activating peptides induce Ca^{2+} mobilization, barrier dysfunction, prostaglandin synthesis, and platelet-derived growth factor mRNA expression in cultured endothelium. *J Cell Physiol* 156:541–549
 68. **Herkert O, Kuhl H, Sandow J, Busse R, Schini-Kerth VB** 2001 Sex steroids used in hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR-1) expression: role of the glucocorticoid receptor. *Circulation* 104:2826–2831
 69. **Weksler BB, Ley CW, Jaffe EA** 1978 Stimulation of endothelial cell prostacyclin production by thrombin, trypsin, and the ionophore A 23187. *J Clin Invest* 62:923–930
 70. **Kameda H, Morita I, Handa M, Kaburaki J, Yoshida T, Mimori T, Murota S, Ikeda Y** 1997 Re-expression of functional P-selectin molecules on the endothelial cell surface by repeated stimulation with thrombin. *Br J Haematol* 97:348–355
 71. **Kaplanski G, Fabrigoule M, Boulay V, Dinarello CA, Bongrand P, Kaplanski S, Farnarier C** 1997 Thrombin induces endothelial type II activation in vitro: IL-1 and TNF- α -independent IL-8 secretion and E-selectin expression. *J Immunol* 158:5435–5441
 72. **Chi L, Li Y, Stehno-Bittel L, Gao J, Morrison DC, Stechschulte DJ, Dileepan KN** 2001 Interleukin-6 production by endothelial cells via stimulation of protease-activated receptors is amplified by endotoxin and tumor necrosis factor- α . *J Interferon Cytokine Res* 21:231–240
 73. **Kaplanski G, Marin V, Fabrigoule M, Boulay V, Benoliel AM, Bongrand P, Kaplanski S, Farnarier C** 1998 Thrombin-activated human endothelial cells support monocyte adhesion in vitro following expression of intercellular adhesion molecule-1 (ICAM-1; CD54) and vascular cell adhesion molecule-1 (VCAM-1; CD106). *Blood* 92:1259–1267
 74. **Vergnolle N, Derian CK, D'Andrea MR, Steinhoff M, Andrade-**

- Gordon P 2002 Characterization of thrombin-induced leukocyte rolling and adherence: a potential proinflammatory role for proteinase-activated receptor-4. *J Immunol* 169:1467–1473
75. Nelken NA, Soifer SJ, O'Keefe J, Vu TK, Charo IF, Coughlin SR 1992 Thrombin receptor expression in normal and atherosclerotic human arteries. *J Clin Invest* 90:1614–1621
76. Takada M, Tanaka H, Yamada T, Ito O, Kogushi M, Yanagimachi M, Kawamura T, Musha T, Yoshida F, Ito M, Kobayashi H, Yoshitake S, Saito I 1998 Antibody to thrombin receptor inhibits neointimal smooth muscle cell accumulation without causing inhibition of platelet aggregation or altering hemostatic parameters after angioplasty in rat. *Circ Res* 82:980–987
77. Asokanathan N, Graham PT, Fink J, Knight DA, Bakker AJ, McWilliam AS, Thompson PJ, Stewart GA 2002 Activation of protease-activated receptor (PAR)-1, PAR-2, and PAR-4 stimulates IL-6, IL-8, and prostaglandin E2 release from human respiratory epithelial cells. *J Immunol* 168:3577–3585
78. Houliston RA, Keogh RJ, Sugden D, Dudhia J, Carter TD, Wheeler-Jones CP 2002 Protease-activated receptors upregulate cyclooxygenase-2 expression in human endothelial cells. *Thromb Haemost* 88:321–328
79. Temkin V, Kantor B, Weg V, Hartman ML, Levi-Schaffer F 2002 Trypsin activates the mitogen-activated protein kinase/activator protein-1 pathway in human peripheral blood eosinophils, causing cytokine production and release. *J Immunol* 169:2662–2669
80. Hirano F, Kobayashi A, Hirano Y, Nomura Y, Fukawa E, Makino I 2002 Thrombin-induced expression of RANTES mRNA through protease activated receptor-1 in human synovial fibroblasts. *Ann Rheum Dis* 61:834–837
81. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W 2002 Activation of endothelial cell protease activated receptor 1 by the protein C pathway. *Science* 296:1880–1882
82. Naldini A, Carney DH, Pucci A, Pasquali A, Carraro F 2000 Thrombin regulates the expression of proangiogenic cytokines via proteolytic activation of protease-activated receptor-1. *Gen Pharmacol* 35:255–259
83. Suo Z, Wu M, Ameenuddin S, Anderson HE, Zoloty JE, Citron BA, Andrade-Gordon P, Festoff BW 2002 Participation of protease-activated receptor-1 in thrombin-induced microglial activation. *J Neurochem* 80:655–666
84. Szaba FM, Smiley ST 2002 Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. *Blood* 99:1053–1059
85. Meli R, Raso GM, Cicala C, Esposito E, Fiorino F, Cirino G 2001 Thrombin and PAR-1 activating peptide increase iNOS expression in cytokine-stimulated C6 glioma cells. *J Neurochem* 79:556–563
86. McLean K, Schirm S, Johns A, Morser J, Light DR 2001 FXa-induced responses in vascular wall cells are PAR-mediated and inhibited by ZK-807834. *Thromb Res* 103:281–297
87. Bassus S, Herkert O, Kronemann N, Gorchach A, Bremerich D, Kirchmaier CM, Busse R, Schini-Kerth VB 2001 Thrombin causes vascular endothelial growth factor expression in vascular smooth muscle cells: role of reactive oxygen species. *Arterioscler Thromb Vasc Biol* 21:1550–1555
88. Carmeliet P 2001 Biomedicine. Clotting factors build blood vessels. *Science* 293:1602–1604
89. Marin V, Farnarier C, Gres S, Kaplanski S, Su MS, Dinarello CA, Kaplanski G 2001 The p38 mitogen-activated protein kinase pathway plays a critical role in thrombin-induced endothelial chemokine production and leukocyte recruitment. *Blood* 98:667–673
90. Martin CB, Mahon GM, Klinger MB, Kay RJ, Symons M, Der CJ, Whitehead IP 2001 The thrombin receptor, PAR-1, causes transformation by activation of Rho-mediated signaling pathways. *Oncogene* 20:1953–1963
91. Chow JM, Moffatt JD, Cocks TM 2000 Effect of protease-activated receptor (PAR)-1, -2 and -4-activating peptides, thrombin and trypsin in rat isolated airways. *Br J Pharmacol* 131:1584–1591
92. Kawabata A, Saifeddine M, Al Ani B, Leblond L, Hollenberg MD 1999 Evaluation of proteinase-activated receptor-1 (PAR1) agonists and antagonists using a cultured cell receptor desensitization assay: activation of PAR2 by PAR1-targeted ligands. *J Pharmacol Exp Ther* 288:358–370
93. Cheung WM, Andrade-Gordon P, Derian CK, Damiano BP 1998 Receptor-activating peptides distinguish thrombin receptor (PAR-1) and protease activated receptor 2 (PAR-2) mediated hemodynamic responses in vivo. *Can J Physiol Pharmacol* 76:16–25
94. Johnson K, Choi Y, DeGroot E, Samuels I, Creasey A, Aarden L 1998 Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation. *J Immunol* 160:5130–5135
95. Anrather D, Millan MT, Palmethofer A, Robson SC, Geczy C, Ritchie AJ, Bach FH, Ewenstein BM 1997 Thrombin activates nuclear factor- κ B and potentiates endothelial cell activation by TNF. *J Immunol* 159:5620–5628
96. Griffin CT, Srinivasan Y, Zheng YW, Huang W, Coughlin SR 2001 A role for thrombin receptor signaling in endothelial cells during embryonic development. *Science* 293:1666–1670
97. Mirza H, Yatsula V, Bahou WF 1996 The proteinase activated receptor-2 (PAR-2) mediates mitogenic responses in human vascular endothelial cells. *J Clin Invest* 97:1705–1714
98. Schaeffer P, Riera E, Dupuy E, Herbert JM 1997 Nonproteolytic activation of the thrombin receptor promotes human umbilical vein endothelial cell growth but not intracellular Ca²⁺, prostacyclin, or permeability. *Biochem Pharmacol* 53:487–491
99. Hamilton JR, Moffatt JD, Frauman AG, Cocks TM 2001 Protease-activated receptor (PAR) 1 but not PAR2 or PAR4 mediates endothelium-dependent relaxation to thrombin and trypsin in human pulmonary arteries. *J Cardiovasc Pharmacol* 38:108–119
100. Dabbagh K, Laurent GJ, McAnulty RJ, Chambers RC 1998 Thrombin stimulates smooth muscle cell procollagen synthesis and mRNA levels via a PAR-1 mediated mechanism. *Thromb Haemost* 79:405–409
101. Nguyen KT, Eskin SG, Patterson C, Runge MS, McIntire LV 2001 Shear stress reduces protease activated receptor-1 expression in human endothelial cells. *Ann Biomed Eng* 29:145–152
102. Shinohara T, Suzuki K, Takada K, Okada M, Ohsuzu F 2002 Regulation of proteinase-activated receptor 1 by inflammatory mediators in human vascular endothelial cells. *Cytokine* 19:66–75
103. Bhattacharya A, Cohen ML 2000 Vascular contraction and relaxation to thrombin and trypsin: thrombomodulin preferentially attenuates thrombin-induced contraction. *J Pharmacol Exp Ther* 295:284–290
104. Nguyen KT, Frye SR, Eskin SG, Patterson C, Runge MS, McIntire LV 2001 Cyclic strain increases protease-activated receptor-1 expression in vascular smooth muscle cells. *Hypertension* 38:1038–1043
105. Tiruppathi C, Yan W, Sandoval R, Naqvi T, Pronin AN, Benovic JL, Malik AB 2000 G protein-coupled receptor kinase-5 regulates thrombin-activated signaling in endothelial cells. *Proc Natl Acad Sci USA* 97:7440–7445
106. Cook JJ, Sitko GR, Bednar B, Condra C, Mellott MJ, Feng DM, Nutt RF, Shafer JA, Gould RJ, Connolly TM 1995 An antibody against the exosite of the cloned thrombin receptor inhibits experimental arterial thrombosis in the African green monkey. *Circulation* 91:2961–2971
107. Derian CK, Damiano BP, Addo MF, Darrow AL, D'Andrea MR, Nedelman M, Zhang HC, Maryanoff BE, Andrade-Gordon P 2003 Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. *J Pharmacol Exp Ther* 304:855–861
108. Hasan AA, Amenta S, Schmaier AH 1996 Bradykinin and its metabolite, Arg-Pro-Gly-Phe, are selective inhibitors of α -thrombin-induced platelet activation. *Circulation* 94:517–528
109. Bahou WF, Collier BS, Potter CL, Norton KJ, Kutok JL, Goligorsky MS 1993 The thrombin receptor extracellular domain contains sites crucial for peptide ligand-induced activation. *J Clin Invest* 140:5–1413
110. Zhang HC, Derian CK, Andrade-Gordon P, Hoekstra WJ, McComsey DF, White KB, Poulter BL, Addo MF, Cheung WM, Damiano BP, Oksenberg D, Reynolds EE, Pandey A, Scarborough RM, Maryanoff BE 2001 Discovery and optimization of a novel series of thrombin receptor (par-1) antagonists: potent, selective peptide mimetics based on indole and indazole templates. *J Med Chem* 44:1021–1024
111. Derian CK, Maryanoff BE, Zhang HC, Andrade-Gordon P 2003

- Therapeutic potential of protease-activated receptor-1 antagonists. *Expert Opin Investig Drugs* 12:209-221
112. Gilchrist A, Vanhauwe JF, Li A, Thomas TO, Voyno-Yasenetskaya T, Hamm HE 2001 $G\alpha$ minigenes expressing C-terminal peptides serve as specific inhibitors of thrombin-mediated endothelial activation. *J Biol Chem* 276:25672-25679
 113. Covic L, Misra M, Badar J, Singh C, Kuliopulos A 2002 Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. *Nat Med* 8:1161-1165
 114. Covic L, Gresser AL, Talavera J, Swift S, Kuliopulos A 2002 Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides. *Proc Natl Acad Sci USA* 99:643-648
 115. Hung DT, Wong YH, Vu TK, Coughlin SR 1992 The cloned platelet thrombin receptor couples to at least two distinct effectors to stimulate phosphoinositide hydrolysis and inhibit adenylyl cyclase. *J Biol Chem* 267:20831-20834
 116. Vassallo Jr RR, Kieber-Emmons T, Cichowski K, Brass LF 1992 Structure-function relationships in the activation of platelet thrombin receptors by receptor-derived peptides. *J Biol Chem* 267:6081-6085
 117. Henriksen RA, Hanks VK 2002 PAR-4 agonist AYPGKF stimulates thromboxane production by human platelets. *Arterioscler Thromb Vasc Biol* 22:861-866
 118. Ma L, Hollenberg MD, Wallace JL 2001 Thrombin-induced platelet endostatin release is blocked by a proteinase-activated receptor-4 (PAR4) antagonist. *Br J Pharmacol* 134:701-704
 119. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczeck RA 1998 CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. *Nature* 391:591-594
 120. Smith CC, Wilson AP, Prichard BN, Betteridge DJ 1986 Stimulus-induced release of endogenous catecholamines from human washed platelets. *Clin Sci (Lond)* 70:495-500
 121. Graff J, Klinkhardt U, Schini-Kerth VB, Harder S, Franz N, Basus S, Kirchmaier CM 2002 Close relationship between the platelet activation marker CD62 and the granular release of platelet-derived growth factor. *J Pharmacol Exp Ther* 300:952-957
 122. Andersen H, Greenberg DL, Fujikawa K, Xu W, Chung DW, Davie EW 1999 Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity. *Proc Natl Acad Sci USA* 96:11189-11193
 123. Mohle R, Green D, Moore MA, Nachman RL, Rafii S 1997 Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. *Proc Natl Acad Sci USA* 94:663-668
 124. Radomski A, Jurasz P, Sanders EJ, Overall CM, Bigg HF, Edwards DR, Radomski MW 2002 Identification, regulation and role of tissue inhibitor of metalloproteinases-4 (TIMP-4) in human platelets. *Br J Pharmacol* 137:1330-1338
 125. Brass LF, Vassallo Jr RR, Belmonte E, Ahuja M, Cichowski K, Hoxie JA 1992 Structure and function of the human platelet thrombin receptor. Studies using monoclonal antibodies directed against a defined domain within the receptor N terminus. *J Biol Chem* 267:13795-13798
 126. Arnaud E, Nicaud V, Poirier O, Rendu F, Alhenc-Gelas M, Fiessinger JN, Emmerich J, Aiach M 2000 Protective effect of a thrombin receptor (protease-activated receptor 1) gene polymorphism toward venous thromboembolism. *Arterioscler Thromb Vasc Biol* 20:585-592
 127. Dupont A, Fontana P, Bachelot-Loza C, Reny JL, Bieche I, Desvard F, Aiach M, Gaussem P 2003 An intronic polymorphism in the PAR-1 gene is associated with platelet receptor density and the response to SFLLRN. *Blood* 101:1833-1840
 128. Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR 1999 Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. *J Clin Invest* 103:879-887
 129. De Marco L, Mazzucato M, Masotti A, Fenton JW, Ruggeri ZM 1991 Function of glycoprotein Ib α in platelet activation induced by α -thrombin. *J Biol Chem* 266:23776-23783
 130. Greco NJ, Jones GD, Tandon NN, Kornhauser R, Jackson B, Jamieson GA 1996 Differentiation of the two forms of GPIb functioning as receptors for α -thrombin and von Willebrand factor: Ca^{2+} responses of protease-treated human platelets activated with α -thrombin and the tethered ligand peptide. *Biochemistry* 35:915-921
 131. Schmidt VA, Scudder L, Devoe CE, Bernards A, Cupit LD, Bahou WF 2003 IQGAP2 functions as a GTP-dependent effector protein in thrombin-induced platelet cytoskeletal reorganization. *Blood* 101:3021-3028
 132. Schmidt VA, Vitale E, Bahou WF 1996 Genomic cloning and characterization of the human thrombin receptor gene. Structural similarity to the proteinase activated receptor-2 gene. *J Biol Chem* 271:9307-9312
 133. McRedmond JP, Harriott P, Walker B, Fitzgerald DJ 2000 Strep-tokinase-induced platelet activation involves antistreptokinase antibodies and cleavage of protease-activated receptor-1. *Blood* 95:1301-1308
 134. Derian CK, Santulli RJ, Tomko KA, Haertlein BJ, Andrade-Gordon P 1995 Species differences in platelet responses to thrombin and SFLLRN. Receptor-mediated calcium mobilization and aggregation and regulation by protein kinases. *Thromb Res* 78:505-519
 135. Connolly AJ, Ishihara H, Kahn ML, Farese Jr RV, Coughlin SR 1996 Role of the thrombin receptor in development and evidence for a second receptor. *Nature* 381:516-519
 136. Altieri DC 1995 Proteases and protease receptors in modulation of leukocyte effector functions. *J Leukoc Biol* 58:120-127
 137. Naldini A, Sower L, Bocci V, Meyers B, Carney DH 1998 Thrombin receptor expression and responsiveness of human monocytic cells to thrombin is linked to interferon-induced cellular differentiation. *J Cell Physiol* 177:76-84
 138. Raza SL, Nehring LC, Shapiro SD, Cornelius LA 2000 Proteinase-activated receptor-1 regulation of macrophage elastase (MMP-12) secretion by serine proteinases. *J Biol Chem* 275:41243-41250
 139. Tordai A, Fenton JW, Andersen T, Gelfand EW 1993 Functional thrombin receptors on human T lymphoblastoid cells. *J Immunol* 150:4876-4886
 140. Suidan HS, Niclou SP, Monard D 1996 The thrombin receptor in the nervous system. *Semin Thromb Hemost* 22:125-133
 141. Naldini A, Carney DH, Pucci A, Carraro F 2002 Human α -thrombin stimulates proliferation of interferon- γ differentiated, growth-arrested U937 cells, overcoming differentiation-related changes in expression of p21CIP1/WAF1 and cyclin D1. *J Cell Physiol* 191:290-297
 142. Morris R, Winyard PG, Brass LF, Blake DR, Morris CJ 1996 Thrombin receptor expression in rheumatoid and osteoarthritic synovial tissue. *Ann Rheum Dis* 55:841-843
 143. Shin H, Nakajima T, Kitajima I, Shigeta K, Abeyama K, Imamura T, Okano T, Kawahara K, Nakamura T, Maruyama I 1995 Thrombin receptor-mediated synovial proliferation in patients with rheumatoid arthritis. *Clin Immunol Immunopathol* 76:225-233
 144. Macey MG, McCarthy DA, Gaffney K, Perry JD, Brown KA, Newland AC 1998 CD11b positive blood lymphocytes correlate with disease activity in patients with RA. *Clin Exp Rheumatol* 16:108-109
 145. Walker TR, Moore SM, Lawson MF, Panettieri Jr RA, Chilvers ER 1998 Platelet-derived growth factor-BB and thrombin activate phosphoinositide 3-kinase and protein kinase B: role in mediating airway smooth muscle proliferation. *Mol Pharmacol* 54:1007-1015
 146. Chambers RC, Dabbagh K, McAnulty RJ, Gray AJ, Blanc-Brude OP, Laurent GJ 1998 Thrombin stimulates fibroblast procollagen production via proteolytic activation of protease-activated receptor 1. *Biochem J* 333:121-127
 147. D'Andrea MR, Rogahn CJ, Andrade-Gordon P 2000 Localization of protease-activated receptors-1 and -2 in human mast cells: indications for an amplified mast cell degranulation cascade. *Biotech Histochem* 75:85-90
 148. Chambers RC, Leoni P, Blanc-Brude OP, Wembridge DE, Laurent GJ 2000 Thrombin is a potent inducer of connective tissue growth factor production via proteolytic activation of protease-activated receptor-1. *J Biol Chem* 275:35584-35591
 149. Shimizu S, Gabazza EC, Hayashi T, Ido M, Adachi Y, Suzuki K 2000 Thrombin stimulates the expression of PDGF in lung epithelial cells. *Am J Physiol Lung Cell Mol Physiol* 279:L503-L510
 150. Hauck RW, Schulz C, Schomig A, Hoffman RK, Panettieri Jr RA 1999 α -Thrombin stimulates contraction of human bronchial rings

- by activation of protease-activated receptors. *Am J Physiol* 277: L22–L29
151. **Cicala C, Bucci M, De Dominicis G, Harriot P, Sorrentino L, Cirino G** 1999 Bronchoconstrictor effect of thrombin and thrombin receptor activating peptide in guinea-pigs in vivo. *Br J Pharmacol* 126:478–484
152. **Lan RS, Stewart GA, Henry PJ** 2000 Modulation of airway smooth muscle tone by protease activated receptor-1,-2,-3 and -4 in trachea isolated from influenza A virus-infected mice. *Br J Pharmacol* 129: 63–70
153. **Lan RS, Knight DA, Stewart GA, Henry PJ** 2001 Role of PGE(2) in protease-activated receptor-1, -2 and -4 mediated relaxation in the mouse isolated trachea. *Br J Pharmacol* 132:93–100
154. **Böhm SK, Kong W, Bromme D, Smeekens SP, Anderson DC, Connolly A, Kahn M, Nelken NA, Coughlin SR, Payan DG, Bunnett NW** 1996 Molecular cloning, expression and potential functions of the human proteinase-activated receptor-2. *Biochem J* 314:1009–1016
155. **de Garavilla L, Vergnolle N, Young SH, Ennes H, Steinhoff M, Ossovskaya VS, D'Andrea MR, Mayer EA, Wallace JL, Hollenberg MD, Andrade-Gordon P, Bunnett NW** 2001 Agonists of protease-activated receptor 1 induce plasma extravasation by a neurogenic mechanism. *Br J Pharmacol* 133:975–987
156. **Buresi MC, Schleihauf E, Vergnolle N, Buret A, Wallace JL, Hollenberg MD, Macnaughton WK** 2001 Protease-activated receptor-1 stimulates Ca(2+)-dependent Cl(−) secretion in human intestinal epithelial cells. *Am J Physiol Gastrointest Liver Physiol* 281:G323–G332
157. **Vergnolle N** 2000 Review article: proteinase-activated receptors—novel signals for gastrointestinal pathophysiology. *Aliment Pharmacol Ther* 14:257–266
158. **Hollenberg MD, Yang SG, Laniyonu AA, Moore GJ, Saifeddine M** 1992 Action of thrombin receptor polypeptide in gastric smooth muscle: identification of a core pentapeptide retaining full thrombin-mimetic intrinsic activity. *Mol Pharmacol* 42:186–191
159. **Saifeddine M, Al Ani B, Sandhu S, Wijesuriya SJ, Hollenberg MD** 2001 Contractile actions of proteinase-activated receptor-derived polypeptides in guinea-pig gastric and lung parenchymal strips: evidence for distinct receptor systems. *Br J Pharmacol* 132: 556–566
160. **Nishikawa H, Kawabata A, Kuroda R, Nishida M, Kawai K** 2000 Characterization of protease-activated receptors in rat peritoneal mast cells. *Jpn J Pharmacol* 82:74–77
161. **Kawabata A, Kuroda R, Nagata N, Kawao N, Masuko T, Nishikawa H, Kawai K** 2001 In vivo evidence that protease-activated receptors 1 and 2 modulate gastrointestinal transit in the mouse. *Br J Pharmacol* 133:1213–1218
162. **Mule F, Baffi MC, Falzone M, Cerra MC** 2002 Signal transduction pathways involved in the mechanical responses to protease-activated receptors in rat colon. *J Pharmacol Exp Ther* 303:1265–1272
163. **Mule F, Baffi MC, Cerra MC** 2002 Dual effect mediated by protease-activated receptors on the mechanical activity of rat colon. *Br J Pharmacol* 136:367–374
164. **Wang J, Zheng H, Ou X, Fink LM, Hauer-Jensen M** 2002 Deficiency of microvascular thrombomodulin and up-regulation of protease-activated receptor-1 in irradiated rat intestine: possible link between endothelial dysfunction and chronic radiation fibrosis. *Am J Pathol* 160:2063–2072
165. **Rudroff C, Striegler S, Schilli M, Scheele J** 2001 Thrombin enhances adhesion in pancreatic cancer in vitro through the activation of the thrombin receptor PAR 1. *Eur J Surg Oncol* 27:472–476
166. **Rudroff C, Seibold S, Kaufmann R, Zetina CC, Reise K, Schafer U, Schneider A, Brockmann M, Scheele J, Neugebauer EA** 2002 Expression of the thrombin receptor PAR-1 correlates with tumour cell differentiation of pancreatic adenocarcinoma in vitro. *Clin Exp Metastasis* 19:181–189
167. **Kawabata A, Kuroda R, Hollenberg MD** 1999 Physiology of protease-activated receptors (PARs): involvement of PARs in digestive functions. *Nippon Yakurigaku Zasshi* 114(Suppl 1):173P–179P
168. **Faivre S, Regnaud K, Bruyneel E, Nguyen QD, Mareel M, Emami S, Gespach C** 2001 Suppression of cellular invasion by activated G-protein subunits Gαo, Gαi1, Gαi2, and Gαi3 and sequestration of Gβγ. *Mol Pharmacol* 60:363–372
169. **Regnaud K, Nguyen QD, Vakaet L, Bruyneel E, Launay JM, Endo T, Mareel M, Gespach C, Emami S** 2002 G-protein α (olf) subunit promotes cellular invasion, survival, and neuroendocrine differentiation in digestive and urogenital epithelial cells. *Oncogene* 21:4020–4031
170. **McHowat J, Creer MH, Rickard A** 2001 Stimulation of protease activated receptors on RT4 cells mediates arachidonic acid release via Ca²⁺ independent phospholipase A2. *J Urol* 165:2063–2067
171. **Festoff BW, Smirnova IV, Ma J, Citron BA** 1996 Thrombin, its receptor and protease nexin I, its potent serpin, in the nervous system. *Semin Thromb Hemost* 22:267–271
172. **Grand RJ, Turnell AS, Grabham PW** 1996 Cellular consequences of thrombin-receptor activation. *Biochem J* 313:353–368
173. **Dihanich M, Kaser M, Reinhard E, Cunningham D, Monard D** 1991 Prothrombin mRNA is expressed by cells of the nervous system. *Neuron* 6:575–581
174. **Wang H, Ubl JJ, Stricker R, Reiser G** 2002 Thrombin (PAR-1)-induced proliferation in astrocytes via MAPK involves multiple signaling pathways. *Am J Physiol Cell Physiol* 283:C1351–C1364
175. **Strigrow F, Riek-Burchardt M, Kiesel A, Schmidt W, Henrich-Noack P, Breder J, Krug M, Reymann KG, Reiser G** 2001 Four different types of protease-activated receptors are widely expressed in the brain and are up-regulated in hippocampus by severe ischemia. *Eur J Neurosci* 14:595–608
176. **Ubl JJ, Vohringer C, Reiser G** 1998 Co-existence of two types of [Ca²⁺]_i-inducing protease-activated receptors (PAR-1 and PAR-2) in rat astrocytes and C6 glioma cells. *Neuroscience* 86:597–609
177. **Kaufmann R, Bone B, Westermann M, Nowak G, Ramakrishnan V** 1998 Investigation of PAR-1-type thrombin receptors in rat glioma C6 cells with a novel monoclonal anti-PAR-1 antibody (Mab COR7-6H9). *J Neurocytol* 27:661–666
178. **Strigrow F, Riek M, Breder J, Henrich-Noack P, Reymann KG, Reiser G** 2000 The protease thrombin is an endogenous mediator of hippocampal neuroprotection against ischemia at low concentrations but causes degeneration at high concentrations. *Proc Natl Acad Sci USA* 97:2264–2269
179. **Xi G, Keep RF, Hua Y, Xiang J, Hoff JT** 1999 Attenuation of thrombin-induced brain edema by cerebral thrombin preconditioning. *Stroke* 30:1247–1255
180. **Vaughan PJ, Pike CJ, Cotman CW, Cunningham DD** 1995 Thrombin receptor activation protects neurons and astrocytes from cell death produced by environmental insults. *J Neurosci* 15:5389–5401
181. **Gurwitz D, Cunningham DD** 1988 Thrombin modulates and reverses neuroblastoma neurite outgrowth. *Proc Natl Acad Sci USA* 85:3440–3444
182. **Suidan HS, Stone SR, Hemmings BA, Monard D** 1992 Thrombin causes neurite retraction in neuronal cells through activation of cell surface receptors. *Neuron* 8:363–375
183. **Smirnova IV, Zhang SX, Citron BA, Arnold PM, Festoff BW** 1998 Thrombin is an extracellular signal that activates intracellular death protease pathways inducing apoptosis in model motor neurons. *J Neurobiol* 36:64–80
184. **Donovan FM, Pike CJ, Cotman CW, Cunningham DD** 1997 Thrombin induces apoptosis in cultured neurons and astrocytes via a pathway requiring tyrosine kinase and RhoA activities. *J Neurosci* 17:5316–5326
185. **Wang H, Ubl JJ, Reiser G** 2002 Four subtypes of protease-activated receptors, co-expressed in rat astrocytes, evoke different physiological signaling. *Glia* 37:53–63
186. **Friedmann I, Hauben E, Yoles E, Kardash L, Schwartz M** 2001 T cell-mediated neuroprotection involves antithrombin activity. *J Neuroimmunol* 121:12–21
187. **Riek-Burchardt M, Strigrow F, Henrich-Noack P, Reiser G, Reymann KG** 2002 Increase of prothrombin-mRNA after global cerebral ischemia in rats, with constant expression of protease nexin-1 and protease-activated receptors. *Neurosci Lett* 329:181–184
188. **Niclou SP, Suidan HS, Pavlik A, Vejsada R, Monard D** 1998 Changes in the expression of protease-activated receptor 1 and protease nexin-1 mRNA during rat nervous system development and after nerve lesion. *Eur J Neurosci* 10:1590–1607
189. **Beecher KL, Andersen TT, Fenton JW, Festoff BW** 1994 Thrombin

- receptor peptides induce shape change in neonatal murine astrocytes in culture. *J Neurosci Res* 37:108–115
190. **Pindon A, Festoff BW, Hantai D** 1998 Thrombin-induced reversal of astrocyte stellation is mediated by activation of protein kinase C β -1. *Eur J Biochem* 255:766–774
 191. **Debeir T, Vige X, Benavides J** 1997 Pharmacological characterization of protease-activated receptor (PAR-1) in rat astrocytes. *Eur J Pharmacol* 323:111–117
 192. **Pindon A, Berry M, Hantai D** 2000 Thrombomodulin as a new marker of lesion-induced astrogliosis: involvement of thrombin through the G-protein-coupled protease-activated receptor-1. *J Neurosci* 20:2543–2550
 193. **Festoff BW, D'Andrea MR, Citron BA, Salcedo RM, Smirnova IV, Andrade-Gordon P** 2000 Motor neuron cell death in wobbler mutant mice follows overexpression of the G-protein-coupled, protease-activated receptor for thrombin. *Mol Med* 6:410–429
 194. **Boven LA, Vergnolle N, Henry SD, Silva C, Imai Y, Holden J, Warren K, Hollenberg MD, Power C** 2003 Up-regulation of proteinase-activated receptor 1 expression in astrocytes during HIV encephalitis. *J Immunol* 170:2638–2646
 195. **Gill JS, Pitts K, Rusnak FM, Owen WG, Windebank AJ** 1998 Thrombin induced inhibition of neurite outgrowth from dorsal root ganglion neurons. *Brain Res* 797:321–327
 196. **Corvera CU, Déry O, McConalogue K, Gamp P, Thoma M, Al Ani B, Caughey GH, Hollenberg MD, Bunnett NW** 1999 Thrombin and mast cell tryptase regulate guinea-pig myenteric neurons through proteinase-activated receptors-1 and -2. *J Physiol* 517:741–756
 197. **Asfaha S, Brussee V, Chapman K, Zochodne DW, Vergnolle N** 2002 Proteinase-activated receptor-1 agonists attenuate nociception in response to noxious stimuli. *Br J Pharmacol* 135:1101–1106
 198. **Kawabata A, Kawao N, Kuroda R, Tanaka A, Shimada C** 2002 The PAR-1-activating peptide attenuates carrageenan-induced hyperalgesia in rats. *Peptides* 23:1181–1183
 199. **Brass LF** 2003 Thrombin and platelet activation. *Chest* 124:18S–25S
 200. **Swift S, Sheridan PJ, Covic L, Kuliopulos A** 2000 PAR1 thrombin receptor-G protein interactions. Separation of binding and coupling determinants in the α subunit. *J Biol Chem* 275:2627–2635
 201. **Kim S, Foster C, Lecchi A, Quinton TM, Prosser DM, Jin J, Cattaneo M, Kunapuli SP** 2002 Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling. *Blood* 99:3629–3636
 202. **Offermanns S, Laugwitz KL, Spicher K, Schultz G** 1994 G proteins of the G12 family are activated via thromboxane A2 and thrombin receptors in human platelets. *Proc Natl Acad Sci USA* 91:504–508
 203. **Ohmori T, Yatomi Y, Asazuma N, Satoh K, Ozaki Y** 1999 Suppression of protein kinase C is associated with inhibition of PYK2 tyrosine phosphorylation and enhancement of PYK2 interaction with Src in thrombin-activated platelets. *Thromb Res* 93:291–298
 204. **Zhang J, Zhang J, Benovic JL, Sugai M, Wetzker R, Gout I, Rittenhouse SE** 1995 Sequestration of a G-protein β γ subunit or ADP-ribosylation of Rho can inhibit thrombin-induced activation of platelet phosphoinositide 3-kinases. *J Biol Chem* 270:6589–6594
 205. **Trumel C, Payrastré Y, Plantavid M, Hechler B, Viala C, Presek P, Martinson EA, Cazenave JP, Chap H, Gachet C** 1999 A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1-activating peptide through the late activation of phosphoinositide 3-kinase. *Blood* 94:4156–4165
 206. **Azim AC, Barkalow K, Chou J, Hartwig JH** 2000 Activation of the small GTPases, rac and cdc42, after ligation of the platelet PAR-1 receptor. *Blood* 95:959–964
 207. **Vaidyula VR, Rao AK** 2003 Role of $G_{\alpha q}$ and phospholipase C- β 2 in human platelets activation by thrombin receptors PAR1 and PAR4: studies in human platelets deficient in $G_{\alpha q}$ and phospholipase C- β 2. *Br J Haematol* 121:491–496
 208. **Covic L, Gresser AL, Kuliopulos A** 2000 Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets. *Biochemistry* 39:5458–5467
 209. **Shapiro MJ, Weiss EJ, Faruqi TR, Coughlin SR** 2000 Protease-activated receptors 1 and 4 are shut off with distinct kinetics after activation by thrombin. *J Biol Chem* 275:25216–25221
 210. **Wang H, Reiser G** 2003 Thrombin signaling in the brain: the role of protease-activated receptors. *Biol Chem* 384:193–202
 211. **Post GR, Collins LR, Kennedy ED, Moskowitz SA, Aragay AM, Goldstein D, Brown JH** 1996 Coupling of the thrombin receptor to G12 may account for selective effects of thrombin on gene expression and DNA synthesis in 1321N1 astrocytoma cells. *Mol Biol Cell* 7:1679–1690
 212. **Aragay AM, Collins LR, Post GR, Watson AJ, Feramisco JR, Brown JH, Simon MI** 1995 G12 requirement for thrombin-stimulated gene expression and DNA synthesis in 1321N1 astrocytoma cells. *J Biol Chem* 270:20073–20077
 213. **Majumdar M, Seasholtz TM, Buckmaster C, Toksoz D, Brown JH** 1999 A rho exchange factor mediates thrombin and G_{α} (12)-induced cytoskeletal responses. *J Biol Chem* 274:26815–26821
 214. **LaMorte VJ, Kennedy ED, Collins LR, Goldstein D, Harootyanian AT, Brown JH, Feramisco JR** 1993 A requirement for Ras protein function in thrombin-stimulated mitogenesis in astrocytoma cells. *J Biol Chem* 268:19411–19415
 215. **Friedmann I, Yoles E, Schwartz M** 2001 Thrombin attenuation is neuroprotective in the injured rat optic nerve. *J Neurochem* 76:641–649
 216. **Donovan FM, Cunningham DD** 1998 Signaling pathways involved in thrombin-induced cell protection. *J Biol Chem* 273:12746–12752
 217. **Zieger M, Tausch S, Henklein P, Nowak G, Kaufmann R** 2001 A novel PAR-1-type thrombin receptor signaling pathway: cyclic AMP-independent activation of PKA in SNB-19 glioblastoma cells. *Biochem Biophys Res Commun* 282:952–957
 218. **Patterson C, Stouffer GA, Madamanchi N, Runge MS** 2001 New tricks for old dogs: nonthrombotic effects of thrombin in vessel wall biology. *Circ Res* 88:987–997
 219. **Seasholtz TM, Majumdar M, Kaplan DD, Brown JH** 1999 Rho and rho kinase mediate thrombin-stimulated vascular smooth muscle cell DNA synthesis and migration. *Circ Res* 84:1186–1193
 220. **Bretschneider E, Kaufmann R, Braun M, Nowak G, Glusa E, Schror K** 2001 Evidence for functionally active protease-activated receptor-4 (PAR-4) in human vascular smooth muscle cells. *Br J Pharmacol* 132:1441–1446
 221. **Ghosh SK, Gadiparthi L, Zeng ZZ, Bhanoori M, Tellez C, Bar-Eli M, Rao GN** 2002 ATF-1 mediates protease-activated receptor-1 but not receptor tyrosine kinase-induced DNA synthesis in vascular smooth muscle cells. *J Biol Chem* 277:21325–21331
 222. **Sabri A, Muske G, Zhang H, Pak E, Darrow A, Andrade-Gordon P, Steinberg SF** 2000 Signaling properties and functions of two distinct cardiomyocyte protease-activated receptors. *Circ Res* 86:1054–1061
 223. **Krymskaya VP, Penn RB, Orsini MJ, Scott PH, Plevin RJ, Walker TR, Eszterhas AJ, Amrani Y, Chilvers ER, Panettieri Jr RA** 1999 Phosphatidylinositol 3-kinase mediates mitogen-induced human airway smooth muscle cell proliferation. *Am J Physiol* 277:L65–L78
 224. **Bhat GJ, Abraham ST, Singer HA, Baker KM** 1997 α -Thrombin stimulates sis-inducing factor-A DNA binding activity in rat aortic smooth muscle cells. *Hypertension* 29:356–360
 225. **Vouret-Craviari V, Grall D, Van Obberghen-Schilling E** 2003 Modulation of rho GTPase activity in endothelial cells by selective proteinase-activated receptor (PAR) agonists. *J Thromb Haemost* 1:1103–1111
 226. **Jin E, Fujiwara M, Pan X, Ghazizadeh M, Arai S, Ohaki Y, Kajiwara K, Takemura T, Kawanami O** 2003 Protease-activated receptor (PAR)-1 and PAR-2 participate in the cell growth of alveolar capillary endothelium in primary lung adenocarcinomas. *Cancer* 97:703–713
 227. **Minami T, Sugiyama A, Wu SQ, Abid R, Kodama T, Aird WC** 2004 Thrombin and phenotypic modulation of the endothelium. *Arterioscler Thromb Vasc Biol* 24:41–53
 228. **Rahman A, True AL, Anwar KN, Ye RD, Voyno-Yasenetskaya TA, Malik AB** 2002 G_{α} (q) and $G_{\beta\gamma}$ regulate PAR-1 signaling of thrombin-induced NF- κ B activation and ICAM-1 transcription in endothelial cells. *Circ Res* 91:398–405
 229. **Vanhauwe JF, Thomas TO, Minshall RD, Tirupathi C, Li A, Gilchrist A, Yoon EJ, Malik AB, Hamm HE** 2002 Thrombin receptors activate G(o) proteins in endothelial cells to regulate $[Ca^{2+}]_i$ and cell shape changes. *J Biol Chem* 277:34143–34149

230. Takata M, Urakaze M, Temaru R, Yamazaki K, Nakamura N, Nobata Y, Kishida M, Sato A, Kobayashi M 2001 Pravastatin suppresses the interleukin-8 production induced by thrombin in human aortic endothelial cells cultured with high glucose by inhibiting the p44/42 mitogen activated protein kinase. *Br J Pharmacol* 134:753–762
231. Rahman A, Anwar KN, Uddin S, Xu N, Ye RD, Platanius LC, Malik AB 2001 Protein kinase C- δ regulates thrombin-induced ICAM-1 gene expression in endothelial cells via activation of p38 mitogen-activated protein kinase. *Mol Cell Biol* 21:5554–5565
232. Rahman A, Anwar KN, True AL, Malik AB 1999 Thrombin-induced p65 homodimer binding to downstream NF- κ B site of the promoter mediates endothelial ICAM-1 expression and neutrophil adhesion. *J Immunol* 162:5466–5476
233. Minami T, Abid MR, Zhang J, King G, Kodama T, Aird WC 2003 Thrombin stimulation of vascular adhesion molecule-1 in endothelial cells is mediated by protein kinase C (PKC)- δ -NF- κ B and PKC- ζ -GATA signaling pathways. *J Biol Chem* 278:6976–6984
234. Minami T, Rosenberg RD, Aird WC 2001 Transforming growth factor- β 1-mediated inhibition of the flk-1/KDR gene is mediated by a 5'-untranslated region palindromic GATA site. *J Biol Chem* 276:5395–5402
235. Mari B, Imbert V, Belhacene N, Far DF, Peyron JF, Pouyssegur J, Obberghen-Schilling E, Rossi B, Auberger P 1994 Thrombin and thrombin receptor agonist peptide induce early events of T cell activation and synergize with TCR cross-linking for CD69 expression and interleukin 2 production. *J Biol Chem* 269:8517–8523
236. Bar-Shavit R, Maoz M, Yongjun Y, Groysman M, Dekel I, Katzav S 2002 Signalling pathways induced by protease-activated receptors and integrins in T cells. *Immunology* 105:35–46
237. Bustelo XR 2000 Regulatory and signaling properties of the Vav family. *Mol Cell Biol* 20:1461–1477
238. Nicholson AC, Nachman RL, Altieri DC, Summers BD, Ruf W, Edgington TS, Hajjar DP 1996 Effector cell protease receptor-1 is a vascular receptor for coagulation factor Xa. *J Biol Chem* 271:28407–28413
239. Riewald M, Kravchenko VV, Petrovan RJ, O'Brien PJ, Brass LF, Ulevitch RJ, Ruf W 2001 Gene induction by coagulation factor Xa is mediated by activation of protease-activated receptor 1. *Blood* 97:3109–3116
240. Camerer E, Kataoka H, Kahn M, Lease K, Coughlin SR 2002 Genetic evidence that protease-activated receptors mediate factor Xa signaling in endothelial cells. *J Biol Chem* 277:16081–16087
241. Riewald M, Ruf W 2001 Mechanistic coupling of protease signaling and initiation of coagulation by tissue factor. *Proc Natl Acad Sci USA* 98:7742–7747
242. Nystedt S, Emilsson K, Wahlestedt C, Sundelin J 1994 Molecular cloning of a potential proteinase activated receptor. *Proc Natl Acad Sci USA* 91:9208–9212
243. Steinhoff M, Vergnolle N, Young SH, Tognetto M, Amadesi S, Ennes HS, Trevisani M, Hollenberg MD, Wallace JL, Caughey GH, Mitchell SE, Williams LM, Geppetti P, Mayer EA, Bunnett NW 2000 Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. *Nat Med* 6:151–158
244. Hou L, Howells GL, Kapas S, Macey MG 1998 The protease-activated receptors and their cellular expression and function in blood-related cells. *Br J Haematol* 101:1–9
245. Frungieri MB, Weidinger S, Meineke V, Kohn FM, Mayerhofer A 2002 Proliferative action of mast-cell tryptase is mediated by PAR2, COX2, prostaglandins, and PPAR γ : possible relevance to human fibrotic disorders. *Proc Natl Acad Sci USA* 99:15072–15077
246. Al Ani B, Saifeddine M, Hollenberg MD 1995 Detection of functional receptors for the proteinase-activated-receptor-2-activating polypeptide, SLIGRL-NH₂, in rat vascular and gastric smooth muscle. *Can J Physiol Pharmacol* 73:1203–1207
247. Santulli RJ, Derian CK, Darrow AL, Tomko KA, Eckardt AJ, Seiberg M, Scarborough RM, Andrade-Gordon P 1995 Evidence for the presence of a protease-activated receptor distinct from the thrombin receptor in human keratinocytes. *Proc Natl Acad Sci USA* 92:9151–9155
248. Hwa JJ, Ghibaudi L, Williams P, Chintala M, Zhang R, Chatterjee M, Sybertz E 1996 Evidence for the presence of a proteinase-activated receptor distinct from the thrombin receptor in vascular endothelial cells. *Circ Res* 78:581–588
249. Mari B, Guerin S, Far DF, Breitmayer JP, Belhacene N, Peyron JF, Rossi B, Auberger P 1996 Thrombin and trypsin-induced Ca(2+) mobilization in human T cell lines through interaction with different protease-activated receptors. *FASEB J* 10:309–316
250. Saifeddine M, Al Ani B, Cheng CH, Wang L, Hollenberg MD 1996 Rat proteinase-activated receptor-2 (PAR-2): cDNA sequence and activity of receptor-derived peptides in gastric and vascular tissue. *Br J Pharmacol* 118:521–530
251. Corvera CU, Déry O, McConalogue K, Böhm SK, Khitin LM, Caughey GH, Payan DG, Bunnett NW 1997 Mast cell tryptase regulates rat colonic myocytes through proteinase-activated receptor 2. *J Clin Invest* 100:1383–1393
252. Howells GL, Macey MG, Chinni C, Hou L, Fox MT, Harriott P, Stone SR 1997 Proteinase-activated receptor-2: expression by human neutrophils. *J Cell Sci* 110:881–887
253. Kong W, McConalogue K, Khitin LM, Hollenberg MD, Payan DG, Böhm SK, Bunnett NW 1997 Luminal trypsin may regulate enterocytes through proteinase-activated receptor 2. *Proc Natl Acad Sci USA* 94:8884–8889
254. Abraham LA, Chinni C, Jenkins AL, Loubakos A, Ally N, Pike RN, Mackie EJ 2000 Expression of protease-activated receptor-2 by osteoblasts. *Bone* 26:7–14
255. Koshikawa N, Nagashima Y, Miyagi Y, Mizushima H, Yanoma S, Yasumitsu H, Miyazaki K 1997 Expression of trypsin in vascular endothelial cells. *FEBS Lett* 409:442–448
256. Reed DE, Barajas-Lopez C, Cottrell G, Velazquez-Rocha S, Déry O, Grady EF, Bunnett NW, Vanner SJ 2003 Mast cell tryptase and proteinase-activated receptor 2 induce hyperexcitability of guinea-pig submucosal neurons. *J Physiol* 547:531–542
257. Biedermann T, Kneilling M, Mailhammer R, Maier K, Sander CA, Kollias G, Kunkel SL, Hultner L, Rocken M 2000 Mast cells control neutrophil recruitment during T cell-mediated delayed-type hypersensitivity reactions through tumor necrosis factor and macrophage inflammatory protein 2. *J Exp Med* 192:1441–1452
258. Compton SJ, Renaux B, Wijesuriya SJ, Hollenberg MD 2001 Glycosylation and the activation of proteinase-activated receptor 2 (PAR2) by human mast cell tryptase. *Br J Pharmacol* 134:705–718
259. Compton SJ, McGuire JJ, Saifeddine M, Hollenberg MD 2002 Restricted ability of human mast cell tryptase to activate proteinase-activated receptor-2 in rat aorta. *Can J Physiol Pharmacol* 80:987–992
260. Brown JK, Tyler CL, Jones CA, Ruoss SJ, Hartmann T, Caughey GH 1995 Tryptase, the dominant secretory granular protein in human mast cells, is a potent mitogen for cultured dog tracheal smooth muscle cells. *Am J Respir Cell Mol Biol* 13:227–236
261. Brown JK, Jones CA, Tyler CL, Ruoss SJ, Hartmann T, Caughey GH 1995 Tryptase-induced mitogenesis in airway smooth muscle cells. Potency, mechanisms, and interactions with other mast cell mediators. *Chest* 107:95S–96S
262. Vergnolle N 1999 Proteinase-activated receptor-2-activating peptides induce leukocyte rolling, adhesion, and extravasation in vivo. *J Immunol* 163:5064–5069
263. Shpacovitch VM, Brzoska T, Buddenkotte J, Stroh C, Sommerhoff CP, Ansel JC, Schulze-Osthoff K, Bunnett NW, Luger TA, Steinhoff M 2002 Agonists of proteinase-activated receptor 2 induce cytokine release and activation of nuclear transcription factor κ B in human dermal microvascular endothelial cells. *J Invest Dermatol* 118:380–385
264. Komuro T, Miwa S, Minowa T, Okamoto Y, Enoki T, Ninomiya H, Zhang XF, Uemura Y, Kikuchi H, Masaki T 1997 The involvement of a novel mechanism distinct from the thrombin receptor in the vasoconstriction induced by trypsin. *Br J Pharmacol* 120:851–856
265. Nystedt S, Ramakrishnan V, Sundelin J 1996 The proteinase-activated receptor 2 is induced by inflammatory mediators in human endothelial cells. Comparison with the thrombin receptor. *J Biol Chem* 271:14910–14915
266. Storck J, Kusters B, Vahland M, Morys-Wortmann C, Zimmermann ER 1996 Trypsin induced von Willebrand factor release from human endothelial cells in mediated by PAR-2 activation. *Thromb Res* 84:463–473

267. **Miike S, McWilliam AS, Kita H** 2001 Trypsin induces activation and inflammatory mediator release from human eosinophils through protease-activated receptor-2. *J Immunol* 167:6615-6622
268. **Lindner JR, Kahn ML, Coughlin SR, Sambrano GR, Schauble E, Bernstein D, Foy D, Hafezi-Moghadam A, Ley K** 2000 Delayed onset of inflammation in protease-activated receptor-2-deficient mice. *J Immunol* 165:6504-6510
269. **Shpacovitch VM, Varga G, Strey A, Gunzer M, Buddenkotte J, Vergnolle N, Sommerhoff CP, Grabbe S, Gerke V, Homey B, Hollenberg M, Luger TA, Steinhoff M** 2004 Agonists of proteinase-activated receptor-2 modulate human neutrophil cytokine secretion, expression of cell adhesion molecules and migration within 3-D collagen lattices. *J Leukoc Biol* 76:388-398
270. **Moffatt JD, Jeffrey KL, Cocks TM** 2002 Protease-activated receptor-2 activating peptide SLIGRL inhibits bacterial lipopolysaccharide-induced recruitment of polymorphonuclear leukocytes into the airways of mice. *Am J Respir Cell Mol Biol* 26:680-684
271. **Schmidlin F, Amadesi S, Dabbagh K, Lewis DE, Knott P, Bunnett NW, Gater PR, Geppetti P, Bertrand C, Stevens ME** 2002 Protease-activated receptor 2 mediates eosinophil infiltration and hyperactivity in allergic inflammation of the airway. *J Immunol* 169:5315-5321
272. **Vliagoftis H, Befus AD, Hollenberg MD, Moqbel R** 2001 Airway epithelial cells release eosinophil survival-promoting factors (GM-CSF) after stimulation of proteinase-activated receptor 2. *J Allergy Clin Immunol* 107:679-685
273. **Stenton GR, Nohara O, Déry RE, Vliagoftis H, Gilchrist M, Johri A, Wallace JL, Hollenberg MD, Moqbel R, Befus AD** 2002 Proteinase-activated receptor (PAR)-1 and -2 agonists induce mediator release from mast cells by pathways distinct from PAR-1 and PAR-2. *J Pharmacol Exp Ther* 302:466-474
274. **Ferrell WR, Lockhart JC, Kelso EB, Dunning L, Plevin R, Meek SE, Smith AJ, Hunter GD, McLean JS, McGarry F, Ramage R, Jiang L, Kanke T, Kawagoe J** 2003 Essential role for proteinase-activated receptor-2 in arthritis. *J Clin Invest* 111:35-41
275. **Derian CK, Eckardt AJ, Andrade-Gordon P** 1997 Differential regulation of human keratinocyte growth and differentiation by a novel family of protease-activated receptors. *Cell Growth Differ* 8:743-749
276. **D'Andrea MR, Derian CK, Leturcq D, Baker SM, Brunmark A, Ling P, Darrow AL, Santulli RJ, Brass LF, Andrade-Gordon P** 1998 Characterization of protease-activated receptor-2 immunoreactivity in normal human tissues. *J Histochem Cytochem* 46:157-164
277. **Steinhoff M, Neisius U, Ikoma A, Fartasch M, Heyer G, Luger TA, Skov P, Schmelz M** 2003 Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. *J Neurosci* 23:6176-6180
278. **Harvima IT, Naukkarinen A, Harvima RJ, Horsmanheimo M** 1989 Enzyme- and immunohistochemical localization of mast cell tryptase in psoriatic skin. *Arch Dermatol Res* 281:387-391
279. **Fraki JE** 1977 Human skin proteases: effect of separated proteases on vascular permeability and leukocyte emigration in skin. *Acta Derm Venereol* 57:393-398
280. **Schwartz LB** 1994 Tryptase: a clinical indicator of mast cell-dependent events. *Allergy Proc* 15:119-123
281. **Wood GS, Mueller C, Warnke RA, Weissman IL** 1988 In situ localization of HuHF serine protease mRNA and cytotoxic cell-associated antigens in human dermatoses. A novel method for the detection of cytotoxic cells in human tissues. *Am J Pathol* 133:218-225
282. **Hou L, Kapas S, Cruchley AT, Macey MG, Harriott P, Chinni C, Stone SR, Howells GL** 1998 Immunolocalization of protease-activated receptor-2 in skin: receptor activation stimulates interleukin-8 secretion by keratinocytes in vitro. *Immunology* 94:356-362
283. **Wakita H, Furukawa F, Takigawa M** 1997 Thrombin and trypsin induce granulocyte-macrophage colony-stimulating factor and interleukin-6 gene expression in cultured normal human keratinocytes. *Proc Assoc Am Physicians* 109:190-207
284. **Shpacovitch VM, Brzoska T, Bunnett NW, Sommerhoff CP, Ansel JC, Luger T, Steinhoff M** 2001 Agonists of protease-activated receptor-2 induce cytokine release and upregulation of cell adhesion molecules in human dermal microvascular endothelial cells (293). *J Invest Dermatol* 117:458 (Abstract)
285. **Seeliger S, Derian C, Vergnolle N, Bunnett N, Nawroth R, Schmelz M, von der Weid P, Buddenkotte J, Sunderkötter C, Andrade-Gordon P, Harms E, Vestweber D, Luger TA, Steinhoff M** 2003 Proinflammatory role of proteinase-activated receptor-2 in humans and mice during cutaneous inflammation in vivo. *FASEB J* 17:1871-1885
286. **Kanke T, Macfarlane SR, Seatter MJ, Davenport E, Paul A, McKenzie RC, Plevin R** 2001 Proteinase-activated receptor-2-mediated activation of stress-activated protein kinases and inhibitory κ B kinases in NCTC 2544 keratinocytes. *J Biol Chem* 276:31657-31666
287. **Buddenkotte J, Stroh C, Moormann C, Engels I, Shpacovitch VM, Vestweber D, Schulze-Osthoff K, Luger TA, Steinhoff M** Agonists of proteinase-activated receptor-2 stimulate activation of NF κ B and upregulation of ICAM-1 in human keratinocytes. *J Invest Dermatol*, in press
288. **Kawagoe J, Takizawa T, Matsumoto J, Tamiya M, Meek SE, Smith AJ, Hunter GD, Plevin R, Saito N, Kanke T, Fujii M, Wada Y** 2002 Effect of protease-activated receptor-2 deficiency on allergic dermatitis in the mouse ear. *Jpn J Pharmacol* 88:77-84
289. **Schechter NM, Brass LF, Lavker RM, Jensen PJ** 1998 Reaction of mast cell proteases tryptase and chymase with protease activated receptors (PARs) on keratinocytes and fibroblasts. *J Cell Physiol* 176:365-373
290. **Ricciardolo FL, Steinhoff M, Amadesi S, Guerrini R, Tognetto M, Trevisani M, Creminon C, Bertrand C, Bunnett NW, Fabbri LM, Salvadori S, Geppetti P** 2000 Presence and bronchomotor activity of protease-activated receptor-2 in guinea pig airways. *Am J Respir Crit Care Med* 161:1672-1680
291. **Schmidlin F, Amadesi S, Vidil R, Trevisani M, Martinet N, Caughey G, Tognetto M, Cavallesco G, Mapp C, Geppetti P, Bunnett NW** 2001 Expression and function of proteinase-activated receptor 2 in human bronchial smooth muscle. *Am J Respir Crit Care Med* 164:1276-1281
292. **Cocks TM, Fong B, Chow JM, Anderson GP, Frauman AG, Goldie RG, Henry PJ, Carr MJ, Hamilton JR, Moffatt JD** 1999 A protective role for protease-activated receptors in the airways. *Nature* 398:156-160
293. **Cicala C, Spina D, Keir SD, Severino B, Meli R, Page CP, Cirino G** 2001 Protective effect of a PAR2-activating peptide on histamine-induced bronchoconstriction in guinea-pig. *Br J Pharmacol* 132:1229-1234
294. **Chambers LS, Black JL, Poronnik P, Johnson PR** 2001 Functional effects of protease-activated receptor-2 stimulation on human airway smooth muscle. *Am J Physiol Lung Cell Mol Physiol* 281:L1369-L1378
295. **Asokanathan N, Graham PT, Stewart DJ, Bakker AJ, Eidne KA, Thompson PJ, Stewart GA** 2002 House dust mite allergens induce proinflammatory cytokines from respiratory epithelial cells: the cysteine protease allergen, Der p 1, activates protease-activated receptor (PAR)-2 and inactivates PAR-1. *J Immunol* 169:4572-4578
296. **Ubl JJ, Grishina ZV, Sukhomlin TK, Welte T, Sedehizade F, Reiser G** 2002 Human bronchial epithelial cells express PAR-2 with different sensitivity to thermolysin. *Am J Physiol Lung Cell Mol Physiol* 282:L1339-L1348
297. **Vliagoftis H, Schwingshackl A, Milne CD, Duszyk M, Hollenberg MD, Wallace JL, Befus AD, Moqbel R** 2000 Proteinase-activated receptor-2-mediated matrix metalloproteinase-9 release from airway epithelial cells. *J Allergy Clin Immunol* 106:537-545
298. **Fiorucci S, Mencarelli A, Palazzetti B, Distrutti E, Vergnolle N, Hollenberg MD, Wallace JL, Morelli A, Cirino G** 2001 Proteinase-activated receptor 2 is an anti-inflammatory signal for colonic lamina propria lymphocytes in a mouse model of colitis. *Proc Natl Acad Sci USA* 98:13936-13941
299. **Jenkins AL, Chinni C, De Niese MR, Blackhart B, Mackie EJ** 2000 Expression of protease-activated receptor-2 during embryonic development. *Dev Dyn* 218:465-471
300. **Smith-Swintosky VL, Cheo-Isaacs CT, D'Andrea MR, Santulli RJ, Darrow AL, Andrade-Gordon P** 1997 Protease-activated receptor-2 (PAR-2) is present in the rat hippocampus and is associated with neurodegeneration. *J Neurochem* 69:1890-1896

301. Kaufmann R, Patt S, Zieger M, Kraft R, Nowak G 1999 Presence of the proteinase-activated receptor-2 (PAR-2) in human brain tumor cells—trypsin- and SLIGRL-induced calcium response in primary cultured meningiomas. *Cancer Lett* 139:109–113
302. Domotor E, Bartha K, Machovich R, Adam-Vizi V 2002 Protease-activated receptor-2 (PAR-2) in brain microvascular endothelium and its regulation by plasmin and elastase. *J Neurochem* 80:746–754
303. Carr MJ, Schechter NM, Udem BJ 2000 Trypsin-induced, neurokinin-mediated contraction of guinea pig bronchus. *Am J Respir Crit Care Med* 162:1662–1667
304. Kawabata A, Kawao N, Kuroda R, Tanaka A, Itoh H, Nishikawa H 2001 Peripheral PAR-2 triggers thermal hyperalgesia and nociceptive responses in rats. *Neuroreport* 12:715–719
305. Vergnolle N, Bunnett NW, Sharkey KA, Brussee V, Compton SJ, Grady EF, Cirino G, Gerard N, Basbaum AI, Andrade-Gordon P, Hollenberg MD, Wallace JL 2001 Proteinase-activated receptor-2 and hyperalgesia: a novel pain pathway. *Nat Med* 7:821–826
306. Kawabata A, Kawao N, Itoh H, Shimada C, Takebe K, Kuroda R, Masuko T, Kataoka K, Ogawa S 2002 Role of *N*-methyl-D-aspartate receptors and the nitric oxide pathway in nociception/hyperalgesia elicited by protease-activated receptor-2 activation in mice and rats. *Neurosci Lett* 329:349–353
307. Kawabata A, Kawao N, Kuroda R, Itoh H, Nishikawa H 2002 Specific expression of spinal Fos after PAR-2 stimulation in mast cell-depleted rats. *Neuroreport* 13:511–514
308. Coelho AM, Vergnolle N, Guiard B, Fioramonti J, Bueno L 2002 Proteinases and proteinase-activated receptor 2: a possible role to promote visceral hyperalgesia in rats. *Gastroenterology* 122:1035–1047
309. Brain SD 2000 New feelings about the role of sensory nerves in inflammation. *Nat Med* 6:134–135
310. Kawabata A, Morimoto N, Nishikawa H, Kuroda R, Oda Y, Kakehi K 2000 Activation of protease-activated receptor-2 (PAR-2) triggers mucin secretion in the rat sublingual gland. *Biochem Biophys Res Commun* 270:298–302
311. Kawabata A, Nishikawa H, Kuroda R, Kawai K, Hollenberg MD 2000 Proteinase-activated receptor-2 (PAR-2): regulation of salivary and pancreatic exocrine secretion in vivo in rats and mice. *Br J Pharmacol* 129:1808–1814
312. Kawabata A, Kinoshita M, Nishikawa H, Kuroda R, Nishida M, Araki H, Arizono N, Oda Y, Kakehi K 2001 The protease-activated receptor-2 agonist induces gastric mucus secretion and mucosal cytoprotection. *J Clin Invest* 107:1443–1450
313. Green BT, Bunnett NW, Kulkarni-Narla A, Steinhoff M, Brown DR 2000 Intestinal type 2 proteinase-activated receptors: expression in opioid-sensitive secretomotor neural circuits that mediate epithelial ion transport. *J Pharmacol Exp Ther* 295:410–416
314. Hoogerwerf WA, Zou L, Shenoy M, Sun D, Micci MA, Lee-Hellmich H, Xiao SY, Winston JH, Pasricha PJ 2001 The proteinase-activated receptor 2 is involved in nociception. *J Neurosci* 21:9036–9042
315. Nguyen TD, Moody MW, Steinhoff M, Okolo C, Koh DS, Bunnett NW 1999 Trypsin activates pancreatic duct epithelial cell ion channels through proteinase-activated receptor-2. *J Clin Invest* 103:261–269
316. Schultheiss M, Neumcke B, Richter HP 1997 Endogenous trypsin receptors in *Xenopus* oocytes: linkage to internal calcium stores. *Cell Mol Life Sci* 53:842–849
317. Okamoto T, Nishibori M, Sawada K, Iwagaki H, Nakaya N, Jikuhara A, Tanaka N, Saeki K 2001 The effects of stimulating protease-activated receptor-1 and -2 in A172 human glioblastoma. *J Neural Transm* 108:125–140
318. Berger P, Tunon-De-Lara JM, Savineau JP, Marthan R 2001 Selected contribution: trypsin-induced PAR-2-mediated Ca(2+) signaling in human airway smooth muscle cells. *J Appl Physiol* 91:995–1003
319. Gao C, Liu S, Hu HZ, Gao N, Kim GY, Xia Y, Wood JD 2002 Serine proteases excite myenteric neurons through protease-activated receptors in guinea pig small intestine. *Gastroenterology* 123:1554–1564
320. Berger P, Perng DW, Thabrew H, Compton SJ, Cairns JA, McEuen AR, Marthan R, Tunon De Lara JM, Walls AF 2001 Trypsin and agonists of PAR-2 induce the proliferation of human airway smooth muscle cells. *J Appl Physiol* 91:1372–1379
321. Bretschneider E, Kaufmann R, Braun M, Wittpoth M, Glusa E, Nowak G, Schror K 1999 Evidence for proteinase-activated receptor-2 (PAR-2)-mediated mitogenesis in coronary artery smooth muscle cells. *Br J Pharmacol* 126:1735–1740
322. Bono F, Schaeffer P, Herault JP, Michaux C, Nestor AL, Guillemot JC, Herbert JM 2000 Factor Xa activates endothelial cells by a receptor cascade between EPR-1 and PAR-2. *Arterioscler Thromb Vasc Biol* 20:E107–E112
323. Koo BH, Chung KH, Hwang KC, Kim DS 2002 Factor Xa induces mitogenesis of coronary artery smooth muscle cell via activation of PAR-2. *FEBS Lett* 523:85–89
324. Ishihara H, Zeng D, Connolly AJ, Tam C, Coughlin SR 1998 Antibodies to protease-activated receptor 3 inhibit activation of mouse platelets by thrombin. *Blood* 91:4152–4157
325. Weiss EJ, Hamilton JR, Lease KE, Coughlin SR 2002 Protection against thrombosis in mice lacking PAR3. *Blood* 100:3240–3244
326. Hung DT, Vu TK, Wheaton VI, Ishii K, Coughlin SR 1992 Cloned platelet thrombin receptor is necessary for thrombin-induced platelet activation. *J Clin Invest* 89:1350–1353
327. Hoogerwerf WA, Hellmich HL, Micci M, Winston JH, Zou L, Pasricha PJ 2002 Molecular cloning of the rat proteinase-activated receptor 4 (PAR4). *BMC Mol Biol* 3:2
328. Kaufmann R, Patt S, Zieger M, Kraft R, Tausch S, Henklein P, Nowak G 2000 The two-receptor system PAR-1/PAR-4 mediates α -thrombin-induced [Ca(2+)]_i mobilization in human astrocytoma cells. *J Cancer Res Clin Oncol* 126:91–94
329. Lourbakos A, Yuan YP, Jenkins AL, Travis J, Andrade-Gordon P, Santulli R, Potempa J, Pike RN 2001 Activation of protease-activated receptors by gingipains from *Porphyromonas gingivalis* leads to platelet aggregation: a new trait in microbial pathogenicity. *Blood* 97:3790–3797
330. Sambrano GR, Huang W, Faruqi T, Mahrus S, Craik C, Coughlin SR 2000 Cathepsin G activates protease-activated receptor-4 in human platelets. *J Biol Chem* 275:6819–6823
331. King RA, Hearing VJ, Creel D, Oetting WS 2000 Albinism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. *The metabolic and molecular basis of inherited disease*. New York: McGraw-Hill; 5587–5627
332. Anikster Y, Huizing M, White J, Shevchenko YO, Fitzpatrick DL, Touchman JW, Compton JG, Bale SJ, Swank RT, Gahl WA, Toro JR 2001 Mutation of a new gene causes a unique form of Hermansky-Pudlak syndrome in a genetic isolate of central Puerto Rico. *Nat Genet* 28:376–380
333. Covic L, Singh C, Smith H, Kuliopulos A 2002 Role of the PAR4 thrombin receptor in stabilizing platelet-platelet aggregates as revealed by a patient with Hermansky-Pudlak syndrome. *Thromb Haemostasis* 87:722–727
334. Chung AW, Jurasz P, Hollenberg MD, Radomski MW 2002 Mechanisms of action of proteinase-activated receptor agonists on human platelets. *Br J Pharmacol* 135:1123–1132
335. Yin YJ, Salah Z, Maoz M, Ram SC, Ochayon S, Neufeld G, Katzav S, Bar-Shavit R 2003 Oncogenic transformation induces tumor angiogenesis: a role for PAR1 activation. *FASEB J* 17:163–174
336. Kanthou C, Kanse SM, Kakkar VV, Benzakour O 1996 Involvement of pertussis toxin-sensitive and -insensitive G proteins in α -thrombin signalling on cultured human vascular smooth muscle cells. *Cell Signal* 8:59–66
337. Faruqi TR, Weiss EJ, Shapiro MJ, Huang W, Coughlin SR 2000 Structure-function analysis of protease-activated receptor 4 tethered ligand peptides. Determinants of specificity and utility in assays of receptor function. *J Biol Chem* 275:19728–19734
338. Sabri A, Guo J, Elouardighi H, Darrow AL, Andrade-Gordon P, Steinberg SF 2003 Mechanisms of protease-activated receptor-4 actions in cardiomyocytes: role of Src tyrosine kinase. *J Biol Chem* 278:11714–11720
339. Lang R, Song PI, Legat FJ, Lavker RM, Harten B, Kalden H, Grady EF, Bunnett NW, Armstrong CA, Ansel JC 2003 Human corneal epithelial cells express functional PAR-1 and PAR-2. *Invest Ophthalmol Vis Sci* 44:99–105
340. Cenac N, Coelho AM, Nguyen C, Compton S, Andrade-Gordon P, Macnaughton WK, Wallace JL, Hollenberg MD, Bunnett NW,

- Garcia-Villar R, Bueno L, Vergnolle N 2002 Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2. *Am J Pathol* 161:1903–1915
341. Uehara A, Sugawara S, Muramoto K, Takada H 2002 Activation of human oral epithelial cells by neutrophil proteinase 3 through protease-activated receptor-2. *J Immunol* 169:4594–4603
342. Mascia F, Mariani V, Giannetti A, Girolomoni G, Pastore S 2002 House dust mite allergen exerts no direct proinflammatory effects on human keratinocytes. *J Allergy Clin Immunol* 109:532–538
343. Sun G, Stacey MA, Schmidt M, Mori L, Mattoli S 2001 Interaction of mite allergens Der p3 and Der p9 with protease-activated receptor-2 expressed by lung epithelial cells. *J Immunol* 167:1014–1021
344. Gordon JR, Zhang X, Stevenson K, Cosford K 2000 Thrombin induces IL-6 but not TNF α secretion by mouse mast cells: threshold-level thrombin receptor and very low level Fc ϵ RI signaling synergistically enhance IL-6 secretion. *Cell Immunol* 205:128–135
345. Napoli C, De Nigris F, Cicala C, Wallace JL, Caliendo G, Condorelli M, Santagada V, Cirino G 2002 Protease-activated receptor-2 activation improves efficiency of experimental ischemic preconditioning. *Am J Physiol Heart Circ Physiol* 282:H2004–H2010
346. Lan RS, Stewart GA, Henry PJ 2002 Role of protease-activated receptors in airway function: a target for therapeutic intervention? *Pharmacol Ther* 95:239–257
347. Trotter G, Hollenberg M, Wang X, Gui Y, Loutzenhiser K, Loutzenhiser R 2002 PAR-2 elicits afferent arteriolar vasodilation by NO-dependent and NO-independent actions. *Am J Physiol Renal Physiol* 282:F891–F897
348. Cocks TM, Moffatt JD 2000 Protease-activated receptors: sentries for inflammation? *Trends Pharmacol Sci* 21:103–108
349. Chen YH, Pouyssegur J, Courtneidge SA, Obberghen-Schilling E 1994 Activation of Src family kinase activity by the G protein-coupled thrombin receptor in growth-responsive fibroblasts. *J Biol Chem* 269:27372–27377
350. Chen Y, Grall D, Salcini AE, Pelicci PG, Pouyssegur J, Obberghen-Schilling E 1996 Shc adaptor proteins are key transducers of mitogenic signaling mediated by the G protein-coupled thrombin receptor. *EMBO J* 15:1037–1044
351. Trejo J, Connolly AJ, Coughlin SR 1996 The cloned thrombin receptor is necessary and sufficient for activation of mitogen-activated protein kinase and mitogenesis in mouse lung fibroblasts. Loss of responses in fibroblasts from receptor knockout mice. *J Biol Chem* 271:21536–21541
352. Ramars AS, Mukhopadhyay S, Dash D 2002 Regulation of post-aggregation events induced by protease-activated receptor 1 ligation in human platelets: evidence of differential signaling pathways. *Arch Biochem Biophys* 398:253–260
353. Huang RS, Sorisky A, Church WR, Simons ER, Rittenhouse SE 1991 “Thrombin” receptor-directed ligand accounts for activation by thrombin of platelet phospholipase C and accumulation of 3-phosphorylated phosphoinositides. *J Biol Chem* 266:18435–18438
354. Henriksen RA, Samokhin GP, Tracy PB 1997 Thrombin-induced thromboxane synthesis by human platelets. Properties of anion binding exosite I-independent receptor. *Arterioscler Thromb Vasc Biol* 17:3519–3526
355. Ohmori T, Yatomi Y, Asazuma N, Satoh K, Ozaki Y 2000 Involvement of proline-rich tyrosine kinase 2 in platelet activation: tyrosine phosphorylation mostly dependent on α IIb β 3 integrin and protein kinase C, translocation to the cytoskeleton and association with Shc through Grb2. *Biochem J* 347:561–569
356. Dorsam RT, Kim S, Jin J, Kunapuli SP 2002 Coordinated signaling through both G12/13 and G(i) pathways is sufficient to activate GPIIb/IIIa in human platelets. *J Biol Chem* 277:47588–47595
357. Han Y, Nurdan A, Combrie F, Pasquet JM 2003 Redistribution of glycoprotein Ib within platelets in response to protease-activated receptors 1 and 4: roles of cytoskeleton and calcium. *J Thromb Haemost* 1:2206–2215
358. Klarenbach S, Chipiuk A, Nelson RC, Hollenberg M, Murray AG 2003 Differential actions of PAR2 and PAR1 in stimulating human endothelial cell exocytosis and permeability: the role of Rho-GTPases. *Circ Res* 92:272–278
359. Riewald M, Petrovan RJ, Donner A, Ruf W 2003 Activated protein C signals through the thrombin receptor PAR1 in endothelial cells. *J Endotoxin Res* 9:317–321
360. Domotor E, Benzakour O, Griffin JH, Yule D, Fukudome K, Zlokovic BV 2003 Activated protein C alters cytosolic calcium flux in human brain endothelium via binding to endothelial protein C receptor and activation of protease activated receptor-1. *Blood* 101:4797–4801
361. Cheng T, Liu D, Griffin JH, Fernandez JA, Castellino F, Rosen ED, Fukudome K, Zlokovic BV 2003 Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. *Nat Med* 9:338–342
362. Pai KS, Mahajan VB, Lau A, Cunningham DD 2001 Thrombin receptor signaling to cytoskeleton requires Hsp90. *J Biol Chem* 276:32642–32647
363. Ubl JJ, Sergeeva M, Reiser G 2000 Desensitisation of protease-activated receptor-1 (PAR-1) in rat astrocytes: evidence for a novel mechanism for terminating Ca²⁺ signalling evoked by the tethered ligand. *J Physiol* 525:319–330
364. Mahajan VB, Pai KS, Lau A, Cunningham DD 2000 Creatine kinase, an ATP-generating enzyme, is required for thrombin receptor signaling to the cytoskeleton. *Proc Natl Acad Sci USA* 97:12062–12067
365. Kamath L, Meydani A, Foss F, Kuliopulos A 2001 Signaling from protease-activated receptor-1 inhibits migration and invasion of breast cancer cells. *Cancer Res* 61:5933–5940
366. Sabri A, Short J, Guo J, Steinberg SF 2002 Protease-activated receptor-1-mediated DNA synthesis in cardiac fibroblast is via epidermal growth factor receptor transactivation: distinct PAR-1 signaling pathways in cardiac fibroblasts and cardiomyocytes. *Circ Res* 91:532–539
367. Steinberg SF, Robinson RB, Lieberman HB, Stern DM, Rosen MR 1991 Thrombin modulates phosphoinositide metabolism, cytosolic calcium, and impulse initiation in the heart. *Circ Res* 68:1216–1229
368. Jiang T, Danilo Jr P, Steinberg SF 1998 The thrombin receptor elevates intracellular calcium in adult rat ventricular myocytes. *J Mol Cell Cardiol* 30:2193–2199
369. Hague S, Oehler MK, MacKenzie IZ, Bicknell R, Rees MC 2002 Protease activated receptor-1 is down regulated by levonorgestrel in endometrial stromal cells. *Angiogenesis* 5:93–98
370. Tognetto M, Trevisani M, Maggiore B, Navarra G, Turini A, Guerrini R, Bunnett NW, Geppetti P, Harrison S 2000 Evidence that PAR-1 and PAR-2 mediate prostanoid-dependent contraction in isolated guinea-pig gallbladder. *Br J Pharmacol* 131:689–694
371. Kawabata A, Kuroda R, Kuroki N, Nishikawa H, Kawai K 2000 Dual modulation by thrombin of the motility of rat oesophageal muscularis mucosae via two distinct protease-activated receptors (PARs): a novel role for PAR-4 as opposed to PAR-1. *Br J Pharmacol* 131:578–584
372. Roche N, Stirling RG, Lim S, Oliver BG, Oates T, Jazrawi E, Caramori G, Chung KF 2003 Effect of acute and chronic inflammatory stimuli on expression of protease-activated receptors 1 and 2 in alveolar macrophages. *J Allergy Clin Immunol* 111:367–373
373. Vliagoftis H 2002 Thrombin induces mast cell adhesion to fibronectin: evidence for involvement of protease-activated receptor-1. *J Immunol* 169:4551–4558
374. Umarova BA, Dugina TN, Shestakova EV, Gluza E, Strukova SM 2000 Activation of rat mast cells upon stimulation of protease-activated receptor (PAR-1). *Bull Exp Biol Med* 129:314–317
375. Colognato R, Slupsky JR, Jendrach M, Burysek L, Syrovets T, Simmet T 2003 Differential expression and regulation of proteinase-activated receptors in human peripheral monocytes and monocyte-derived antigen-presenting cells. *Blood* 102:2645–2652
376. Cocks TM, Sozzi V, Moffatt JD, Selemidis S 1999 Protease-activated receptors mediate apamin-sensitive relaxation of mouse and guinea pig gastrointestinal smooth muscle. *Gastroenterology* 116:586–592
377. Nguyen QD, Faivre S, Bruyneel E, Rivat C, Seto M, Endo T, Mareel M, Emami S, Gespach C 2002 RhoA- and RhoD-dependent regulatory switch of α subunit signaling by PAR-1 receptors in cellular invasion. *FASEB J* 16:565–576
378. Buresi MC, Buret AG, Hollenberg MD, Macnaughton WK 2002 Activation of proteinase-activated receptor 1 stimulates epithelial

- chloride secretion through a unique MAP kinase- and cyclo-oxygenase-dependent pathway. *FASEB J* 16:1515–1525
379. Kawabata A, Kuroda R, Kuroki N, Nishikawa H, Kawai K, Araki H 2000 Characterization of the protease-activated receptor-1-mediated contraction and relaxation in the rat duodenal smooth muscle. *Life Sci* 67:2521–2530
380. Greenberg DL, Mize GJ, Takayama TK 2003 Protease-activated receptor mediated RhoA signaling and cytoskeletal reorganization in LNCaP cells. *Biochemistry* 42:702–709
381. de Niese MR, Chinni C, Pike RN, Bottomley SP, Mackie EJ 2002 Dissection of protease-activated receptor-1-dependent and -independent responses to thrombin in skeletal myoblasts. *Exp Cell Res* 274:149–156
382. Garrido R, Segura B, Zhang W, Mulholland M 2002 Presence of functionally active protease-activated receptors 1 and 2 in myenteric glia. *J Neurochem* 83:556–564
383. Conant K, Haughey N, Nath A, St Hillaire C, Gary DS, Pardo CA, Wahl LM, Bilak M, Milward E, Mattson MP 2002 Matrix metalloproteinase-1 activates a pertussis toxin-sensitive signaling pathway that stimulates the release of matrix metalloproteinase-9. *J Neurochem* 82:885–893
384. Fang M, Kovacs KJ, Fisher LL, Larson AA 2003 Thrombin inhibits NMDA-mediated nociceptive activity in the mouse: possible mediation by endothelin. *J Physiol* 549:903–917
385. Ellis CA, Malik AB, Gilchrist A, Hamm H, Sandoval R, Voynoyasenetskaya T, Tiruppathi C 1999 Thrombin induces proteinase-activated receptor-1 gene expression in endothelial cells via activation of Gi-linked Ras/mitogen-activated protein kinase pathway. *J Biol Chem* 274:13718–13727
386. Algermissen B, Sitzmann J, Nurnberg W, Laubscher JC, Henz BM, Bauer F 2000 Distribution and potential biologic function of the thrombin receptor PAR-1 on human keratinocytes. *Arch Dermatol Res* 292:488–495
387. Bromberg ME, Bailly MA, Konigsberg WH 2001 Role of protease-activated receptor 1 in tumor metastasis promoted by tissue factor. *Thromb Haemost* 86:1210–1214
388. Pendurthi UR, Ngyuen M, Andrade-Gordon P, Petersen LC, Rao LV 2002 Plasmin induces Cyr61 gene expression in fibroblasts via protease-activated receptor-1 and p44/42 mitogen-activated protein kinase-dependent signaling pathway. *Arterioscler Thromb Vasc Biol* 22:1421–1426
389. Papadaki M, Ruef J, Nguyen KT, Li F, Patterson C, Eskin SG, McIntire LV, Runge MS 1998 Differential regulation of protease activated receptor-1 and tissue plasminogen activator expression by shear stress in vascular smooth muscle cells. *Circ Res* 83:1027–1034
390. Chen X, Berrou J, Vigneau C, Rondeau E 2001 Role of the third intracellular loop and of the cytoplasmic tail in the mitogenic signaling of the protease-activated receptor 1. *Int J Mol Med* 8:309–314
391. Chen X, Berrou J, Vigneau C, Delarue F, Rondeau E 2001 Internalisation of the protease-activated receptor-1: role of the third intracellular loop and of the cytoplasmic tail. *Int J Mol Med* 7:653–658
392. Shapiro MJ, Trejo J, Zeng D, Coughlin SR 1996 Role of the thrombin receptor's cytoplasmic tail in intracellular trafficking. Distinct determinants for agonist-triggered versus tonic internalization and intracellular localization. *J Biol Chem* 271:32874–32880
393. Fukuhara S, Marinissen MJ, Chiariello M, Gutkind JS 2000 Signaling from G protein-coupled receptors to ERK5/Big MAPK 1 involves G α q and G α 12/13 families of heterotrimeric G proteins. Evidence for the existence of a novel Ras and Rho-independent pathway. *J Biol Chem* 275:21730–21736
394. Madamanchi NR, Hu ZY, Li F, Horaist C, Moon SK, Patterson C, Runge MS 2002 A noncoding RNA regulates human protease-activated receptor-1 gene during embryogenesis. *Biochim Biophys Acta* 1576:237–245
395. Darmoul D, Gratio V, Devaud H, Lehy T, Laburthe M 2003 Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells. *Am J Pathol* 162:1503–1513
396. Kahan C, Seuwen K, Meloche S, Pouyssegur J 1992 Coordinate, biphasic activation of p44 mitogen-activated protein kinase and S6 kinase by growth factors in hamster fibroblasts. Evidence for thrombin-induced signals different from phosphoinositide turnover and adenylcyclase inhibition. *J Biol Chem* 267:13369–13375
397. van Corven EJ, Hordijk PL, Medema RH, Bos JL, Moolenaar WH 1993 Pertussis toxin-sensitive activation of p21ras by G protein-coupled receptor agonists in fibroblasts. *Proc Natl Acad Sci USA* 90:1257–1261
398. Tran T, Stewart AG 2003 Protease-activated receptor (PAR)-independent growth and pro-inflammatory actions of thrombin on human cultured airway smooth muscle. *Br J Pharmacol* 138:865–875
399. Storck J, Zimmermann ER 1996 Regulation of the thrombin receptor response in human endothelial cells. *Thromb Res* 81:121–131
400. Tiruppathi C, Lum H, Andersen TT, Fenton JW, Malik AB 1992 Thrombin receptor 14-amino acid peptide binds to endothelial cells and stimulates calcium transients. *Am J Physiol* 263:L595–L601
401. Belham CM, Scott PH, Twomey DP, Gould GW, Wadsworth RM, Plevin R 1997 Evidence that thrombin-stimulated DNA synthesis in pulmonary arterial fibroblasts involves phosphatidylinositol 3-kinase-dependent p70 ribosomal S6 kinase activation. *Cell Signal* 9:109–116
402. Kranzhofer R, Clinton SK, Ishii K, Coughlin SR, Fenton JW, Libby P 1996 Thrombin potently stimulates cytokine production in human vascular smooth muscle cells but not in mononuclear phagocytes. *Circ Res* 79:286–294
403. Keogh RJ, Houliston RA, Wheeler-Jones CP 2002 Thrombin-stimulated Pyk2 phosphorylation in human endothelium is dependent on intracellular calcium and independent of protein kinase C and Src kinases. *Biochem Biophys Res Commun* 294:1001–1008
404. Jenkins AL, Bootman MD, Taylor CW, Mackie EJ, Stone SR 1993 Characterization of the receptor responsible for thrombin-induced intracellular calcium responses in osteoblast-like cells. *J Biol Chem* 268:21432–21437
405. Abraham LA, Mackie EJ 1999 Modulation of osteoblast-like cell behavior by activation of protease-activated receptor-1. *J Bone Miner Res* 14:1320–1329
406. Chay CH, Cooper CR, Gendernalik JD, Dhanasekaran SM, Chinnaiyan AM, Rubin MA, Schmaier AH, Pienta KJ 2002 A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines. *Urology* 60:760–765
407. Kaufmann R, Patt S, Kraft R, Zieger M, Henklein P, Neupert G, Nowak G 1999 PAR 1-type thrombin receptors are involved in thrombin-induced calcium signaling in human meningioma cells. *J Neurooncol* 42:131–136
408. Debeir T, Gueugnon J, Vige X, Benavides J 1996 Transduction mechanisms involved in thrombin receptor-induced nerve growth factor secretion and cell division in primary cultures of astrocytes. *J Neurochem* 66:2320–2328
409. McNamara CA, Sarembock IJ, Gimple LW, Fenton JW, Coughlin SR, Owens GK 1993 Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. *J Clin Invest* 91:94–98
410. Chaikof EL, Caban R, Yan CN, Rao GN, Runge MS 1995 Growth-related responses in arterial smooth muscle cells are arrested by thrombin receptor antisense sequences. *J Biol Chem* 270:7431–7436
411. Cicala C, Morello S, Santagada V, Caliendo G, Sorrentino L, Cirino G 2001 Pharmacological dissection of vascular effects caused by activation of protease-activated receptors 1 and 2 in anesthetized rats. *FASEB J* 15:1433–1435
412. Shin H, Kitajima I, Nakajima T, Shao Q, Tokioka T, Takasaki I, Hanu N, Kubo T, Maruyama I 1999 Thrombin receptor mediated signals induce expressions of interleukin 6 and granulocyte colony stimulating factor via NF- κ B activation in synovial fibroblasts. *Ann Rheum Dis* 58:55–60
413. Naldini A, Pucci A, Carney DH, Fanetti G, Carraro F 2002 Thrombin enhancement of interleukin-1 expression in mononuclear cells: involvement of proteinase-activated receptor-1. *Cytokine* 20:191–199
414. Strukova SM, Dugina TN, Chistov IV, Lange M, Markvicheva EA, Kuptsova S, Zubov VP, Glusa E 2001 Immobilized thrombin receptor agonist peptide accelerates wound healing in mice. *Clin Appl Thromb Hemost* 7:325–329
415. Choudhury GG, Marra F, Abboud HE 1996 Thrombin stimulates

- association of src homology domain containing adaptor protein Nck with pp125FAK. *Am J Physiol* 270:F295–F300
416. **Laping NJ, Olson BA, Short B, Albrightson CR** 1997 Thrombin increases clusterin mRNA in glomerular epithelial and mesangial cells. *J Am Soc Nephrol* 8:906–914
 417. **Mitsui H, Maruyama T, Kimura S, Takuwa Y** 1998 Thrombin activates two stress-activated protein kinases, c-Jun N-terminal kinase and p38, in HepG2 cells. *Hepatology* 27:1362–1367
 418. **Turgeon VL, Lloyd ED, Wang S, Festoff BW, Houenou LJ** 1998 Thrombin perturbs neurite outgrowth and induces apoptotic cell death in enriched chick spinal motoneuron cultures through caspase activation. *J Neurosci* 18:6882–6891
 419. **Pai KS, Cunningham DD** 2002 Geldanamycin specifically modulates thrombin-mediated morphological changes in mouse neuroblasts. *J Neurochem* 80:715–718
 420. **Mbebi C, Rohn T, Doyennette MA, Chevessier F, Jandrot-Perrus M, Hantai D, Verdier-Sahuque M** 2001 Thrombin receptor induction by injury-related factors in human skeletal muscle cells. *Exp Cell Res* 263:77–87
 421. **Huang YQ, Li JJ, Hu L, Lee M, Karpatkin S** 2001 Thrombin induces increased expression and secretion of VEGF from human F54 fibroblasts, DU145 prostate cells and CHRF megakaryocytes. *Thromb Haemost* 86:1094–1098
 422. **Apostolidis A, Weiss RH** 1997 Divergence in the G-protein-coupled receptor mitogenic signalling pathway at the level of Raf kinase. *Cell Signal* 9:439–445
 423. **Rickard A, McHowat J** 2002 Phospholipid metabolite production in human urothelial cells after protease-activated receptor cleavage. *Am J Physiol Renal Physiol* 283:F944–F951
 424. **Vemuri GS, Zhang J, Huang R, Keen JH, Rittenhouse SE** 1996 Thrombin stimulates wortmannin-inhibitable phosphoinositide 3-kinase and membrane blebbing in CHRF-288 cells. *Biochem J* 314:805–810
 425. **Oshiro A, Otani H, Yagi Y, Fukuhara S, Inagaki C** 2002 Protease-activated receptor-2-mediated Ca^{2+} signaling in guinea pig tracheal epithelial cells. *Life Sci* 71:547–558
 426. **Danahay H, Withey L, Poll CT, van de Graaf SF, Bridges RJ** 2001 Protease-activated receptor-2-mediated inhibition of ion transport in human bronchial epithelial cells. *Am J Physiol Cell Physiol* 280:C1455–C1464
 427. **Knight DA, Lim S, Scaffidi AK, Roche N, Chung KF, Stewart GA, Thompson PJ** 2001 Protease-activated receptors in human airways: upregulation of PAR-2 in respiratory epithelium from patients with asthma. *J Allergy Clin Immunol* 108:797–803
 428. **Akers IA, Parsons M, Hill MR, Hollenberg MD, Sanjar S, Laurent GJ, McAnulty RJ** 2000 Mast cell tryptase stimulates human lung fibroblast proliferation via protease-activated receptor-2. *Am J Physiol Lung Cell Mol Physiol* 278:L193–L201
 429. **Oshiro A, Otani H, Yagi Y, Fukuhara S, Inagaki C** 2004 Protease-activated receptor-2-mediated inhibition for Ca^{2+} response to lipopolysaccharide in guinea pig tracheal epithelial cells. *Am J Respir Cell Mol Biol* 30:886–892
 430. **Robin J, Kharbanda R, McLean P, Campbell R, Vallance P** 2003 Protease-activated receptor 2-mediated vasodilatation in humans in vivo: role of nitric oxide and prostanoids. *Circulation* 107:954–959
 431. **Marutsuka K, Hatakeyama K, Sato Y, Yamashita A, Sumiyoshi A, Asada Y** 2002 Protease-activated receptor 2 (PAR2) mediates vascular smooth muscle cell migration induced by tissue factor/factor VIIa complex. *Thromb Res* 107:271–276
 432. **McGuire JJ, Hollenberg MD, Andrade-Gordon P, Triggle CR** 2002 Multiple mechanisms of vascular smooth muscle relaxation by the activation of proteinase-activated receptor 2 in mouse mesenteric arterioles. *Br J Pharmacol* 135:155–169
 433. **Milia AF, Salis MB, Stacca T, Pinna A, Madeddu P, Trevisani M, Geppetti P, Emanuelli C** 2002 Protease-activated receptor-2 stimulates angiogenesis and accelerates hemodynamic recovery in a mouse model of hindlimb ischemia. *Circ Res* 91:346–352
 434. **Cicala C, Pinto A, Bucci M, Sorrentino R, Walker B, Harriot P, Cruchley A, Kapas S, Howells GL, Cirino G** 1999 Protease-activated receptor-2 involvement in hypotension in normal and endotoxemic rats in vivo. *Circulation* 99:2590–2597
 435. **Kim MS, Jo H, Um JY, Yi JM, Kim DK, Choi SC, Kim TH, Nah YH, Kim HM, Lee YM** 2002 Agonists of proteinase-activated receptor 2 induce TNF- α secretion from astrocytoma cells. *Cell Biochem Funct* 20:339–345
 436. **Bono F, Lamarche I, Herbert JM** 1997 Induction of vascular smooth muscle cell growth by selective activation of the proteinase activated receptor-2 (PAR-2). *Biochem Biophys Res Commun* 241:762–764
 437. **Kawabata A, Kuroda R, Nakaya Y, Kawai K, Nishikawa H, Kawao N** 2001 Factor Xa-evoked relaxation in rat aorta: involvement of PAR-2. *Biochem Biophys Res Commun* 282:432–435
 438. **Emilsson K, Wahlestedt C, Sun MK, Nystedt S, Owman C, Sundelin J** 1997 Vascular effects of proteinase-activated receptor 2 agonist peptide. *J Vasc Res* 34:267–272
 439. **Roy SS, Saifeddine M, Loutzenhiser R, Triggle CR, Hollenberg MD** 1998 Dual endothelium-dependent vascular activities of proteinase-activated receptor-2-activating peptides: evidence for receptor heterogeneity. *Br J Pharmacol* 123:1434–1440
 440. **Kawabata A, Kuroda R, Nishida M, Nagata N, Sakaguchi Y, Kawao N, Nishikawa H, Arizono N, Kawai K** 2002 Protease-activated receptor-2 (PAR-2) in the pancreas and parotid gland: immunolocalization and involvement of nitric oxide in the evoked amylase secretion. *Life Sci* 71:2435–2446
 441. **Miyata S, Koshikawa N, Yasumitsu H, Miyazaki K** 2000 Trypsin stimulates integrin $\alpha(5)\beta(1)$ -dependent adhesion to fibronectin and proliferation of human gastric carcinoma cells through activation of proteinase-activated receptor-2. *J Biol Chem* 275:4592–4598
 442. **Fiorucci S, Distrutti E, Federici B, Palazzetti B, Baldoni M, Morelli A, Cirino G** 2003 PAR-2 modulates pepsinogen secretion from gastric-isolated chief cells. *Am J Physiol Gastrointest Liver Physiol* 285:G611–G620
 443. **He SH, He YS, Xie H** 2004 Activation of human colon mast cells through proteinase activated receptor-2. *World J Gastroenterol* 10:327–331
 444. **Nishikawa H, Kawai K, Nishimura S, Tanaka S, Araki H, Al Ani B, Hollenberg MD, Kuroda R, Kawabata A** 2002 Suppression by protease-activated receptor-2 activation of gastric acid secretion in rats. *Eur J Pharmacol* 447:87–90
 445. **McLean PG, Aston D, Sarkar D, Ahluwalia A** 2002 Protease-activated receptor-2 activation causes EDHF-like coronary vasodilation: selective preservation in ischemia/reperfusion injury: involvement of lipoxygenase products, VR1 receptors, and C-fibers. *Circ Res* 90:465–472
 446. **Ducroc R, Bontemps C, Marazova K, Devaud H, Darmoul D, Laburthe M** 2002 Trypsin is produced by and activates protease-activated receptor-2 in human cancer colon cells: evidence for new autocrine loop. *Life Sci* 70:1359–1367
 447. **Darmoul D, Marie JC, Devaud H, Gratio V, Laburthe M** 2001 Initiation of human colon cancer cell proliferation by trypsin acting at protease-activated receptor-2. *Br J Cancer* 85:772–779
 448. **Mall M, Gonska T, Thomas J, Hirtz S, Schreiber R, Kunzelmann K** 2002 Activation of ion secretion via proteinase-activated receptor-2 in human colon. *Am J Physiol Gastrointest Liver Physiol* 282:G200–G210
 449. **Cuffe JE, Bertog M, Velazquez-Rocha S, Déry O, Bunnett N, Korbmacher C** 2002 Basolateral PAR-2 receptors mediate KCl secretion and inhibition of Na^{+} absorption in the mouse distal colon. *J Physiol* 539:209–222
 450. **Zhao A, Shea-Donohue T** 2003 PAR-2 agonists induce contraction of murine small intestine through neurokinin receptors. *Am J Physiol Gastrointest Liver Physiol* 285:G696–G703
 451. **Cenac N, Garcia-Villar R, Ferrier L, Larauche M, Vergnolle N, Bunnett N, Coelho AM, Fioramonti J, Bueno L** 2003 Proteinase-activated receptor-2-induced colonic inflammation in mice: possible involvement of afferent neurons, nitric oxide, and paracellular permeability. *J Immunol* 170:4296–4300
 452. **Kawao N, Sakaguchi Y, Tagome A, Kuroda R, Nishida S, Irimajiri K, Nishikawa H, Kawai K, Hollenberg MD, Kawabata A** 2002 Protease-activated receptor-2 (PAR-2) in the rat gastric mucosa: immunolocalization and facilitation of pepsin/pepsinogen secretion. *Br J Pharmacol* 135:1292–1296
 453. **Bertog M, Letz B, Kong W, Steinhoff M, Higgins MA, Bielfeld-Ackermann A, Fromter E, Bunnett NW, Korbmacher C** 1999 Basolateral proteinase-activated receptor (PAR-2) induces chloride

- secretion in M-1 mouse renal cortical collecting duct cells. *J Physiol* 521:3–17
454. **Kawao N, Shimada C, Itoh H, Kuroda R, Kawabata A** 2002 Capsazepine inhibits thermal hyperalgesia but not nociception triggered by protease-activated receptor-2 in rats. *Jpn J Pharmacol* 89:184–187
 455. **Kaufmann R, Schafberg H, Nowak G** 1998 Proteinase-activated receptor-2-mediated signaling and inhibition of DNA synthesis in human pancreatic cancer cells. *Int J Pancreatol* 24:97–102
 456. **Chinni C, De Niese MR, Jenkins AL, Pike RN, Bottomley SP, Mackie EJ** 2000 Protease-activated receptor-2 mediates proliferative responses in skeletal myoblasts. *J Cell Sci* 113:4427–4433
 457. **Seiberg M, Paine C, Sharlow E, Andrade-Gordon P, Costanzo M, Eisinger M, Shapiro SS** 2000 The protease-activated receptor 2 regulates pigmentation via keratinocyte-melanocyte interactions. *Exp Cell Res* 254:25–32
 458. **Sharlow ER, Paine CS, Babiarz L, Eisinger M, Shapiro S, Seiberg M** 2000 The protease-activated receptor-2 upregulates keratinocyte phagocytosis. *J Cell Sci* 113:3093–3101
 459. **Meinhardt A, Kim M, Rodewald M, Steinhoff M**, Functional proteinase-activated receptor-2 is expressed in rat testis. Proc 12th European Workshop on Molecular and Cellular Endocrinology of the Testis, Doorwerth, The Netherlands, 2002, pp 6.4–10.4 (Abstract)
 460. **Moffatt JD, Cocks TM** 1999 The role of protease-activated receptor-2 (PAR2) in the modulation of beating of the mouse isolated ureter: lack of involvement of mast cells or sensory nerves. *Br J Pharmacol* 128:860–864
 461. **Compton SJ, Sandhu S, Wijesuriya SJ, Hollenberg MD** 2002 Glycosylation of human proteinase-activated receptor-2 (hPAR2): role in cell surface expression and signalling. *Biochem J* 368:495–505
 462. **Li Y, Sarkar FH** 2002 Down-regulation of invasion and angiogenesis-related genes identified by cDNA microarray analysis of PC3 prostate cancer cells treated with genistein. *Cancer Lett* 186:157–164
 463. **Kim JA, Choi SC, Yun KJ, Kim DK, Han MK, Seo GS, Yeom JJ, Kim TH, Nah YH, Lee YM** 2003 Expression of protease-activated receptor 2 in ulcerative colitis. *Inflamm Bowel Dis* 9:224–229
 464. **Hamilton JR, Frauman AG, Cocks TM** 2001 Increased expression of protease-activated receptor-2 (PAR2) and PAR4 in human coronary artery by inflammatory stimuli unveils endothelium-dependent relaxations to PAR2 and PAR4 agonists. *Circ Res* 89:92–98
 465. **Donnan GA, Dewey HM, Chambers BR** 2004 Warfarin for atrial fibrillation: the end of an era? *Lancet Neurol* 3:305–308
 466. **Wang H, Reiser G** 2003 The role of the Ca²⁺-sensitive tyrosine kinase Pyk2 and Src in thrombin signalling in rat astrocytes. *J Neurochem* 84:1349–1357
 467. **Darmoul D, Gratio V, Devaud H, Laburthe M** 2004 Proteinase-activated receptor 2 in colon cancer: trypsin-induced MAPK phosphorylation and cell proliferation are mediated by epidermal growth factor receptor transactivation. *J Biol Chem* 279:20927–20934
 468. **Scott G, Leopardi S, Parker L, Babiarz L, Seiberg M, Han R** 2003 The proteinase-activated receptor-2 mediates phagocytosis in a rho-dependent manner in human keratinocytes. *J Invest Dermatol* 121:529–541

Bone Quality: What Is It and Can We Measure It?

A Scientific Meeting Sponsored by the National Institute of Arthritis and Musculoskeletal Skin Diseases (NIAMS) and the American Society for Bone and Mineral Research (ASBMR)

May 2–3, 2005

Hyatt Regency Bethesda
Bethesda, Maryland, USA

Abstract Submission Deadline is Tuesday, February 8, 2005, at 5:00 p.m. EST.

For more information, call (202) 367-1161, e-mail asbmr@smithbucklin.com, or visit our website at <http://www.asbmr.org/bonequality.cfm>

American Society for Bone and Mineral Research (ASBMR)

27th Annual Meeting

September 23–27, 2005

Gaylord Opryland Resort and Convention Center
Nashville, Tennessee, USA

Abstract Submission Deadline is April 27, 2005.

For more information, call (202) 367-1161, e-mail asbmr@smithbucklin.com, or visit our website at www.asbmr.org